



Biochemical and functional analysis of a novel lineage-specific gd T cell surface antigen (GD3.5Ag)
by Ward McAlister Jones

A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in
Veterinary Molecular Biology MONTANA STATE UNIVERSITY Bozeman, Montana

Montana State University

© Copyright by Ward McAlister Jones (1997)

Abstract:

Gamma-delta ($\gamma\delta$) T cell lymphocytes were discovered over a decade ago. Since that time, a great deal of research has been done to gain an understanding of them. Here, I define a novel $\gamma\delta$ T cell lineage-specific antigen (GD3.5Ag) at the biochemical, regulatory, and functional level. GD3.5Ag is expressed on 90% of the bovine peripheral blood $\gamma\delta$ T cell population. GD3.5Ag is approximately 230kD and considerable evidence suggests that it does not represent one of the known WC1 isotypes. GD3.5Ag and WC1 exhibit disparate sensitivity to V-8 protease digestion as well as to PNGase-F, O-sialoglycoprotein endopeptidase, and neuraminidase treatment. GD3.5Ag expression on the cell surface is extremely sensitive to low-dose chymotrypsin treatment, while WC1 is not. I show that large numbers of $\gamma\delta$ T cells that express lower levels of GD3.5Ag are found in the spleen. Treatment of $\gamma\delta$ T cells with PHA or ConA results in the downregulation of GD3.5Ag expression, mimicking the findings in the spleen. Functional analyses revealed that chymotrypsin removal of GD3.5Ag from the cell surface in a dose-dependent manner correlates well with the loss of ability to roll on 24hr activated endothelium. Also, polyclonal antibodies against GD3.5Ag partially inhibit $\gamma\delta$ T cell interactions with 24hr activated endothelium. Although GD3.5Ag is not an E-selectin ligand itself, I confirmed that $\gamma\delta$ T cells express a 250kD E-selectin ligand and possibly 200kD and 300kD E-selectin ligands. Additionally, I define three potentially relevant E-selectin ligands of 120kD, ~220kD, and 260kD on human lymphocytes.

**Biochemical and Functional Analysis of a Novel Lineage-Specific
 $\gamma\delta$ T Cell Surface Antigen (GD3.5Ag)**

by

Ward McAlister Jones

A thesis submitted in partial fulfillment
of the requirements for the degree

of

Doctor of Philosophy

in

Veterinary Molecular Biology

MONTANA STATE UNIVERSITY

Bozeman, Montana

July, 1997

© COPYRIGHT

by

Ward McAlister Jones

1997

All Rights Reserved

D378
J728

ii

APPROVAL

of a thesis submitted by

Ward McAlister Jones

This thesis has been read by each member of the thesis committee and has been found to be satisfactory regarding content, English usage, format, citations, bibliographic style, and consistency, and is ready for submission to the College of Graduate Studies.

7/3/97

Date

Ward Jones

Chairperson, Graduate Committee

Approved for the Major Department

7/3/97

Date

Ward Jones

Head, Major Department

Approved for the College of Graduate Studies

7/9/97

Date

RL Brown

Graduate Dean

STATEMENT OF PERMISSION TO USE

In presenting this thesis in partial fulfillment of the requirements for a doctoral degree at Montana State University, I agree that the Library shall make it available to borrowers under rules of the Library. I further agree that copying of this thesis is allowable only for scholarly purposes, consistent with "fair use" as prescribed in the U.S. Copyright Law. Requests for extensive copying or reproduction of this thesis should be referred to University Microfilms International, 300 North Zeeb Road, Ann Arbor, Michigan 48106, to whom I have granted "the exclusive right to reproduce and distribute my dissertation in and from microform along with the non-exclusive right to reproduce and distribute my abstract in any format in whole or in part."

Signature Ward W. Jones

Date 7-3-97

PREPARATION OF THE DISSERTATION

To assist the reader, I decided to include this section to describe how the dissertation was compiled and formatted. In the Introduction (Chapter 1), a general overview is given to provide sufficient background information for the understanding of subsequent chapters. The chapters that follow the Introduction also include an introductory section. The purpose for using this format is to allow those chapters that have been published or submitted for publication to be integrated into the dissertation in a logical manner. Chapters 2 and 4 represent data that has been published or submitted for publication. The manuscripts included in Chapters 2 and 4 , respectively, are as follows:

Jones, W. M., B. Walcheck, and M. A. Jutila. 1996. Generation of a new $\gamma\delta$ T cell-specific monoclonal antibody (GD3.5): biochemical comparisons of GD3.5 antigen with the previously described workshop cluster 1 (WC1) family. *J. Immunol.* 156:3772.

Jones, W. M., G. M. Watts, M. K. Robinson, D. Vestweber, and M. A. Jutila. 1997. Comparison of E-selectin binding glycoprotein ligands on human lymphocytes, neutrophils, and bovine $\gamma\delta$ T cells. Submitted to *J. Immunol.*

During the process of obtaining my degree, several collaborative projects within the lab were established. We performed experiments involving several individuals, including the study of E-selectin ligand and GD3.5Ag expression on bovine lymphocytes. Figures 9 and 20 are the result of these collaborative studies. Therefore, I would like to specifically acknowledge Gayle Watts and Karen Sipes for their assistance in generating Figures 9 and 20, respectively. In addition, I would like to acknowledge Martyn Robinson and Dietmar Vestweber for providing critical reagents (P11.4 chimera and ESL-1 polyclonal antibody). Finally, I would like to acknowledge Bruce Walcheck who generated the GD3.5 mAb.

I dedicate this thesis to my wife, Betsy Jones, and children, Krystal Fix and Erica Fix,
for their unending patience in my endeavors to obtain this degree.

ACKNOWLEDGMENTS

I thank my thesis advisor Dr. Mark Jutila for his direction, support, and especially his patience. In addition, I thank my thesis committee: Dr. Michael White, Dr. Bruce Granger, Dr. Mark Quinn, and Dr. Martin Tientze for their support and direction.

For all of their help and support, I respectfully thank:

Gayle Watts

Ginger Perry

Sandy Kurk

Dana Hoover

Jim Thompson

Kerri Miller

Bruce Walcheck

Robert Bargatze

Eric Wilson

Jeff Leid

Linda Rees

Joan Haynes

TABLE OF CONTENTS

LIST OF TABLES.....	xi
LIST OF FIGURES.....	xii
ABSTRACT.....	xv
1 . Introduction.....	1
Historical Background.....	1
T cell receptor γ and δ chain: Lineage-specific $\gamma\delta$ T cell marker.....	2
Workshop Cluster 1 (WC1): Lineage-specific $\gamma\delta$ T cell marker.....	3
Other lineage-specific antigens.....	6
$\gamma\delta$ T cell distribution and function.....	6
Lymphocyte trafficking.....	8
Similarities in the trafficking of memory $\alpha\beta$ T cells and $\gamma\delta$ T cells.....	11
Leukocyte ligands for vascular E-selectin.....	13
Summary.....	17
References.....	18
2 . Generation of a new $\gamma\delta$ T cell-specific monoclonal antibody	
(GD3.5): Biochemical comparisons of GD3.5 antigen with the	
previously described WC1 family.....	29
Introduction.....	29
Materials and Methods.....	31
$\gamma\delta$ T cell purification and ^{125}I labeling.....	31
mAbs and FACS analysis.....	32
Western blot.....	33
Immunoprecipitation/Crossprecipitation.....	33
V-8 protease peptide mapping.....	34

Enzymatic deglycosylation of GD3.5 antigen and WC1.....	34
Chymotrypsin sensitivity assay.....	35
Results.....	35
Surface expression of the GD3.5 antigen on bovine lymphocytes.....	35
Western Blot and immunoprecipitation analysis of the GD3.5 antigen.....	36
Crossprecipitation analysis, V-8 protease peptide mapping, enzymatic deglycosylation and WC1 and GD3.5 antigen cell surface expression.....	40
Discussion.....	47
References.....	51
3. Regulation and functional characterization of a novel $\gamma\delta$ T cell- specific surface antigen (GD3.5).....	55
Introduction.....	55
Materials and Methods.....	57
Lymphocyte purification, $\gamma\delta$ T cell isolation, and biotin labeling.....	57
mAbs, polyclonal antibodies, and FACS analysis.....	58
Tissue distribution of bovine $\gamma\delta$ T cells.....	59
Immunoprecipitation/Crossprecipitation.....	59
Mitogen stimulation of total lymphocyte populations.....	60
In-vitro low-shear adhesion assay.....	61
In-vitro capillary tube shear-dependent rolling assay.....	61
Results.....	62
Distribution of $\gamma\delta$ T cells in organized lymphatic tissue.....	62
Mitogen stimulation of bovine lymphocyte populations.....	63
Effect of GD3.5 mAb on established lymphocyte rolling or tight adhesion to 4hr activated endothelium.....	64

Effect of pretreating bovine lymphocytes with GD3.5 mAb on their interaction with 24hr activated endothelium.....	66
Chymotrypsin-treated bovine lymphocyte interactions in adhesion assays...	70
Characterization of polyclonal antibodies against GD3.5Ag.....	73
Discussion.....	78
References.....	84
4. Comparison of E-selectin-binding glycoprotein ligands on human lymphocytes, neutrophils, and bovine $\gamma\delta$ T cells: Identification of novel E-selectin ligands on human lymphocytes and bovine $\gamma\delta$ T cells.....	87
Introduction.....	87
Materials and Methods.....	89
Human and bovine leukocyte purification and biotin labeling.....	89
mAbs, E- and P-selectin chimeras, and FACS analysis.....	90
Western Blot.....	92
Immunoprecipitation/Crossprecipitation.....	92
Results.....	94
Flow cytometric analysis of bovine leukocytes.....	94
Western Blot and immunoprecipitation of bovine E-selectin ligands.....	95
Flow cytometric analysis of human leukocytes.....	99
Immunoprecipitation of human leukocyte E-selectin ligands.....	101
Role of L-selectin and ESL-1 as neutrophil and lymphocyte ligands for E-selectin.....	105
Discussion.....	108
References.....	114

5 . Conclusions and Recent Results.....	118
Introduction.....	118
Description of GD3.5Ag by biochemical, regulatory, and functional analyses...	118
GD3.5Ag as a unique WC1 isotype?.....	119
E-selectin ligands expressed on human and bovine lymphocytes.....	123
Summary.....	124
6 . Future and Collaborative Studies.....	125

LIST OF TABLES

1. List of reagents used for E-selectin ligand analysis.....	91
--	----

LIST OF FIGURES

1. Two-color FACS analysis illustrating GD3.5 staining patterns of peripheral blood lymphocytes from a single individual	37
2. Nonreducing Western Blot of $\gamma\delta$ T cell lysate, illustrating electrophoretic mobility of GD3.5 antigen and WC1.....	38
3. Comparisons of ^{125}I -labeled lysate immunoprecipitations of WC1, GD3.5 antigen, and TCR under nonreducing and reducing conditions.....	40
4. ^{125}I -labeled lysate immunoprecipitation/crossprecipitation experiment.....	42
5. GD3.5 antigen and WC1 immunoprecipitates treated with varying concentrations of V-8 protease and electrophoresed under reducing conditions to illustrate/compare digestion profiles.....	43
6. Comparison of ^{125}I -labeled lysates of WC1 and GD3.5 antigen treated with O-sialoglycoprotease, PNGase F, or neuraminidase.....	45
7. Effects of low-dose chymotrypsin on cell surface expression of WC1 and GD3.5 antigen.....	46
8. $\gamma\delta$ T cells found in organized lymphatic tissues express varying levels of GD3.5Ag	63
9. Mitogen stimulation differentially downregulates cell surface expression of GD3.5Ag and WC1.....	65

10. GD3.5 mAb does not block lymphocyte adhesion to 4hr activated BUVECs or HUVECs.....	67
11. GD3.5 mAb does not block lymphocyte binding to E- or P-selectin.....	68
12. Injection of GD3.5 mAb does not block lymphocyte binding to 24hr activated endothelium.....	69
13. Pretreatment of lymphocytes with GD3.5 mAb blocks lymphocyte interactions with 24hr activated endothelium.....	70
14. Loss of GD3.5Ag expression inhibits lymphocyte rolling on P-selectin, but not E-selectin.....	72
15. $\gamma\delta$ T cell rolling on 24hr activated endothelium is inhibited by low-dose chymotrypsin treatment of the rolling cells.....	74
16. Anti-GD3.5 polyclonal sera stains bovine $\gamma\delta$ T cells.....	75
17. Anti-GD3.5 polyclonal sera immunoprecipitates GD3.5Ag.....	76
18. Anti-GD3.5 polyclonal sera specifically inhibits accumulation of bovine $\gamma\delta$ T cells on 24hr activated endothelial cells.....	77
19. Bovine $\gamma\delta$ T cells are specifically stained by E-selectin chimera.....	96
20. $\gamma\delta$ T cell lysates contain four E-selectin-reactive molecules by Western Blot.....	97

21. Two distinct E-selectin ligands are immunoprecipitated from surface biotinylated $\gamma\delta$ T cell lysates using E-selectin chimera.....	98
22. E- and P-selectin chimeras do not immunoprecipitate GD3.5Ag or WC1.....	100
23. Human neutrophils and a subset of lymphocytes are specifically stained by E-selectin chimera.....	102
24. Distinct E-selectin ligands are immunoprecipitated from biotinylated human neutrophil and human lymphocyte lysates using E-selectin chimera.....	104
25. Human neutrophil L-selectin binds to E-selectin.....	106
26. ESL-1 is not the major E-selectin-binding ligand on human and bovine lymphocytes.....	107
27. Multiple monoclonal antibodies against WC1 do not immunoprecipitate GD3.5Ag.....	121
28. GD3.5 polyclonal antibody crossprecipitation of IL-A29 and GD3.5 cleared biotinylated lysates.....	122

ABSTRACT

Gamma-delta ($\gamma\delta$) T cell lymphocytes were discovered over a decade ago. Since that time, a great deal of research has been done to gain an understanding of them. Here, I define a novel $\gamma\delta$ T cell lineage-specific antigen (GD3.5Ag) at the biochemical, regulatory, and functional level. GD3.5Ag is expressed on 90% of the bovine peripheral blood $\gamma\delta$ T cell population. GD3.5Ag is approximately 230kD and considerable evidence suggests that it does not represent one of the known WC1 isotypes. GD3.5Ag and WC1 exhibit disparate sensitivity to V-8 protease digestion as well as to PNGase-F, O-sialoglycoprotein endopeptidase, and neuraminidase treatment. GD3.5Ag expression on the cell surface is extremely sensitive to low-dose chymotrypsin treatment, while WC1 is not. I show that large numbers of $\gamma\delta$ T cells that express lower levels of GD3.5Ag are found in the spleen. Treatment of $\gamma\delta$ T cells with PHA or ConA results in the downregulation of GD3.5Ag expression, mimicking the findings in the spleen. Functional analyses revealed that chymotrypsin removal of GD3.5Ag from the cell surface in a dose-dependent manner correlates well with the loss of ability to roll on 24hr activated endothelium. Also, polyclonal antibodies against GD3.5Ag partially inhibit $\gamma\delta$ T cell interactions with 24hr activated endothelium. Although GD3.5Ag is not an E-selectin ligand itself, I confirmed that $\gamma\delta$ T cells express a 250kD E-selectin ligand and possibly 200kD and 300kD E-selectin ligands. Additionally, I define three potentially relevant E-selectin ligands of 120kD, ~220kD, and 260kD on human lymphocytes.

CHAPTER 1

INTRODUCTION

Historical Background

A large portion of T cells found in circulation express the $\alpha\beta$ T cell receptor (TCR), which is associated with the "invariant components" of the CD3 signalling complex (1). Importantly, the TCR recognizes, in conjunction with coreceptors CD8 or CD4, processed antigen that is presented in the context of MHC Class-I or MHC Class-II molecules, respectively (2). In 1984, cDNAs encoding the $\alpha\beta$ TCR were identified. Initially, subtractive hybridization and differential screening revealed a cDNA clone that encoded the β chain molecule (3,4). Soon after this discovery, a second cDNA clone was identified and thought to encode the α chain (5). Paradoxically, this particular clone did not encode any potential N-linked glycosylation sites which were known to exist in the α chain (1). Subsequent studies uncovered the "true" α chain cDNA; the protein encoded by the original " α " chain cDNA was termed the " γ " chain (6-8).

Although the α and β chain cDNAs had been identified, the function of the third " γ " chain remained unknown. Several investigators suggested that the γ chain was expressed in less mature thymocytes and represented an $\alpha\beta$ T cell progenitor (9,10). Others suggested that cloned $\alpha\beta$ T cells possessed "nonproductive γ rearrangements" and, therefore, γ genes played no role in $\alpha\beta$ T cell function (8). In 1986, several groups described TCR heterodimers associated with the CD3 complex that contained the γ chain (11-13), and some suggested that the γ chain was associated with an

unidentified fourth chain (11,13). Finally, in 1987, the fourth unidentified gene, termed the " δ " chain, was discovered in studies looking at C, D, and J region gene rearrangements in CD4⁻ and CD8⁻ thymocytes (14,15). In addition, the human δ chain cDNA was discovered using subtractive hybridization (16). This new heterodimeric TCR, comprised of the γ and δ chain molecules, was found on a subset of CD4⁻ and CD8⁻ T cells that were collectively termed $\gamma\delta$ T cells.

Determining the biological function of this novel T cell subset continues to generate a great deal of attention. Although the function of $\gamma\delta$ T cells has not been completely defined, several investigators suggest that these cells are involved in the initial host response to infectious agents, contributing to what is referred to as "the first line of defense," which will be discussed later.

T cell receptor γ and δ chain: Lineage-specific $\gamma\delta$ T cell marker

As described earlier, $\gamma\delta$ T cells received their namesake from the γ and δ TCR gene products on their cell surface. Therefore, $\gamma\delta$ T cells can be identified by mAbs directed against the TCR. As found for $\alpha\beta$ T cells, the TCR on $\gamma\delta$ T cells is associated with an array of proteins referred to as the CD3 complex. The complex is similar to CD3 on $\alpha\beta$ T cells and consists of γ , δ , ϵ , and ζ CD3 proteins on most cells (17) though some reports indicate that epithelial $\gamma\delta$ T cells do not express ζ chain proteins (18-21). $\alpha\beta$ T cell TCR function involves the recognition of peptide in the context of Class I or Class II MHC. The CD4⁺ $\alpha\beta$ T helper cells recognize antigen expressed with MHC Class II, while CD8⁺ T cytolytic cells recognize antigen in conjunction with Class I MHC (22). Both CD4 and CD8 are referred to as coreceptors assisting in the TCR recognition of MHC complexes (22). $\gamma\delta$ T cells appear to have a less restricted antigen recognition event. Interestingly, most $\gamma\delta$ T cells lack CD4 or CD8 and apparently are not restricted by MHC Class-I or Class-II recognition. Although some $\gamma\delta$ T cells have been isolated that react

with classical MHC I and II, many appear to react with other nonclassical MHC gene products (23-26).

Recently, some reports indicate that $\gamma\delta$ T cell antigen recognition may be independent of antigen processing, suggesting a direct recognition event (27,28). It has been suggested that $\gamma\delta$ TCRs are more closely related to immunoglobulins than to $\alpha\beta$ TCRs based upon CDR3 length analysis (27,29). $\gamma\delta$ T cells demonstrate greater diversity in CDR3 length than do $\alpha\beta$ T cells. It is thought that $\alpha\beta$ T cells demonstrate limited variability in CDR3 length because of MHC-restricted interactions with antigen presenting cells (APCs). Therefore, CDR3 length variability may explain the apparent lack of MHC restriction demonstrated by some $\gamma\delta$ T cells. The authors suggest that this may mediate $\gamma\delta$ T cell cytotoxicity in the absence of APCs with a direct response to antigen (18,27).

Several reports suggest that $\gamma\delta$ T cells recognize unconventional antigens, such as heat shock proteins (HSP) and nonpeptide antigens (18,23,28,30-36). Very small (<1kD) protease-resistant mycobacterial antigens are capable of activating $\gamma\delta$ T cell subsets (32-34). In addition, human $\gamma\delta$ T cell lines have been shown to respond to PPD and recombinant HSP (36). More recently, $\gamma\delta$ T cell response to heat-killed mycobacteria has been attributed to small, nonpeptide, phosphate-containing antigens (28,35). Specifically, a 1-3kD phosphate-containing carbohydrate has been identified as the stimulatory component in mycobacterium (28,37). Therefore, $\gamma\delta$ T cells have the capacity to respond to rather unusual or unconventional antigens.

Workshop Cluster 1 (WC1): Lineage-specific $\gamma\delta$ T cell marker

In 1986, MacKay et al. described a unique, lineage-specific, $\gamma\delta$ T cell marker in sheep (38). This cell surface marker (T19) is found on as many as 60% of ovine peripheral blood lymphocytes (PBLs). In comparison, only 1-3% of lymph node (LN)

lymphocytes' and thymocytes express T19 (38). Later reports show that ovine T19⁺ cells comprising 30-60% of PBLs are positive for the $\gamma\delta$ TCR and negative for CD4 and CD8 (39).

T19 can be distinguished from TCRs by SDS-PAGE analysis. The T19 antigen migrates under reducing and nonreducing conditions at ~215kD and ~300kD, while $\gamma\delta$ TCRs demonstrate a migratory pattern of approximately 40kD under reducing conditions and 70-75kD under nonreducing conditions (39). The $\gamma\delta$ TCR and T19 appear at different times during fetal and neonate development. Cells expressing $\gamma\delta$ TCR are detected at 40 days gestation while T19⁺ cells are not detected until 15 days later (39). The percentage of $\gamma\delta$ TCR⁺ cells in all tissues is higher than the percentage of T19⁺ cells, indicating that some $\gamma\delta$ TCR-bearing T cells are T19⁻ (39).

Soon after the discovery of T19 in sheep, several groups identified a similar antigen on bovine $\gamma\delta$ T cells (40-43). Many mAbs were generated against this antigen and are now clustered into a group collectively called Workshop Cluster 1 (WC1) (44). As in the sheep, bovine WC1 is characterized by ~210kD and ~300kD bands (43). Additionally, as described for T19 in sheep, the percentage of WC1⁺ cells in tissues is lower than the percentage of $\gamma\delta$ TCR⁺ cells (43,45).

By 1992, it became apparent that the multitude of mAbs that recognized WC1 were widely variable relative to the percentage of the population stained in a single individual. This prompted studies looking for the DNA that codes for WC1. A full length cDNA clone of WC1 was reported in bovine by Wijngaard et al. (46). Sequence analysis revealed a predicted protein containing a N-terminal leader peptide with a transmembrane region located in proximity to the C-terminus (46). In addition, 17 potential N-linked glycosylation sites are located in the extracellular domain. The extracellular domain contains 11 homologous regions that demonstrate strong identity to the scavenger receptor cysteine-rich (SRCR) family (46). In this same report,

Southern blots indicate that bovine genomic DNA contains several similar sequences, suggesting the potential for a WC1 gene family. Goats, pigs, sheep, and horse genomes appear to present similar complexity, while man and rodents appear to have fewer related sequences (46).

A plethora of mAbs to WC1 are clustered into two groups according to their reactivity to two different WC1 cDNA clones transfected into mouse L-cells (47). Several mAbs react with both WC1.1 and WC1.2 L-cell transfectants, while other antibodies react with either transfectant, but not both. Simultaneous reports indicated that WC1.1 and WC1.2 can be differentiated into two groups by apparent molecular weights of 205 and 215kD, respectively (48). Subsequently, a third cDNA was isolated (WC1.3) which shares significant nucleic acid identity with the first two cDNAs (49). Upon comparison, all three cDNAs share approximately 90% nucleic acid identity. Interestingly, a portion of the first SRCR domain, the most N-terminal, demonstrates only 50% identity among the three cDNA clones (49). Thus, this portion of the molecule could provide a unique N-terminal domain for each isotype, thereby directing its function and suggesting one reason that multiple WC1 species exist. Most importantly, mAbs IL-A29 and CC15 stain all three cDNA transfectants, providing pan-markers for the three known WC1 isotypes (49).

Although molecular biological techniques and mAbs have somewhat elucidated WC1 structure and tissue distribution, little is known about its function. MacKay et al. suggest that WC1 may play a role in tissue-specific homing, since WC1 is lost once some $\gamma\delta$ T cell populations enter certain tissues (39). Taking it one step further, Wijngaard et al. suggest that expressing different WC1 genes may provide a mechanism for tissue-specific homing (49). However, direct evidence supporting a role for WC1 in homing has not been shown.

Some authors speculate that WC1 may play a role similar to CD4 and CD8 on $\alpha\beta$ T cells (49,50), whereas others suggest that WC1 does not "substitute" for these antigens (51). Binding of WC1 with mAbs augments proliferation of $\gamma\delta$ T cells under certain circumstances (51). More specifically, cell-bound IL-A29 specifically enhances $\gamma\delta$ T cell proliferation in autologous mixed leukocyte reactions. Additionally, immobilized IL-A29 enhances $\gamma\delta$ T cell proliferation when cells are treated with anti-CD3 mAb, suggesting that WC1 engagement may augment TCR signalling events (51). Another report indicates that WC1 signals cell-cycle arrest, but not apoptosis (52). In this report, anti-WC1 antibodies induce cell-cycle arrest in G0/G1 in a dose-dependent manner that is reversible upon removal of the antibody (52). The antibody-induced cell arrest could be overcome by treating with anti-CD3 mAb. Therefore, engagement of the TCR and WC1 may provide an enhanced stimulatory event while immobilized WC1 alone signals cell-cycle arrest.

Other lineage-specific antigens

In our lab, we (my colleagues and I) have endeavored to generate mAbs against bovine $\gamma\delta$ T cell surface antigens by injecting mice with purified $\gamma\delta$ T cells. During this process, as expected, many mAbs against $\gamma\delta$ TCR and WC1 were generated. However, one of the mAbs generated in a fusion piqued our interest. Preliminary results suggested that this mAb (GD3.5) stained a unique population of $\gamma\delta$ T cells and recognized a unique antigen by Western Blotting. This antigen (GD3.5Ag) is described in Chapters 2 and 3.

$\gamma\delta$ T cell distribution and function

Even though many laboratories have performed elegant studies of the function of $\gamma\delta$ T cells, a clear consensus of their importance has not been established. We and others

hypothesize that their tissue distribution may lend some clues to their function. In ruminants, $\gamma\delta$ T cells comprise 60-80% of the peripheral blood lymphocyte (PBL) population (45,50), but do not appreciably accumulate in the organized lymphatic tissues, such as the lymph node (39,43,53). Studies have demonstrated considerable homing of bovine $\gamma\delta$ T cells into epithelial tissues, such as the skin and gut (50,53,54). In addition to epithelial tissues, bovine $\gamma\delta$ T cells home to sites of inflammation. For example, intradermal injection of PPD results in accumulation of $\gamma\delta$ T cells at the inflammatory site (55).

Many studies have been conducted in mice describing $\gamma\delta$ T cells in association with extralymphoid sites, including the mucosal epithelial of the gut, tongue, vaginal areas and the skin (56-58). Interestingly, tissue localization of these cells seems to correlate with TCR gene usage in some cases (31,58,59). For example, murine $\gamma\delta$ T cells expressing the V γ 5 V δ 1 TCR migrate to the skin (30,58,60). Therefore, localization may be either linked to or correlate with TCR gene usage (58,59). Several authors have hypothesized that specific homing receptors are expressed by the different T cell subsets directing their tissue-specific homing (30,58).

Human $\gamma\delta$ T cell tissue localization is different in comparison to the bovine and mouse. Human $\gamma\delta$ T cells are found in lymphoid as well as nonlymphoid tissues and are not as tightly associated with epithelial tissues as seen in the mouse and bovine models (35,53). Human TCR gene usage has been associated with circulating $\gamma\delta$ T cell populations (35,61,62). V γ 9 V δ 2 $\gamma\delta$ T cells represent a large subset of human peripheral blood $\gamma\delta$ T cells (35,62). Importantly, this $\gamma\delta$ T cell subset binds small molecular mass, non-protein antigens (32,35). Hence, it has been suggested that these cells respond quickly to antigen, performing as sentinels (35).

Since $\gamma\delta$ T cells locate in areas where invading pathogens would first be encountered (portals of entry into the body) in what appears to be "directed" localization of $\gamma\delta$ T

cells to epithelial tissues, many hypothesize that $\gamma\delta$ T cells play a major role in "the first line of defense" and, in fact, recent reports support this hypothesis. In studies using $\gamma\delta$ and $\alpha\beta$ TCR-knockout mice, the role of the $\gamma\delta$ T cells in malarial infection appears to be during initial protection (63). $\gamma\delta$ TCR-deficient mice exhibit early, acute malaria, but eventually clear the infection. In contrast, $\alpha\beta$ -deficient mice exhibit chronic, almost subclinical malaria (63). Other reports indicate that $\gamma\delta$ T cells may play a role in eradication of intracellular bacterial pathogens, such as *Listeria* and *Mycobacteria* species (28,64,65). $\gamma\delta$ T cells are crucial in reducing bacterial growth during early infection (28). Additionally, $\alpha\beta$ T cells appear to play a role in bacterial eradication in the later stages of infection (28,65). Therefore, $\gamma\delta$ T cell function during these bacterial infections appears to be similar to their response during malarial infections. Lastly, $\gamma\delta$ T cells are involved in protection against viral infections (66,67). In one report, cytotoxic $\gamma\delta$ T cells were shown to recognize and lyse HSV-infected target cells (66).

In general, $\gamma\delta$ T cells appear to provide protection against intracellular viral, bacterial, and parasitic pathogens, thus supporting the "first line of defense" hypothesis. In addition, their tissue distribution is consistent with "the first line of defense" theory. Finally, unlike $\alpha\beta$ T cells, their ability to recognize unprocessed antigens may suggest that these cells provide a rapid response against invading pathogens (18,27).

Lymphocyte trafficking

To get to specific tissues, lymphocytes follow very distinct steps in a process called trafficking. The study of lymphocyte trafficking greatly enhances our understanding of lymphocyte function. It is known that expression of specific receptors and their ligands regulates lymphocyte trafficking of discrete T cell subsets. $\alpha\beta$ T cells originate from

the hematopoietic stem cells of the bone marrow and develop to maturity in the thymus. Although mature, these cells are naive in relation to exposure to antigen and expression of cell-surface antigens. For instance, these cells express peripheral lymph node homing receptor (L-selectin) and the naive cell-surface marker CD45RA. Naive $\alpha\beta$ T cells recirculate through secondary lymphoid tissues, such as PLN, MLN, and Peyer's patches, using very specific molecular interactions.

Naive $\alpha\beta$ T cells can bind to specific sites in the PLN using the lymphocyte homing receptor L-selectin. In the PLN, specialized high-endothelial venules (HEV) express peripheral node addressin (PNAd) which is recognized by surface-expressed L-selectin (68). This interaction can be inhibited by functionally blocking L-selectin or PNAd. Specifically, anti-L-selectin mAbs inhibit binding of lymphocytes to PNAd (69). Additionally, mAb MECA-79, which recognizes PNAd, blocks binding of lymphocytes to PLN HEV (70). Therefore, L-selectin plays a key role in naive $\alpha\beta$ T cell trafficking into the PLN via binding PNAd expressed on HEVs.

Recirculation of naive $\alpha\beta$ T cells through the gut-associated secondary lymphoid tissues, such as the MLN and Peyer's patches, involves a more complex homing mechanism. As described above, PNAd is expressed on PLNs, which plays a major role in lymphocyte homing into PLN. In experiments using L-selectin-deficient mice, lymphocyte homing to PLN was significantly inhibited while inhibition of homing to MLN and Peyer's patch was less severe (71). Thus, a significant portion of homing to gut-associated secondary lymphoid tissues occurs in the absence of L-selectin. Importantly, low levels of L-selectin ligand (MECA-79-reactive molecules) are expressed in MLNs and Peyer's patches, indicating that L-selectin binding can occur (72,73). However, L-selectin alone is not the only naive lymphocyte ligand that can mediate rolling on MLNs and Peyer's patches (73,74). The integrin $\alpha 4\beta 7$ can initiate rolling on MLNs or Peyer's patches via binding mucosal addressin cell-adhesion

molecule (MAdCAM-1) (72,73). Thus, homing of naive $\alpha\beta$ T cells to gut-associated lymphoid tissues can be initiated by L-selectin and $\alpha 4\beta 7$ interactions with ligands expressed on these tissues (72-74). In fact, it has been proposed that rolling on L-selectin ligands, in Peyer's patch, is too fast to allow cell arrest and $\alpha 4\beta 7$ serves as a "bridge" between rolling and cell arrest by significantly reducing rolling velocity (73,74). Furthermore, Peyer's patch-HEVs express a unique form of MAdCAM-1 which possesses ligands for both L-selectin and $\alpha 4\beta 1$ (74,75).

Once the cells have homed to a particular tissue, they must either perform their function or continue to recirculate. Naive cells that enter the secondary lymphoid tissue and encounter antigen are retained in the tissue where they undergo conversion to memory/effector T cells. If, however, the naive cell does not encounter antigen, it must recirculate throughout the body to continue its search for foreign antigen. The naive cells exit the lymphoid tissue via the efferent lymph. Here, through the lymphatic system, the naive cells are returned to the blood by way of the thoracic duct where they can recirculate through the body and once again home to the secondary lymphoid tissues (76,77).

As opposed to naive T cells, memory T cells express CD45RO and varying levels of L-selectin (72,78). In addition, several adhesion molecules, such as cutaneous leukocyte-associated antigen (CLA), $\alpha 4\beta 1$, and $\alpha 4\beta 7$ are expressed on memory cells (72,79,80). Tissue-specific homing receptor expression on these cells appears to be dependent upon the site where naive to memory conversion occurs (72,81-83). For example, memory T cell production in PLN correlates with CLA upregulation or L-selectin on some memory T cells (83). Importantly, CLA⁺ lymphocytes represent the skin-homing T cell population (79,84). Therefore, conversion to memory in PLN correlates with skin or PLN homing T cells.

Memory T cells can migrate through the secondary lymphoid tissues (73,76), but

unlike naive T cells, they also have the capacity to migrate into extralymphoid tissues. In sites of inflammation, where upregulation of various adhesion molecules occurs, memory T cells have the capacity to bind the endothelium and enter. For example, memory cells expressing $\alpha 4\beta 1$ (VLA-4) can bind vascular cell adhesion molecule-1 (VCAM-1), which is expressed by endothelium at sites of inflammation (68,73,85). In addition, memory cells expressing CLA have the capacity to bind E-selectin, allowing their migration into cutaneous sites of inflammation (79,84,86). Recently, several reports state that recruitment of specific memory T cell subsets is possible. E- and P-selectin are expressed by inflamed endothelium and are capable of initiating leukocyte/endothelial cell rolling interactions. Importantly, Th1 cells bind to these vascular selectins, while Th2 cells do not (87,88). Thus, Th1 cells can be specifically recruited into inflammatory sites where E- and P-selectin are expressed.

In other extralymphoid sites, such as the lamina propria, memory cells have the capacity to bind MAdCAM-1 via $\alpha 4\beta 7$. Interestingly, naive cells cannot bind this form of MAdCAM-1 due to its lack of L-selectin ligand expression and lower level of naive T lymphocyte $\alpha 4\beta 7$ expression (73,89). Therefore, memory cells can home to lamina propria, while naive T cells cannot.

Similarities in the trafficking of memory $\alpha\beta$ T cells and $\gamma\delta$ T cells

Upon initial observation, it becomes apparent that memory $\alpha\beta$ T cells and $\gamma\delta$ T cells possess the ability to home to nonlymphatic epithelial tissues. In addition, $\gamma\delta$ T cells and memory $\alpha\beta$ T cells express CD45RO, possessing a memory-like phenotype (90). Importantly, memory $\alpha\beta$ T cells and $\gamma\delta$ T cells are "primed" for antigen recognition and respond more rapidly than naive $\alpha\beta$ T cells; however, $\alpha\beta$ T cells recognize antigen in the context of MHC while some $\gamma\delta$ T cells recognize antigen in the absence of antigen processing and MHC restriction (27,28). In addition, both subsets appear to be

surveying the portals of entry into the body thereby providing protection from invading pathogens.

In cattle, young animals possess large numbers of circulating $\gamma\delta$ T cells (43). As the animals mature, these numbers drop dramatically (43). Young animals do not possess a large repertoire of memory $\alpha\beta$ T cells, therefore, these animals would need an initial defense mechanism to compensate for the slow response to infection due to the lack of memory $\alpha\beta$ T cells. It is tempting to propose that perhaps the higher number of $\gamma\delta$ T cells in young animals are needed until a sufficient repertoire of memory $\alpha\beta$ T cells can be generated. Thus, later in life, the more responsive memory T cells could respond faster and to a wider variety of antigens thereby requiring fewer $\gamma\delta$ T cells. In fact, it has been suggested that $\gamma\delta$ T cells and $\alpha\beta$ T cells complement and in some cases slightly compensate for each other (28). Therefore, we suggest that $\alpha\beta$ T cells become more like $\gamma\delta$ T cells upon conversion to the memory phenotype. Both subsets migrate to epithelial tissues and possess a heightened response to antigen. Although these subsets do possess some unique features, perhaps their complementary and potentially compensatory functions and rapid response would allow more efficient immune responses in older animals which possess fewer $\gamma\delta$ T cells.

As stated above, memory $\alpha\beta$ T cells and $\gamma\delta$ T cells are capable of entering extralymphoid tissues. In some cases, expression of specific molecules, such as E-selectin, can initiate recruitment of $\gamma\delta$ T cells (98) and specific memory $\alpha\beta$ T cell subsets (87,88). For example, as discussed above, memory Th1 $\alpha\beta$ T cells preferentially bind E-selectin (87,88). Thus, the ligands expressed on lymphocytes that bind this vascular selectin are important.

Leukocyte ligands for vascular E-selectin

Leukocyte adhesion to endothelium is sometimes initiated by an inflammatory response. The expression of multiple adhesion molecules on endothelial cell surfaces and their interactions with leukocyte ligands results in the recruitment of leukocytes into an inflamed site. Leukocyte adhesion and transmigration through the endothelium into inflammatory sites has been described as a multistep process (72,91,92). These events are very complex and include initial tethering and rolling interactions between the leukocyte and endothelium followed by tight adhesion to the endothelium and finally transmigration into the underlying tissue (91,92). Many of the initial adhesion events between leukocytes and endothelial cells require a unique group of molecules called selectins (68,72,93,94). To date, three proteins have been identified and classified as selectins: CD62E or E-selectin, CD62P or P-selectin, and CD62L or L-selectin. The selectins are defined by an NH₂-terminal Ca²⁺-dependent (C-type) lectin domain, an EGF-like region, several consensus repeats and a transmembrane region with a cytoplasmic tail (68,94,95).

E-selectin is expressed on endothelial cells while P-selectin is expressed on endothelium and platelets. L-selectin is expressed on leukocytes and is characterized by a different molecular mass depending upon the expressing cell type. The two vascular selectins support interactions of myeloid cells and unique subsets of T cells, including memory cells and $\gamma\delta$ T cells (79,96-100). P-selectin is stored preformed in Weibel-Palade bodies and α -granules of endothelial cells and platelets, respectively (101-104). Upon stimulation with a variety of activators, P-selectin is rapidly expressed within minutes on the cell surface (103,104). In contrast, E-selectin upregulation upon stimulation with cytokines or LPS requires transcriptional activation exhibiting peak expression 4-6 hours after stimulation (105-108). Therefore, P-selectin expression is capable of mediating rolling interactions minutes after stimulation while

E-selectin interactions occur hours after stimulation. Additionally, E-selectin expression is variable depending upon species and anatomic location (109).

Recent *in vitro* results indicate that leukocyte rolling on chronically inflamed endothelium appears to be independent of E- or P-selectin, suggesting novel adhesion systems that mediate leukocyte/endothelial cell interactions (85,109,110). Because of their critical role in the initial leukocyte tethering to endothelium, many investigators have devoted a great deal of time to defining the ligands for each selectin on various target cells.

E-, L-, and P-selectin ligands have been described in several systems. All three selectins bind to both sialyl Lewis a (SLe^a) and sialyl Lewis x (SLe^x) tetrasaccharide structures which are expressed by many different cell types (111-117). Specific high molecular mass glycoproteins present these carbohydrates in appropriate fashion to support cell/cell adhesion (113,118).

E-selectin ligands on myeloid cells have been well defined. Early reports have demonstrated that L-selectin can bind to E-selectin. *In vitro* reports have shown that neutrophil adhesion to inflamed endothelium, which expresses E-selectin, is blocked by anti-L-selectin mAb (119-121). In addition, adhesion of neutrophils on E-selectin-transfected L-cells was inhibited by both anti-E-selectin and anti-L-selectin mAb, suggesting that E-selectin and L-selectin may represent a receptor/counterreceptor pair (119). Of interest, neutrophil but not lymphocyte L-selectin is sLe^x positive and only neutrophil L-selectin binds E-selectin-transfected L1.2 cells (122). Extensive analyses, including reprecipitation experiments, have revealed that neutrophil L-selectin binds to E-selectin (123). More specifically, an affinity-purified E-selectin ligand of 80-90kD was reprecipitated with anti-L-selectin mAb, revealing that soluble L-selectin binds to E-selectin.

Another neutrophil E-selectin ligand, called ESL-1, has recently been described.

ESL-1, a 150kD ligand under reducing conditions and 130kD under nonreducing conditions, was affinity-isolated from mouse myeloid cells (124,125). In these reports, immobilized E-selectin/Ig chimera immunoprecipitated a 150kD ligand from metabolically labeled PMN lysates. In addition, a weak 250kD ligand was also purified from mature neutrophils. Later reports described two additional but weaker E-selectin ligands of 130kD and 230kD on mouse neutrophils, which were also reactive with a P-selectin chimera (125). Furthermore, these authors indicated that human neutrophils possess similar ligands (125).

Since E- and P-selectin bind the same tetrasaccharides, it is possible that E- and P-selectin would bind the same glycoprotein expressing these carbohydrates. Supporting this possibility are recent reports indicating that PSGL-1 (P-selectin glycoprotein ligand-1), a known P-selectin ligand (126-130), can also serve as an E-selectin ligand (124,129-134). Specifically, transfection of CHO cells with PSGL-1 cDNA and a combination of various glycosyltransferase cDNAs conferred binding to E- and P-selectin, indicating that PSGL-1/E-selectin interactions occur (134). In addition, tyrosine sulfation of PSGL-1 seems to be required for binding to P-selectin, but not E-selectin (134). These results suggest that the PSGL-1 protein backbone provides the support upon which post-translational modifications confer selectin binding specificity.

In contrast to neutrophils, far less is known about the glycoprotein ligands for the vascular selectins expressed by lymphocytes. As stated before, E- and P-selectin support interactions of unique subsets of T cells, including memory cells and $\gamma\delta$ T cells (79,96-100). An appropriate post-translationally modified form of PSGL-1 is likely to be the lymphocyte ligand for P-selectin (99,135); however, the lymphocyte ligands for E-selectin are unknown. Lymphocyte PSGL-1 does not appear to interact appreciably with E-selectin (97,136,137), as has been shown with neutrophil PSGL-1 (124,129-134). Indeed, O-sialoglycoprotease treatment of lymphocytes, which

hydrolyzes PSGL-1, blocks their binding to P-selectin, but not E-selectin (97,136,137). Of importance, mAb HECA-452 recognizes the E-selectin-binding human lymphocytes, but HECA-452 staining does not correlate with the P-selectin-binding subset, further distinguishing the two (84,86,136). The HECA-452 epitope is a carbohydrate structure called cutaneous lymphocyte-associated antigen (CLA) that decorates many different cell surface ligands (79) and correlates with E-selectin binding (84,86). This antigen is associated with cutaneous T lymphocytes and HECA-452 specifically blocks the interaction of CLA⁺ T cells with E-selectin-transfected COS cells (79,84,86). In addition, purified CLA coated onto glass supports specific binding of E-selectin-transfected L1.2 cells to CLA (86). Thus, in humans, CLA is capable of binding E-selectin. In initial reports describing HECA-452-reactive antigens, Picker et al. showed that it reacts with 125kD and 200kD glycoproteins on T lymphocytes (79). Which of the different T lymphocyte CLA glycoproteins serve as the predominant E-selectin binding molecule is unknown at this time.

Recently, we showed that virtually all bovine $\gamma\delta$ T cells in newborn animals have the capacity to bind E-selectin (96). In contrast, $\alpha\beta$ T cells acquire this binding capacity only after conversion to a memory phenotype (79,84,100). We isolated a 250kD E-selectin-binding molecule from $\gamma\delta$ T cells by affinity isolation (96) using purified, recombinant E-selectin immobilized on Sepharose beads by a nonblocking anti-E-selectin mAb. Silver staining of the column fractions revealed a 250kD ligand expressed by these cells. In addition, using an in vitro shear-dependent recirculating loop assay developed while studying neutrophil interactions (138,139), we have shown that bovine $\gamma\delta$ T cells bind E- and P-selectin avidly and in newborn calves $\gamma\delta$ T cells are the only lymphocyte population that bind to E-selectin (98).

In pursuit of the bovine E-selectin ligands, we have proposed that lineage-specific cell-surface antigens may represent selectin ligands. More specifically, GD3.5Ag and

WC1, which share biochemical characteristics with other adhesion ligands, may bind E-selectin.

Summary

Historically, lineage-specific cell-surface markers have been shown to be functionally important. Since the discovery of the $\gamma\delta$ T cell, definition of $\gamma\delta$ T cell lineage-specific markers continues to be a topic of interest. Unfortunately, in the past ten years, only two lineage-specific markers have been described on $\gamma\delta$ T cells (WC1 and TCR). Here, I will describe a new lineage-specific $\gamma\delta$ T cell marker (GD3.5Ag) and determine if this marker is an E-selectin ligand.

References

1. Allison, J. P., and L. L. Lanier. 1987. Structure, function, and serology of the T cell antigen receptor complex. *Annu. Rev. Immunol.* 5:503.
2. Allison, J. P., and W. L. Havran. 1991. The immunobiology of T cells with invariant $\gamma\delta$ antigen receptors. *Annu. Rev. Immunol.* 9:679.
3. Hedrick, S. M., D. I. Cohen, E. A. Nielsen, and M. M. Davis. 1984. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. *Nature* 308:149.
4. Yanagi, Y., Y. Yoshikai, K. Leggett, S. P. Clark, I. Aleksander, and T. W. Mak. 1984. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. *Nature* 308:145.
5. Saito, H., D. M. Kranz, Y. Takagaki, A. C. Hayday, H. N. Eisen, and S. Tonegawa. 1984. Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences. *Nature* 309:757.
6. Chien, Y.-H., D. M. Becker, T. Lindsten, M. Okamura, D. I. Cohen, and M. M. Davis. 1984. A third type of murine T cell receptor gene. *Nature* 312:31.
7. Saito, H., D. M. Kranz, Y. Takagaki, A. C. Hayday, H. N. Eisen, and S. Tonegawa. 1984. A third rearranged and expressed gene in a clone of cytotoxic T lymphocytes. *Nature* 312:36.
8. Raulet, D. H. 1989. The structure, function and molecular genetics of the $\gamma\delta$ T cell receptor. *Annu. Rev. Immunol.* 7:175.
9. Raulet, D. H., R. D. Garman, H. Saito, and S. Tonegawa. 1985. Developmental regulation of T-cell receptor gene expression. *Nature* 314:103.
10. Snodgrass, H. R., Z. Dembic, M. Steinmetz, and H. von Boehmer. 1985. Expression of T-cell antigen receptor genes during fetal development in the thymus. *Nature* 315:232.
11. Brenner, M. B., J. McLean, D. Dialynas, J. Strominger, J. A. Smith, F. L. Owen, J. Seidman, S. Ip, F. Rosen, and M. Krahnge. 1986. Identification of a putative second T cell receptor. *Nature* 308:149.
12. Weiss, A., M. Newton, and D. Crompton. 1986. Expression of T3 in association with a molecule distinct from the T-cell antigen receptor heterodimer. *Proc. Natl. Acad. Sci. USA* 83:6998.
13. Lew, A.M., D. M. Pardoll, W. L. Maloy, B. J. Fowlkes, A. Kruisbeek, S.-F. Cheng, R. N. Germain, J. A. Bluestone, R. H. Schwartz, and J. E. Coligan. 1986. Characterization of T-cell receptor gamma chain expression in a subset of murine thymocytes. *Science* 234:1401.

14. Lindsten, T., B. J. Fowlkes, L. E. Samelson, M. M. Davis, and Y.-H. Chien. 1987. Transient rearrangements of the T cell antigen receptor α locus in early thymocytes. *J. Exp. Med.* 166:761.
15. Chien, Y., M. Iwashima, K. B. Kaplan, J. F. Elliott, and M. M. Davis. 1987. A new T-cell receptor gene located within the alpha locus and expressed early in T-cell differentiation. *Nature* 327:677.
16. Ilata, S., M. B. Brenner, and M. S. Krangel. 1987. Identification of putative human T cell receptor δ complementary DNA clones. *Science* 238:678.
17. Weiss, A. 1993. T cell antigen receptor signal transduction: A tale of tails and cytoplasmic protein-tyrosine kinases. *Cell* 73:209.
18. Havran, W. L., and R. Boismenu. 1994. Activation and function of $\gamma\delta$ T cells. *Curr Opin Immunol* 6:442.
19. Malissen, M., A. Gillet, B. Rocha, J. Trucy, E. Vivier, C. Boyer, F. Kontgen, N. Brun, G. Mazza, E. Spanopoulou, D. Guy-Grand, B. Malissen. 1993. T cell development in mice lacking the CD3-z/h gene. *EMBO. J.* 12:4347.
20. Ohno, H., S. Ono, N. Hirayama, S. Shimada, T. Saito. 1994. Preferential usage of the Fc receptor g chain in the T cell antigen receptor complex by $\gamma\delta$ T cells localized in epithelia. *J. Exp. Med.* 179:365.
21. Kuziel, W. A., J. Lewis, J. Nixon-Fulton, R. E. Tigelaar, and P. W. Tucker. 1991. Murine epidermal $\gamma\delta$ T cells express Fc γ receptor II encoded by the FcRa gene. *Eur. J. Immunol.* 21:1563.
22. Roitt, I. M., J. Brostoff, and D. K. Male. 1993. Antigen Recognition. In: *Immunology*, 3rd Ed. Mosby-Europe Limited, London, UK, pp 6.9.
23. Weintraub, B. C., M. R. Jackson, and S. M. Hedrick. 1994. $\gamma\delta$ T cells can recognize nonclassical MHC in the absence of conventional antigenic peptides. *J. Immunol.* 153:3051.
24. Matis, L. A., A. M. Fry, R. Q. Cron, M. M. Cotterman, R. F. Dick, and J. A. Bluestone. 1989. Structure and specificity of a class II MHC alloreactive $\gamma\delta$ T cell receptor heterodimer. *Science* 245:746.
25. Ciccone, E., O. Viale, C. Bottino, D. Pende, N. Migone, G. Casorati, G. Tambussi, A. Moretta, and L. Moretta. 1988. Antigen recognition by human T cell receptor g-positive lymphocytes: specific lysis of allogeneic cells after activation in mixed lymphocyte culture. *J. Exp. Med.* 167:1517.
26. Rivas, A., J. Koide, M. L. Cleary and E. G. Engleman. 1989. Evidence for involvement of the $\gamma\delta$ T cell antigen receptor in cytotoxicity mediated by human alloantigen-specific T cell clones. *J. Immunol.* 142:1840.
27. Schild, H., N. Mavaddat, C. Litzenberger, E. W. Ehrich, M. M. Davis, J. A. Bluestone, L. Matis, R. K. Draper, and Y. Chien. 1994. The nature of major histocompatibility complex recognition by $\gamma\delta$ T cells. *Cell* 76:29.

28. Chien, Y-H, R. Jores, and M. C. Crowley. 1996. Recognition by $\gamma\delta$ T cells. *Annu. Rev. Immunol.* 14:511.
29. Rock, E. P., P. R. Sibbald, M. M. Davis, and Y. Chien. 1994. CDR3 length in antigen-specific immune receptors. *J. Exp. Med.* 179:323.
30. Haas, W. 1993. Gamma/Delta Cells. *Annu. Rev. Immunol.* 11:637.
31. Bukowski, J. F., C. T. Morita, Y. Tanaka, B. R. Bloom, M. B. Brenner, and H. Band. 1995. V γ 2V δ 2 TCR-Dependent recognition of non-peptide antigens and daudi cells analyzed by TCR gene transfer. *J. Immunol.* 154:998.
32. Pfeffer, K., B. Schoel, H. Gulle, S. H. Kaufmann, and H. Wagner. 1990. Primary responses of human T cells to mycobacteria: a frequent set of $\gamma\delta$ T cells are stimulated by protease-resistant ligands. *Eur. J. Immunol.* 20:1175.
33. Pfeffer, K., B. Schoel, N. Plesnila, G. B. Lipford, S. Kromer, K. Deusch, and H. Wagner. 1992. A lectin-binding, protease-resistant mycobacterial ligand specifically activates Vg9+ human $\gamma\delta$ T cells. *J. Immunol.* 148:575.
34. Tanaka, Y., S. Sano, E. Nieves, G. De Libero, D. Rosa, R. Modlin, M. Brenner, B. Bloom, and C. Morita. 1994. Non-peptide ligands of human $\gamma\delta$ T cells. *Proc. Natl. Acad. Sci. USA* 91:8175.
35. De Libero, G. 1997. Sentinel function of broadly reactive human $\gamma\delta$ T cells. *Immunol. Today* 18:22.
36. Haregewoin, A., G. Soman, R. C. Hom, and R. W. Finberg. 1989. Human $\gamma\delta$ + T cells respond to mycobacterial heat-shock protein. *Nature* 340:309.
37. Schoel, B., S. Sprenger, S. H. Kaufmann. 1994. Phosphate is essential for stimulation of V- γ 9V- δ 2 T-lymphocytes by mycobacterial low-molecular-weight ligand. *Eur. J. Immunol.* 24:1886.
38. Mackay, C. R., J. F. Maddox, and M. R. Brandon. 1986. Three distinct subpopulations of sheep T lymphocytes. *Eur. J. Immunol.* 16:19.
39. Mackay, C. R., M. F. Beya, and P. Matzinger. 1989. $\gamma\delta$ T cells express a unique surface molecule appearing late during thymic development. *Eur. J. Immunol.* 19:1477.
40. Davis, W. C., S. Marusic, H. A. Lewin, G. A. Splitter, L. E. Perryman, T. C. McGuire, and J. R. Gorham. 1987. The development and analysis of species specific and cross-reactive monoclonal antibodies to leukocyte differentiation antigens and antigens of the major histocompatibility complex for use in the study of the immune system in cattle and other species. *Vet. Immunol. Immunopathol.* 15:337.
41. Howard, C. J., P. Sopp, K. R. Parsons, and J. Finch. 1989. In vivo depletion of BoT4 (CD4) and non-T4/T8 lymphocyte subsets in cattle with monoclonal antibodies. *Eur. J. Immunol.* 19:757.

42. Morrison, W. I., N. D. MacHugh, A. Bensaid, B. M. Goddeeris, A. J. Teale, and D. J. McKeever. 1988. A monoclonal antibody which reacts specifically with a population of bovine lymphocytes lacking B cell and T cell markers. In: S. Fossum and B. Rolstad (Editors), *Histophysiology of the Immune System*, Plenum Press, New York, NY pp. 591.
43. Clevers, H., N. D. MacHugh, A. Bensaid, S. Dunlap, C. L. Baldwin, A. Kaushal, K. Iams, C. J. Howard and W. I. Morrison. 1990. Identification of a bovine surface antigen uniquely expressed on CD4/CD8-negative, T cell receptor $\gamma\delta$ T lymphocytes. *Eur. J. Immunol.* 20:809.
44. Morrison, W. I., and W. C. Davis. 1991. Differentiation antigens expressed predominantly on CD4/CD8-negative T lymphocytes. *Vet. Immunol. Immunopathol.* 27:71.
45. Wyatt, C. R., C. Madruga, C. Cluff, S. Parish, M. J. Hamilton, W. Goff, and W. C. Davis. 1994. Differential distribution of $\gamma\delta$ T-cell receptor lymphocyte subpopulations in blood and spleen of young and adult cattle. *Vet. Immunol. Immunopathol.* 40:187.
46. Wijngaard, P. L. J., M. J. Metzelaar, N. D. MacHugh, W. I. Morrison and H. C. Clevers. 1992. Molecular characterization of the WC1 antigen expressed specifically on bovine CD4/CD8-negative $\gamma\delta$ T-lymphocytes. *J. Immunol.* 149:3273.
47. MacHugh, N. D., P. L. J. Wijngaard, H. C. Clevers, and W. C. Davis. 1993. Clustering of monoclonal antibodies recognizing different members of the WC1 gene family. *Vet Immunol. Immunopathol.* 39:155.
48. Crocker, G., P. Sopp, K. Parsons, W. C. Davis and C. J. Howard. 1993. Analysis of the $\gamma\delta$ T cell restricted antigen WC1. 1991. *Vet. Immunol. Immunopathol.* 39:137.
49. Wijngaard, P. L. J., N. K. MacHugh, M. J. Metzelaar, S. Romberg, A. Bensaid, L. Pepin, W. C. Davis, and H. C. Clevers. 1994. Members of the novel WC1 gene family are differentially expressed on subsets of bovine CD4/CD8-negative $\gamma\delta$ T lymphocytes. *J. Immunol.* 152:3476.
50. Hein, W. R., and C. R. Mackay. 1991. Prominence of $\gamma\delta$ T cells in the ruminant immune system. *Immunol. Today* 12:30.
51. Hanby-Florida, M. D., O. J. Trask, T. J. Yang, and C. L. Baldwin. 1996. Modulation of WC1, a lineage-specific cell surface molecule of $\gamma\delta$ T cells, augments cellular proliferation. *Immunol.* 88:116.
52. Takamatsu, H.-H., P. A. Kirkham, and R. M. E. Parkhouse. 1997. A $\gamma\delta$ T cell specific receptor (WC1) signaling G0/G1 cell cycle arrest. *Eur. J. Immunol.* 27:105.
53. Mackay, C.R., and W. R. Hein. 1989. A large proportion of bovine T cells express the $\gamma\delta$ T cell receptor and show a distinct tissue distribution and surface phenotype. *Inter. Immunol.* 1:540.

54. Mackay, C. R., and W. R. Hein. 1990. Analysis of $\gamma\delta$ T cells in ruminants reveals further heterogeneity in $\gamma\delta$ T-cell features and function among species. *Research Immunol.* 141:611.
55. Doherty, M. L., and H. F. Bassett, P. J. Quinn, W. C. Davis, A. P. Kelly, and M. L. Monaghan. 1996. A sequential study of the bovine tuberculin reaction. *Immunol.* 87:9.
56. Bonneville, M., C. A. Janeway, K. Ito, W. Haser, I. Ishida, N. Nakanishi, and S. Tonegawa. 1988. Intestinal intraepithelial lymphocytes are a distinct set of gamma delta T cells. *Nature* 336:497.
57. Goodman, T., and L. Lefrancois. 1988. Expression of the gamma-delta T-cell receptor on intestinal CD8+ intraepithelial lymphocytes. *Nature* 333:855.
58. Itohara, S., A. G. Farr, J. J. Lafaille, M. Bonneville, Y. Takagake, W. Haas, and S. Tonegawa. 1990. Homing of a $\gamma\delta$ thymocyte subset with homogenous T-cell receptors to mucosal epithelia. *Nature* 343:754.
59. Kronenberg, M., 1994. Antigens recognized by $\gamma\delta$ T cells. *Curr Opin Immunol.* 6:64.
60. Asanow, D. M., T. Goodman, L. LeFrancois, and J. P. Allison. 1989. Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells. *Nature* 341:60.
61. Vietor, H., and F. Koning. 1990. $\gamma\delta$ T-cell receptor repertoire in human peripheral blood and thymus. *Immunogenetics* 31:340.
62. Breit, T. M., I. L. M. Wolvers-Tettero, and J. J. M. van Dongen. 1994. Unique selection determinant in polyclonal V δ 2-J δ 1 junctional regions of human peripheral $\gamma\delta$ T lymphocytes. *J. Immunol.* 152:2860.
63. Tsuji, M., P. Mombaerts, L. LeFrancois, R. S. Nussenzweig, F. Zavala, and S. Tonegawa. 1994. $\gamma\delta$ T cells contribute to immunity against the liver stages of malaria in $\alpha\beta$ T-cell-deficient mice. *Proc. Natl. Acad. Sci.* 91:345.
64. Mombaerts, P., J. Arnoldi, F. Russ, S. Tonegawa, and S. H. E. Kaufmann. 1993. Different roles of $\alpha\beta$ and $\gamma\delta$ T cells in immunity against an intracellular bacterial pathogen. *Nature* 365:53.
65. Kaufmann, S. H. E., and C. H. Ladel. 1994. Role of T cell subsets in immunity against intracellular bacteria: experimental infections of knock-out mice with *Listeria monocytogenes* and *Mycobacterium bovis* BCG. *Immunobiol.* 191:509.
66. Bukowski, J. F., C. T. Morita, and M. B. Brenner. 1994. Recognition and destruction of virus-infected cells by human $\gamma\delta$ CTL. *J. Immunol.* 153:5133.
67. Wallace, M., M. Malkovsky, and S. R. Carding. 1995. Gamma/delta T lymphocytes in viral infections. *J. Leuk. Biol.* 58:277.

68. Carlos, T. M., and J. M. Harlan. 1994. Leukocyte-endothelial adhesion molecules. *Blood* 84:2068.
69. Berg, E. L., M. K. Robinson, R. A. Warnock, and E. C. Butcher. 1991. The human peripheral lymph node vascular addressin is a ligand for LECAM-1, the peripheral lymph node homing receptor. *J. Cell. Biol.* 114:343.
70. Streeter, P. R., B. T. N. Rouse, and E. C. Butcher. 1988. Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes. *J. Cell Biol.* 107:853.
71. Arbones, M. L., D. C. Ord, K. Ley, H. Ratech, C. Maynard-Curry, G. Otten, D. J. Capon, and T. F. Tedder. 1994. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. *Immunity* 1:247.
72. Dianzani, U., and F. Malavas. 1995. Lymphocyte adhesion to endothelium. *Critical Rev. Immunol.* 15:167.
73. Butcher, E. C., and L. J. Picker. 1996. Lymphocyte homing and homeostasis. *Science* 272:60.
74. Bargatze, R. F., M. A. Jutila, and E. C. Butcher. 1995. Distinct roles of L-selectin and integrins $\alpha 4\beta 7$ and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined. *Immunity* 3:99.
75. Berg, E. L., L. M. McEvoy, C. Berlin, R. F. Bargatze, and E. C. Butcher. 1993. L-selectin mediated lymphocyte rolling in MAdCAM-1. *Nature* 366:695.
76. Mackay, C. R., W. L. Marston, L. Dudler. 1990. Naïve and memory T cells show distinct pathways of lymphocyte recirculation. *J. Exp. Med.* 171:801.
77. Mackay, C. R. 1991. T-cell memory: the connection between function, phenotype and migration pathways. *Immunol. Today* 12:189.
78. Picker, L. J., L. W. Terstappen, L. S. Rott, P. R. Streeter, H. Stein, and E. C. Butcher. 1990. Differential expression of homing-associated adhesion molecules by T cell subsets in man. *J. Immunol.* 145:3247.
79. Picker, L. J., S. A. Michie, L. S. Rott, and E. C. Butcher. 1990. A unique phenotype of skin-associated lymphocytes in humans. *Am. J. Pathol.* 136:1053.
80. Schweighoffer, T., Y. Tanaka, M. Tidswell, D. J. Erie, K. J. Horgan, G. E. Luce, A. I. Lazarovitz, D. Buck, and S. Shaw. 1993. Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with hallmarks of gut-trophism. *J. Immunol.* 151:717.
81. Salmi, M., K. Granfors, M. Leirisalo-Repo, M. Hamalainen, R. MacDermott, R. Leino, T. Havia, and S. Jalkanen. 1992. Selective endothelial binding of interleukin-2-dependent human T-cell lines derived from different tissues. *Proc. Natl. Acad. Sci. U.S.A.* 89:11436.

82. Mackay, C. R., W. L. Marston, L. Dudler, O. Spertini, T. F. Tedder, and W. R. Hein. 1992. Tissue-specific migration pathways by phenotypically distinct subpopulations of memory T cells. *Eur. J. Immunol.* 22:887.
83. Picker, L. J. 1993. Regulation of tissue-selective T-lymphocyte homing receptors during the virgin to memory/effector cell transition in human secondary lymphoid tissue. *Am. Rev. Respir. Dis.* 148:S47.
84. Picker, L. J., T. K. Kishimoto, C. W. Smith, R. A. Warnock, and E. C. Butcher. 1991. ELAM-1 is an adhesion molecule for skin-homing T cells. *Nature* 349:796.
85. Jones, D. A., L. V. McIntire, C. W. Smith, and L. J. Picker. 1994. A two-step adhesion cascade for T cell/endothelial cell interactions under flow conditions. *J. Clin. Invest.* 94:2443.
86. Berg, E. L., T. Yoshino, L. S. Rott, M. K. Robinson, R. A. Warnock, T. K. Kishimoto, L. J. Picker, and E. C. Butcher. 1991. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. *J. Exp. Med.* 174:1461.
87. Austrup, F., D. Vestweber, E. Borges, M. Lohning, R. Brauer, U. Herz, H. Renz, R. Hallmann, A. Scheffold, A. Radbruch, and A. Hamann. 1997. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. *Nature* 385:81.
88. Borges, E., W. Tietz, M. Steegmaier, T. Moll, R. Hallmann, A. Hamann, and D. Vestweber. 1997. P-selectin glycoprotein ligand-1 (PSGL-1) on T helper 1 but not on T helper 2 cells binds to P-selectin and supports migration into inflamed skin. *J. Exp. Med.* 185:573.
89. Berlin, C., R. F. Bargatze, J. J. Campbell, U. H. von Adrian, M. C. Szabo, S. R. Hasslen, R. D. Nelson, E. L. Berg, S. L. Erlandsen, and E. C. Butcher. 1995. $\alpha 4$ integrins mediate lymphocyte attachment and rolling under physiologic flow. *Cell* 80:413.
90. Bembridge, G. P., N. D. MacHugh, D. McKeever, E. Awino, P. Sopp, R. A. Collins, K. I. Gelder, and C. J. Howard. 1995. CD45RO expression on bovine T cells: relation to biological function. *Immunol.* 86:537.
91. Shimizu, Y., W. Newman, Y. Tanaka, and S. Shaw. 1992. Lymphocyte interactions with endothelial cells. *Immunol. Today.* 13:106.
92. Butcher, E. C. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. *Cell.* 67:1033.
93. Tedder, T. F., D. A. Steeber, A. Shen, and P. Engel. 1995. The selectins: vascular adhesion molecules. *FASEB J.* 9:866.
94. Bevilacqua, M. P. 1993. Endothelial-leukocyte adhesion molecules. *Annu. Rev. Immunol.* 11:767.
95. Bevilacqua, M. P., and R. M. Nelson. 1993. Selectins. *J. Clin. Invest.* 91:379.

96. Walcheck, B., G. Watts, and M. A. Jutila. 1993. Bovine $\gamma\delta$ T cells bind E-selectin via a novel glycoprotein receptor: First characterization of a lymphocyte/E-selectin interaction in an animal model. *J. Exp. Med.* 178:853.
97. Diacovo, T. G., S. J. Roth, C. T. Morita, J.-P. Rosat, M. B. Brenner, and T. A. Springer. 1996. Interactions of human α/β and $\gamma\delta$ T lymphocyte subsets in shear flow with E-selectin and P-selectin. *J. Exp. Med.* 183:1193.
98. Jutila, M. A., R. F. Bargatze, S. Kurk, R. A. Warnock, N. Ehsani, S. R. Watson, and B. Walcheck. 1994. Cell surface P- and E-selectin support shear-dependent rolling of bovine $\gamma\delta$ T cells. *J. Immunol.* 153:3917.
99. Moore, K. L., and L. F. Thompson. 1992. P-selectin (CD62) binds to subpopulations of human memory T lymphocytes and natural killer cells. *Biochem. Biophys. Res. Commun.* 1186:173.
100. Shimizu, Y., S. Shaw, N. Graber, T. V. Gopal, K. J. Horgan, G. A. Van Seventer, and W. Newman. 1991. Activation-independent binding of human memory T cells to adhesion molecule ELAM-1. *Nature* 349:799.
101. Hsu-Lin, S. C., C. L. Berman, B. C. Furie, D. August, and B. Furie. 1984. A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets. *J. Biol. Chem.* 259:9121.
102. Stenberg, P. E., R. P. McEver, M. A. Shuman, Y. V. Jacques, and D. F. Bainton. 1985. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. *J. Cell Biol.* 101:880.
103. McEver, R. P., J. H. Beckstead, K. L. Moore, L. Marshal-Carlson, and D. F. Bainton. 1989. GMP-140, a platelet alpha granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. *J. Clin. Invest.* 84:92.
104. Bonfanti, R., B. C. Furie, B. Furie, and D. D. Wagner. 1989. PADGEM (GMP-140) is a component of Weibel-Palade bodies of human endothelial cells. *Blood* 73:1109.
105. Bevilacqua, M. P., J. S. Pober, D. L. Mendrick, R. S. Cotran, and M. A. Gimbrone, Jr. 1987. Identification of an inducible endothelial-leukocyte adhesion molecule. *Proc. Natl. Acad. Sci. USA* 84:9238.
106. Bevilacqua, M. P., J. S. Pober, M. E. Wheeler, R. S. Cotran, and M. A. Gimbrone, Jr. 1985. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. *J. Clin. Invest.* 76:2003.
107. Pober, J. S., M. P. Bevilacqua, D. L. Mendrick, L. A. Lapierre, W. Fiers, and M. A. Gimbrone, Jr. 1986. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. *J. Immunol.* 136:1680.

108. Cotran, R. S., M. A. Gimbrone, Jr., M. P. Bevilacqua, D. L. Mendrick, and J. S. Pober. 1986. Induction and detection of a human endothelial activation antigen in vivo. *J. Exp. Med.* 164:661.
109. Jutila, M. A., E. Wilson, and S. Kurk. 1997. Characterization of an adhesion molecule that mediates leukocyte rolling on 24-hr cytokine or LPS-activated endothelial cells under flow conditions. Submitted to The Journal of Experimental Medicine.
110. Jones, D. A., C. W. Smith, L. J. Picker, and L. V. McIntire. 1996. Neutrophil adhesion to 24-hr IL-1 stimulated endothelial cells under flow conditions. *J. Immunol.* 157:858.
111. Berg, E. L., M. K. Robinson, O. Mansson, E. C. Butcher, and J. L. Magnani. 1991. A carbohydrate domain common to both sialyl Lea and sialyl Lex is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. *J. Biol. Chem.* 266:14869.
112. Berg, E. L., J. Magnani, R. A. Warnock, M. K. Robinson, and E. C. Butcher. 1992. Comparison of L-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Lex and sialyl Lea. *Biochem. Biophys. Res. Commun.* 184:1048.
113. Polley, M. J., M. L. Phillips, E. Wayner, E. Nudelman, A. K. Singhal, S.-I. Hakomori, and J. C. Paulson. 1991. CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl Lex. *Proc. Natl. Acad. Sci, USA.* 88:6224.
114. Phillips, M. L., E. Nudelman, F. C. A. Gaeta, M. Perez, A. K. Singhal, S.-I. Hakomori, and J. C. Paulson. 1990. ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl Lex. *Science* 250:1130.
115. Foxall, C., S. R. Watson, D. Dowbenko, C. Fennie, L. A. Lasky, M. Kiso, A. Hasegawa, D. Asa, and B. K. Brandley. 1992. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewisx oligosaccharide. *J. Cell Biol.* 117:895.
116. Handa, K., E. D. Nudelman, M. R. Stroud, T. Shiozawa, and S.-I. Hakomori. 1991. Selectin GMP-140 (CD62; PADGEM) binds to sialosyl-Lea and sialosyl-Lex, and sulfated glycans modulate this binding. *Biochem. Biophys. Res. Commun.* 181:1223.
117. Tyrrell, D., P. James, B. N. Narasinga Rao, C. Foxall, S. Abbas, F. Dasgupta, M. Nashed, A. Hasegawa, M. Kiso, D. Asa, J. Kidd, and B. K. Brandley. 1991. Structural requirements for the carbohydrate ligand of E-selectin. *Proc. Natl. Acad. Sci. USA.* 88:10372.
118. Larsen, G. R., D. Sako, T. J. Ahern, M. Shaffer, J. Erban, S. A. Sajer, R. M. Gibson, D. D. Wagner, B. C. Furie, and B. Furie. 1992. P-selectin and E-selectin: Distinct but overlapping leukocyte ligand specificities. *J. Biol. Chem.* 267:11104.

119. Kishimoto, T. K., R. A. Warnock, M. A. Jutila, E. C. Butcher, C. Lane, D. C. Anderson, and C. W. Smith. 1991. Antibodies against human neutrophil LECAM-1 (LAM-1/Leu-8/DREG-56 antigen) and endothelial cell ELAM-1 inhibit a common CD18-independent adhesion pathway in vitro. *Blood* 78:805.
120. Hallman, R., M. A. Jutila, C. W. Smith, D. C. Anderson, T. K. Kishimoto, and E. C. Butcher. 1991. The peripheral lymph node homing receptor, LECAM-1, is involved in CD18-independent adhesion of human neutrophils to endothelium. *Biochem. Biophys. Res. Comm.* 174:236.
121. Smith, C. W., T. K. Kishimoto, O. Abbass, B. Hughes, R. Rothlein, L. V. McIntire, E. Butcher, and D. C. Anderson. 1991. Chemotactic factors regulate lectin adhesion molecule 1 (LECAM-1)-dependent neutrophil adhesion to cytokine-stimulated endothelial cells in vitro. *J. Clin. Invest.* 87:609.
122. Picker, L. J., R. A. Warnock, A. B. Burns, C. M. Doerschuk, E. L. Berg, and E. C. Butcher. 1991. The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. *Cell* 66:921.
123. Zöllner, O., M. C. Lenter, J. E. Blanks, E. Borges, M. Steegmaier, H-G. Zerwes, and D. Vestweber. 1997. L-selectin from human, but not from mouse neutrophils binds directly to E-selectin. *J. Cell Biol.* 136:707.
124. Levinovitz, A., J. Muhlhoff, S. Isenmann, and D. Vestweber. 1993. Identification of a glycoprotein ligand for E-selectin on mouse myeloid cells. *J. Cell Biol.* 121:449.
125. Lenter, M., A. Levinovitz, S. Isenmann, and D. Vestweber. 1994. Monospecific and common ligands for E- and P-selectin on myeloid cells. *J. Cell Biol.* 125:471.
126. Moore, K. L., N. L. Stults, S. Diaz, D. F. Smith, R. D. Cummings, A. Varki, and R. P. McEver. 1992. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. *J. Cell Biol.* 118:445.
127. Moore, K. L., A. Varki, R. P. McEver. 1991. GMP-140 binds to a glycoprotein receptor on human neutrophils: evidence for a lectin-like interaction. *J. Cell Biol.* 112:491.
128. Norgard, K. E., K. L. Moore, S. Diaz, N. L. Stults, S. Ushiyama, R. P. McEver, R. D. Cummings, and A. Varki. 1993. Characterization of a specific ligand for P-selectin on myeloid cells. *J. Biol. Chem.* 268:12764.
129. Sako, D., X.-J. Chang, K. M. Barone, G. Vachino, H. M. White, G. Shaw, G. M. Veldman, K. M. Bean, T. J. Ahern, B. Furie, D. A. Cumming, and G. R. Larsen. 1993. Expression cloning of a functional glycoprotein ligand for P-selectin. *Cell* 75:1179.
130. Sako, D., K. M. Comess, K. M. Barone, R. T. Camphausen, D. A. Cumming, and G. D. Shaw. 1995. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. *Cell* 83:323.

131. Moore, K. L., S. F. Eaton, D. A. Lyons, H. S. Lichenstein, R. D. Cummings, and R. P. McEver. 1994. The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N-acetylactosamine. *J. Biol. Chem.* 269:23318.
132. Asa, D., L. Raycroft, L. Ma, P. A. Aeed, P. S. Kaytes, A. P. Elhammer, and J.-G. Geng. 1995. The P-selectin glycoprotein ligand functions as a common human leukocyte ligand for P- and E-selectins. *J. Biol. Chem.* 270:11662.
133. Patel, K. D., K. L. Moore, M. U. Nollert, and R. P. McEver. 1995. Neutrophils use both shared and distinct mechanisms to adhere to selectins under static and flow conditions. *J. Clin. Invest.* 96:1887.
134. Li, F., P. P. Wilkins, S. Crawley, J. Weinstein, R. D. Cummings, R. P. McEver. 1996. Post-translational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin. *J. Biol. Chem.* 271:3255.
135. Vachino, G., X.-J. Chang, G. M. Veldman, R. Kumar, D. Sako, L. A. Fouser, M. C. Berndt, and D. A. Cumming. 1995. P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells. *J. Biol. Chem.* 270:21966.
136. Alon, R., H. Rossiter, X. Wang, T. A. Springer, and T. S. Kupper. 1994. Distinct cell surface ligands mediate T lymphocyte attachment and rolling on P and E selectin under physiological flow. *J. Cell Biol.* 127:1485-1494.
137. Jutila, M. A., and S. Kurk. 1996. Analysis of bovine $\gamma\delta$ T cell interactions with E-, P-, and L-selectin: characterization of lymphocyte on lymphocyte rolling and the effects of O-glycoprotease. *J. Immunol.* 156:289.
138. Bargatze, R. F., S. Kurk, G. Watts, T. K. Kishimoto, C. A. Speer, and M. A. Jutila. 1994. In vivo and in vitro functional examination of a conserved epitope of L- and E-selectin crucial for leukocyte-endothelial cell interactions. *J. Immunol.* 152:5814.
139. Bargatze, R. F., S. Kurk, E. C. Butcher, and M. A. Jutila. 1994. Neutrophils roll on adherent neutrophils bound to cytokine-induced endothelial cells via L-selectin on the rolling cells. *J. Exp. Med.* 180:1785-1792.

CHAPTER 2

GENERATION OF A NEW $\gamma\delta$ T CELL-SPECIFIC MONOCLONAL ANTIBODY (GD3.5): BIOCHEMICAL COMPARISONS OF GD3.5 ANTIGEN WITH THE PREVIOUSLY DESCRIBED WC1 FAMILY

Introduction

Although gamma/delta ($\gamma\delta$) T cells were discovered a decade ago, their specific biological function has yet to be fully defined. Some suggest that these cells contribute to the initial host response to various infectious agents, which include parasitic, bacterial, and viral pathogens, forming what is referred to as "the first line of defense" (1-3). This hypothesis is consistent with their anatomical location at the portals of entry in nonlymphatic tissues, such as the skin and gut (4-6). In studies using $\gamma\delta$ or $\alpha\beta$ T-cell-deficient mice, the role of $\gamma\delta$ T cells in malarial infection appears to occur during initial host responses against the liver-stage of parasite development (1). In another report, β_2 microglobulin-deficient mice infected with live avirulent mycobacteria appear to respond with increased numbers of $\gamma\delta$ T cells when compared to normal mice indicating that these cells may possess an early compensatory function in the absence of MHC I molecular expression (2). Further reports indicate that $\gamma\delta$ T cells respond to and destroy virally infected target cells (3).

Although $\gamma\delta$ T cells that react with classical MHC I and II have been isolated, they appear to react with other nonclassical MHC gene products, possibly providing a faster and more encompassing immunological response (7-10). Several reports suggest that $\gamma\delta$ T cells may recognize "unconventional" antigens, such as nonpeptide (carbohydrate) antigens and heat-shock proteins (11-16). Recent reports indicate that $\gamma\delta$ T cell antigen recognition may be independent of antigen processing, suggesting a direct recognition event (17).

Historically, lineage-specific cell surface markers have been indispensable in describing various cell functions. In the case of $\gamma\delta$ T cells, only one non-TCR lineage-specific marker (SBU-T19), originally described in sheep, has been defined (4,18). This marker, later demonstrated in cattle, goats, pigs, horses, humans and rodents, is collectively called WC1 (6,19-26). Bovine genomic DNA contains several similar sequences to WC1, suggesting the potential for a WC1 gene family (23). Three WC1 isotypes have been identified to date (23,26) and the IL-A29 monoclonal antibody recognizes all three native species, including gene products of the 3 WC1 cDNAs. At the protein level, bovine WC1 exhibits bands at approximately 215kD and 300kD under reducing conditions (recognized by IL-A29); while under nonreducing conditions, the smaller band migrates somewhat faster (200kD) (4,6,22,23,25,27). WC1 is clearly distinguishable from $\gamma\delta$ TCR which migrates at approximately 45kD under reducing and 70-75kD under nonreducing conditions. Unfortunately, little is known about the function of WC1. Some speculate that WC1 may play a role similar to CD4 and CD8, while others suggest the expression of different WC1 isotypes may provide a mechanism for tissue-specific homing (4,23,26,28).

We have sought the identification of additional lineage-specific markers to better study $\gamma\delta$ T cell function. We chose the bovine model because $\gamma\delta$ T cells represent a major portion of the circulating T cell pool in neonates; thus, their biological function may be

more easily studied. We have raised many specific monoclonal antibodies against purified $\gamma\delta$ T cells with most being shown to recognize either WC1 or TCR. In this report, we provide the characterization of one antibody (GD3.5) that recognizes a $\gamma\delta$ T cell-restricted surface antigen that is distinct from IL-A29-reactive WC1 and TCR. GD3.5 stains approximately 90% of the circulating $\gamma\delta$ T cell population. SDS-PAGE analysis indicates that GD3.5 antigen migrates slightly slower than WC1 under nonreducing conditions and does not exhibit a 300kD band. Crossprecipitation experiments indicate that mAb GD3.5 and mAb IL-A29 immunoprecipitate distinct molecules that exhibit distinct proteolytic digestion profiles. Glycosidase and endopeptidase treatment further characterize and distinguish GD3.5 antigen and WC1 demonstrating unique profiles. Interestingly, GD3.5 antigen and WC1 are sensitive to O-sialoglycoprotease treatment indicating that these molecules possess sialomucin-like characteristics. In addition, GD3.5 is exquisitely sensitive to low-dose α -chymotrypsin, while WC1 is resistant to equivalent protease concentrations.

Materials and Methods

$\gamma\delta$ T cell purification and ^{125}I labeling

Blood was obtained by jugular venipuncture from Holstein calves housed at the Montana State University Large Animal Facility. Lymphocytes were purified by Histopaque gradient centrifugation (Sigma Chemical Co., St. Louis, MO). Lymphocytes were resuspended in HBSS and platelets were removed by Percoll gradient centrifugation (Sigma Chemical Co., St. Louis, MO) with subsequent incubation of lymphocytes in T175 flasks for 30min at 37°C to allow monocytes to adhere and be removed from suspension. $\gamma\delta$ T cell lymphocytes were purified from whole lymphocytes by incubation for 30min at RT in T175 flasks coated with 7×10^6 adherent E-selectin L-cell transfectants.

Remaining unbound cells were discarded and bound $\gamma\delta$ T cells lifted with 2mM EDTA (29). This purification protocol provided >90% pure $\gamma\delta$ T cells (29). 1×10^8 purified $\gamma\delta$ T cells were Na^{125}I (ICN Biomedicals, Inc., Irvine, CA)/lactoperoxidase-labeled according to published methods (30) and lysed for 30min on ice with NP40 lysis buffer (2% NP-40, 100mM NaCl, 1mM MgCl_2 , 1mM CaCl_2 , 5mM NaN_3 , 10mM Hepes, and protease inhibitors: pepstatin A, 1,10-phenanthroline, phenylmethylsulfonyl fluoride, benzamidine, antipain, leupeptin, and chymostatin (Sigma Chemical Co., St. Louis, MO).

mAbs and FACS analysis

Monoclonal antibodies used included IL-A29 (anti-WC1) and two mouse mAbs CC21 (145kD B-cell marker) and CC42 ($\alpha\beta$ T cell-CD2) that recognize bovine and caprine lymphocytes (kindly provided by Chris Howard, Institute for Animal Health, Compton, UK). In house mAbs, GD3.5, GD3.8, and GD197 were produced by immunization (i.p.) of Balb/C mice with 6×10^7 purified $\gamma\delta$ T cells in Gerbu Adjuvant (Biotech, Poway, CA). Mouse serum was screened by FACS analysis to determine reactivity with $\gamma\delta$ T cells after two weeks. Two subsequent immunizations were performed as described at two week intervals. After the third immunization, mouse spleens were aseptically removed 72hrs later and fused as described (31). Fusion wells containing hybrids that positively stained $\gamma\delta$ T cells by FACS analysis were subsequently subcloned and screened by FACS analysis. mAb production resulted in various $\gamma\delta$ T cell-positive mAbs including GD3.5, GD197 ($\gamma\delta$ TCR), and GD3.8 (pan- $\gamma\delta$ TCR) (B. Walcheck and M.A. Jutila, unpublished observations; and Wilson, E. et al., manuscript in preparation).

FACS analysis was performed on ice as follows: cells were blocked with 2% horse serum/PBS for 10min, washed, and incubated with appropriate primary Ab for 30min. Cells were washed and incubated with appropriate FITC-conjugated or PE-conjugated

goat α -mouse secondary Ab (Jackson ImmunoResearch, West Grove, PA) for 30min, washed again, and analyzed. Two-color analysis was performed using PE-conjugated secondary Ab followed by a 10min block with 10% mouse serum and subsequent 30min incubation with FITC-conjugated second-stage Ab. All analyses were performed using a FACScan flow cytometer (Becton Dickinson).

Western Blot

Purified $\gamma\delta$ T cells were lysed with NP-40 lysis buffer (see above), mixed with nonreducing loading buffer and electrophoresed through 8% polyacrylamide gels. Gels were transferred to nitrocellulose (NC) overnight. Resulting NC was washed, blocked for 30min with horse serum, washed again, and placed in a Miniblotter 25 (Immunetics, Cambridge, MA). Lanes were loaded with GD3.5 or IL-A29 supernatants and incubated for 30min. Primary antibody was washed away and α -mouse alkaline phosphatase-conjugated second stage (Sigma Immuno Chemicals, St. Louis MO) applied for 30min. The NC was washed and removed from Miniblotter 25 and developed to desired intensity using Nitro Blue Tetrazolium and 5-Bromo-4-Chloro-3-Indolyl Phosphate (Sigma Chemical Co., St. Louis, MO) in AP buffer (100mM Tris pH 9.5, 100mM NaCl, and 5mM $MgCl_2$).

Immunoprecipitation/Crossprecipitation

To eliminate nonspecific protein interactions, ^{125}I -labeled lysates were incubated for 1hr at RT with 5% rabbit serum and then incubated at 4°C with protein G beads (Boehringer Mannheim Biochemicals, Indianapolis, IN). After overnight incubation, protein G beads were removed and lysates were used in subsequent procedures. Precleared lysates were incubated with 75ug/ml GD3.5 or IL-A29 for 1hr at RT. Ab/Ag complexes were precipitated with protein G at 4°C overnight. Several subsequent

clearing steps with protein G were performed on the lysates to insure removal of all Ab/Ag complexes. IL-A29 and GD3.5 mAbs were added to lysates which had been cleared of GD3.5 and WC1 Ab/Ag complexes, respectively. Ab/Ag complexes were precipitated as described earlier and mixed with standard 2x reducing or nonreducing loading buffer, boiled for two minutes, and loaded onto 8% SDS-polyacrylamide gels. Gels were electrophoresed and dried at 80°C. Gels were exposed 1-2 weeks in a phosphorimaging storage cassette, and images were developed using a phosphorimager (both from Molecular Dynamics).

V-8 protease peptide mapping

¹²⁵I-labeled $\gamma\delta$ T cell lysates, described above, were prepared and immunoprecipitated with IL-A29 and GD3.5. IL-A29 or GD3.5 immunoprecipitates were mixed with reducing buffer, boiled for two minutes, cooled to RT and centrifuged to remove beads. Supernatants were aliquoted (25ul) and incubated with 10, 50, and 100ng of V-8 protease for 40min at RT, loaded, and electrophoresed. Gels were dried at 80°C and exposed/developed using the MD phosphorimager, as described above.

Enzymatic deglycosylation of GD3.5 antigen and WC1

¹²⁵I-labeled $\gamma\delta$ T cell lysates, described above, were prepared and immunoprecipitated with 30ug of IL-A29 or GD3.5. Immunoprecipitates were boiled for 3min after adding 80ul 50mM pH 6.0 phosphate buffer, 20ul 1% SDS, and 20ul .5M β -mercaptoethanol (Sigma Chemical Co., St. Louis, MO) and cooled to RT. After cooling, 35ul 200mM pH 6.0 phosphate buffer, 5ul 100mM CaCl₂, and 40ul 10% NP40 (Sigma Chemical Co., St. Louis, MO) were added to each reaction which were then centrifuged and the supernatants aliquoted (35ul) for treatment with 0.2U PNGase F (Boehringer Mannheim Biochemicals, Indianapolis, IN), 9.6ug O-sialoglycoprotein endopeptidase/O-

sialoglycoprotease (Accurate Chemical & Scientific Corp., Westbury, NY), or 2mU neuraminidase (Boehringer Mannheim Biochemicals, Indianapolis, IN). Aliquots of GD3.5 antigen and WC1 were adjusted to pH 6.0 (control and neuraminidase) or pH 7.4 (PNGase F and O-sialoglycoprotease) with 15ul of 500mM phosphate buffer, mixed with appropriate amount of enzyme, and incubated overnight at 37°C (13-15hrs). Reactions were stopped with 6x reducing loading buffer, boiled for 3min and electrophoresed. Gels were dried at 80°C and exposed/developed using the MD phosphorimager, as described above.

Chymotrypsin Sensitivity Assay

Lymphocytes were purified as described above. Cells (1×10^7) were resuspended in HBSS with Ca^{2+} and Mg^{2+} and 0, 62.5, 125, or 250 mU α -chymotrypsin (Sigma Chemical Co., St. Louis, MO)/ml and incubated for 1hr at 37°C (32). After completion of incubation, cells were washed with 2% horse serum/PBS and analyzed by single-color indirect FACS analysis for GD3.5 antigen and WC1 using PE-conjugated second stage, as described earlier.

Results

Surface expression of the GD3.5 antigen on bovine lymphocytes

GD3.5 was originally identified by flow cytometric analysis as a $\gamma\delta$ T cell-specific staining monoclonal antibody (See Materials and Methods mAb production and see below). Using two-color FACS analysis, we determined the staining characteristics of GD3.5 on bovine peripheral blood lymphocytes. Cells were stained with GD3.5, IL-A29 (WC1), CC21 (B-Cell) or CC42 ($\alpha\beta$ T cell), followed by a PE secondary Ab, and then stained with FITC-labeled GD3.5 or GD3.8 mAb. As shown in Figure 1A, GD3.5 stained 91.8% of

the total GD3.8 (pan-TCR) $\gamma\delta$ T cell population. In comparison, panel 1B shows that IL-A29 stained 78% of the total $\gamma\delta$ T cell population. Figure 1C indicates that a substantial percentage of the GD3.5-positive population was WC1 negative. Additionally, single-color FACS analysis further supported the two-color data indicating that GD3.5 stains approximately 90% of the total $\gamma\delta$ T cell population while IL-A29 stained 70-80% of the total $\gamma\delta$ T cell population (data not shown). To further demonstrate that GD3.5 specifically stained $\gamma\delta$ T cells, cells were stained with B-cell (CC21) or $\alpha\beta$ T cell (CC42) mAbs. Figure 1D and 1E illustrate that GD3.5 stained a population of lymphocytes that were distinct from both B cells (CC21) and $\alpha\beta$ T cells (CC42). Furthermore, using the distinguishing light-scatter profiles of neutrophils and monocytes, gated FACS analysis of these cell populations in whole bovine leukocyte preparations revealed that mAbs GD3.5 and GD3.8 did not stain either cell population (data not shown).

Using single-color FACS analysis of peripheral blood, crossreactivity was determined using dog, horse, human, sheep, pig, and rabbit. GD3.5 crossreacted only with the sheep lymphocytes (data not shown).

Western Blot and immunoprecipitation analysis of the GD3.5 antigen

Western blot analysis was done to determine a Mr for the GD3.5 antigen. As shown in lanes 3 and 4 of Figure 2, GD3.5 recognized a single band migrating at 220-240kD under nonreducing conditions. Interestingly, using this technique sometimes resulted in a single GD3.5-reactive band at approximately 80kD which is likely due to the exquisite sensitivity of GD3.5 antigen to proteolysis (data not shown and see Figure 7). In comparison, lanes 5 and 6 show bands recognized by IL-A29 (anti-WC1) at 200-220kD and 300kD under nonreducing conditions. Therefore, under these conditions, GD3.5 antigen was electrophoretically distinct from IL-A29 antigen (WC1).




Figure 1. Two-color FACS analysis illustrating GD3.5 staining patterns of peripheral blood lymphocytes from a single individual. Two-color analysis was performed according to Materials and Methods. Panel 1A shows cells stained with GD3.5 and GD3.8 (pan- $\gamma\delta$ TCR). Panel 1B shows cells stained with IL-A29 (WC1) and GD3.8. Panel 1C shows cells stained with IL-A29 and GD3.5. Panel 1D shows cells stained with CC21 (B-cell) and GD3.5. Panel 1E shows cells stained with CC42 ($\alpha\beta$ T cell) and GD3.5. Figure 1 is representative of at least three separate experiments.




Figure 2. Nonreducing Western Blot of $\gamma\delta$ T cell lysate, illustrating electrophoretic mobility of GD3.5 antigen and WC1. Western blotting was performed as described in the Materials and Methods. Lanes 1 and 2 represent media control. Lanes 3 and 4 were blotted with GD3.5, and lanes 5 and 6 were blotted with IL-A29. Molecular standards are as marked to the right. Figure 2 is representative of at least three separate experiments.

Interestingly, another IL-A29-reactive band appeared at approximately 180kD. This same band was not present in IL-A29 immunoprecipitates in Figure 3 (see below), indicating that it was not surface labeled by ^{125}I . This suggested that it was exposed after cell lysis, possibly representing an immature molecule that was not yet expressed on the cell surface but was IL-A29-reactive. Neither IL-A29 or GD3.5 worked by Western blot under reducing conditions.

Immunoprecipitation analysis was also done to confirm the Mr of the GD3.5 antigen, particularly under reducing conditions. Purified $\gamma\delta$ T cells were ^{125}I -labeled, lysed, immunoprecipitated with IL-A29 (anti-WC1), GD197 (anti- $\gamma\delta$ TCR), or GD3.5, and separated by SDS-PAGE, as described in Materials and Methods. As shown in lane 2 of Figure 3, IL-A29 immunoprecipitate (WC1) was characterized by two distinct bands at 200-220kD and 300kD under nonreducing conditions. Lane 3 shows that GD3.5 immunoprecipitated a protein that migrated at approximately 220-240kD, slightly slower than the 200-220kD WC1 band. These results were the same as those obtained by Western blotting. As expected, TCR migrated at approximately 75kD under nonreducing conditions (lane 4). Under reducing conditions, the GD3.5 antigen was indistinguishable from the lower (220-240kD) WC1 species (compare lanes 6 and 7) and TCR migrated at 40-50kD (lane 8). Importantly, earlier reports have shown that immunoprecipitation of labeled $\gamma\delta$ T cell lysates with framework anti-CD45 mAb results in a single band that is substantially smaller than the 220kD IL-A29-reactive band (4) showing that GD3.5 does not recognize CD45. In a separate study, we are characterizing the expression of CD45RO on bovine $\gamma\delta$ T cells and have confirmed that GD3.5 is molecularly distinct from CD45 (M. A. Jutila et al., unpublished observations).




Figure 3. Comparisons of ^{125}I -labeled lysate immunoprecipitations of WC1, GD3.5 antigen, and TCR under nonreducing and reducing conditions. Lysates were immunoprecipitated with IL-A29, GD3.5, and GD197, electrophoresed and analyzed, as described in Materials and Methods. Lanes 1 and 5 show the molecular standards as marked. Lanes 2, 3, and 4 show lysates immunoprecipitated with IL-A29, GD3.5 and GD197, respectively, and electrophoresed under nonreducing conditions. Lanes 6, 7, and 8 show lysates immunoprecipitated with IL-A29, GD3.5 and GD197, respectively, and electrophoresed under reducing conditions. Figure 3 is representative of three separate experiments.

Crossprecipitation analysis. V-8 protease peptide mapping. enzymatic deglycosylation. and WC1 and GD3.5 antigen cell surface expression

Even though the molecular mobility of the GD3.5 antigen was distinct from WC1 under nonreducing conditions, their similarity under reducing conditions prompted us to further characterize the difference in the two antigens. Crossimmunoprecipitation experiments were used to confirm if IL-A29 and GD3.5 immunoprecipitated different

molecules, and the results are shown in Figure 4. Excess IL-A29, GD3.5, and GD197 was added to ^{125}I -labeled $\gamma\delta$ T cell lysates. Lanes 2, 3, and 4 show the first round of immunoprecipitation with IL-A29, GD3.5, and GD197, respectively. Lanes 5, 6, and 7 were loaded with immunoprecipitates from the same lysates above that had been cleared 4 additional times of Ag/Ab complex, demonstrating that lysates were cleared of IL-A29/WC1, GD3.5Ab/GD3.5Ag, and GD197/TCR complexes, respectively. Lysates precleared of IL-A29/WC1 were then crossimmunoprecipitated with GD3.5. Lane 8 shows that GD3.5 immunoprecipitated the characteristic 220-240kD protein from a lysate precleared of IL-A29/WC1. In addition, IL-A29 was used to crossimmunoprecipitate the lysate precleared of GD3.5Ab/GD3.5Ag. Lane 9 shows that IL-A29 immunoprecipitated the characteristic 200-220kD and 300kD proteins. Lanes 12-19 represent the same experiments done under reducing conditions and the results were identical.

As another means of comparing WC1 and the GD3.5 antigen, V-8 protease digestion profiles were generated and compared. Immunoprecipitated WC1 was digested with 0ng, 10ng, 50ng, and 100ng V-8 protease/sample and separated by SDS-PAGE. In Figure 5, lanes 1, 3, 5, and 7 show the effects of increasing concentrations of protease treatment on WC1, and lanes 2, 4, 6, and 8 represent immunoprecipitated GD3.5 treated with the same protease regimen. Lanes 5 and 7 indicate protease digestion products unique to WC1, while the arrows indicate products unique to GD3.5 antigen digestion (lanes 6 and 8).




Figure 4. ^{125}I -labeled lysate immunoprecipitation/crossprecipitation experiment. Lanes 1-10 represent antigens electrophoresed under nonreducing conditions, while lanes 11-20, represent antigens electrophoresed under reducing conditions. Lanes 1 and 11 show molecular standards as marked. Lanes 2, 3, and 4 represent three separate lysates immunoprecipitated with IL-A29, GD3.5, and GD197, respectively. Lanes 12, 13, and 14 represent the same treatment electrophoresed under reducing conditions. Lanes 5, 6, and 7 represent the lysates/immunoprecipitations from lanes 2, 3, and 4 that have been cleared 5x, using protein G beads, of IL-A29, GD3.5, and GD197 antigen/antibody complexes, respectively. Lanes 15, 16, and 17 represent the same treatment under reducing conditions. Lanes 8 and 9 represent the crossimmunoprecipitation treatment. Lane 8 shows lysate cleared 5x of IL-A29/WC1 crossimmunoprecipitated with GD3.5. Lane 9 shows lysate cleared 5x of GD3.5Ab/GD3.5Ag and crossimmunoprecipitated with IL-A29. Lanes 18 and 19 represent the same treatment under reducing conditions. Lanes 10 and 20 represent control lanes showing a second attempt to immunoprecipitate TCR with additional GD197 mAb added to lysates cleared 5x of GD197/TCR complexes. Figure 4 is representative of three separate experiments.




Figure 5. GD3.5 antigen and WC1 immunoprecipitates treated with varying concentrations of V-8 protease and electrophoresed under reducing conditions to illustrate/compare digestion profiles. Lanes 1 and 2 represent WC1 and GD3.5 antigen controls, respectively (no protease). Lanes 3 and 4 represent WC1 and GD3.5 antigen, respectively, treated with 10ng of V-8 protease/lane. Lanes 5 and 6 represent WC1 and GD3.5 antigen, respectively, treated with 50ng of V-8 protease/lane. Lanes 7 and 8 represent WC1 and GD3.5 antigen, respectively, treated with 100ng/lane. Arrows indicate unique GD3.5 digestion bands in lanes 6 and 8. Molecular standards are as marked to the left. Figure 5 is representative of three separate experiments.

To provide additional characterization of the GD3.5 antigen, we used PNGase F, O-sialoglycoprotease, and neuraminidase to determine glycosylation characteristics of the molecule. In addition, comparisons of GD3.5 and WC1 were also performed. CD45 was used as a control protein to ensure specific activity of the various enzymes (data not shown). Immunoprecipitated antigen was treated with PNGase F (0.2U/rxn), O-sialoglycoprotease (9.8ug/rxn), or neuraminidase (2mU/rxn). In Figure 6, lanes 1 and 5 represent control WC1 and GD3.5 antigen under reducing conditions. Lanes 2 and 6 represent WC1 and GD3.5 digested with O-sialoglycoprotease, respectively. Interestingly, O-sialoglycoprotease treatment resulted in the loss of both the 220-240kD and 300kD WC1 bands and the appearance of two bands at ~200-220kD and ~100kD (indicated by arrows, lane 2). In contrast, GD3.5 antigen was digested into two bands of ~220kD and ~160kD (indicated by arrows, lane 6). Of note, repeated gels indicated that the upper GD3.5 antigen digestion band may be comprised of 2 separate molecular species. The activity of O-sialoglycoprotein endopeptidase on both WC1 and GD3.5 antigen indicated that both of these molecules are decorated with O-linked sugars containing terminal sialic acid residues characteristic of mucin-like glycoproteins. In addition, the O-sialoglycoprotease data further distinguished GD3.5 antigen from WC1. Lanes 3 and 7 represent digestion patterns of WC1 and GD3.5 antigen with PNGase F, respectively. Both the 220-240kD and 300kD WC1 bands demonstrated sensitivity to PNGase F indicating that WC1 is also N-glycosylated. Both the 300kD and 220-240kD bands were digested into apparently one broad band (lane 3). GD3.5 antigen was deglycosylated with PNGase F resulting in a single band at 160-170kD, representing a greater shift than the lower Mr species of WC1. The results with PNGase F indicated that both WC1 and GD3.5 antigen possess distinguishing N-linked sugars that comprise a significant portion of their total molecular mass. Lanes 4 and 8 illustrate digestion of WC1 and GD3.5 antigen with neuraminidase, respectively. Interestingly, both WC1

bands shift slightly (downward) indicating decoration with sialic acid. The 220-240kD WC1 band has a more pronounced shift than the 300kD band. GD3.5 antigen shifts downward (~10kD) after treatment with neuraminidase, indicating that this molecule is also decorated with sialic acids. These data are not surprising since O-sialoglycoprotease requires sialic acid residues for activity (33). Also, the 220-240kD WC1 band demonstrated a greater shift than did the GD3.5 antigen, consistent with the greater sensitivity of WC1 to O-sialoglycoprotease.




Figure 6. Comparison of ^{125}I -labeled lysates of WC1 (lanes 1-4) and GD3.5 antigen (lanes 5-8) treated with O-sialoglycoprotease, PNGase F, or neuraminidase. Lanes 1 and 5 are untreated controls. Lanes 2 and 6 show lysates treated with O-sialoglycoprotease, lanes 3 and 7 indicate lysates treated with PNGase F, and lanes 4 and 8 show lysates treated with neuraminidase. Lysates were incubated overnight at 37°C , electrophoresed, and analyzed as described in Materials and Methods. Arrows indicate O-sialoglycoprotease degradation products of WC1 and GD3.5 antigen as discussed in the Results section. Molecular standards are as marked to the left. Figure 6 is representative of three separate experiments.

Effects of low-dose chymotrypsin treatment on cell surface expression of GD3.5 antigen and WC1 was used to further distinguish these antigens. Cells were incubated with α -chymotrypsin for 1hr at 37°C and then FACS analysis was done. Figure 7 demonstrates that GD3.5 antigen was very sensitive to low-dose chymotrypsin. GD3.5 antigen mean fluorescence, indicated by the cross-hatched bars, consistently declined as the concentration of chymotrypsin was increased from 62.5 to 250 mU/ml, illustrating dose-response characteristics. In contrast, WC1 (solid bars) mean fluorescence remained similar to control levels (no chymotrypsin) regardless of chymotrypsin concentration.




Figure 7. Effects of low-dose chymotrypsin on cell surface expression of WC1 and GD3.5 antigen. Purified lymphocytes were treated with 0-250mU α -chymotrypsin/ 1×10^7 cells for 1hr at 37°C and analyzed by FACS for GD3.5 antigen and WC1 expression. GD3.5 antigen is indicated by cross-hatched bars and WC1 by solid bars. Figure 7 is representative of three separate experiments indicating average mean fluorescence of duplicate samples.

Therefore, crossprecipitation analysis, V-8 protease digestion, enzymatic deglycosylation, and cell surface chymotrypsin sensitivity conclusively show that the GD3.5-reactive antigen is clearly distinct from the molecules recognized by IL-A29, even though under reducing conditions the smaller Mr WC1 species is similar to GD3.5 antigen by size. Since IL-A29 is thought to recognize all WC1 species, our results suggest that GD3.5 represents a completely distinct lineage-specific antigen or a unique WC1 family member not recognized by IL-A29.

Discussion

The identification and characterization of $\gamma\delta$ T cell-specific surface molecules will be useful in understanding the biology and function of this cell type. In this report, we have demonstrated a novel $\gamma\delta$ T cell-specific marker (GD3.5 antigen), which is distinct from both TCR and other known WC1 species. GD3.5-reactive lymphocytes represent a distinct $\gamma\delta$ T cell-specific population in comparison to IL-A29-reactive WC1. In addition, GD3.5 stains a major subset of $\gamma\delta$ TCR-expressing cells.

Although GD3.5 antigen and IL-A29-reactive WC1 share similar migratory patterns under reducing conditions, they represent distinct molecules. Indeed, because of the similarity in Mr of the GD3.5 antigen and WC1 under reducing conditions, we did an exhaustive analysis of the biochemical nature of the antigens. The most direct evidence supporting our conclusion are the crossprecipitation studies in which we show that GD3.5 antigen can be precipitated from a lysate cleared of IL-A29-reactive WC1 and vice versa. Analysis of the protease and glycosidase sensitivities of GD3.5 antigen further confirmed the molecular differences between the GD3.5 antigen and IL-A29-reactive WC1 species. From our studies, it is clear that GD3.5 antigen does not represent one of the IL-A29-reactive WC1 species. In addition, preclearing lysates

with three different WC1 mAbs and then crossprecipitating with GD3.5mAb did not diminish the immunoprecipitation of GD3.5Ag further suggesting that GD3.5Ag is not a known WC1 isotype (data not shown and see chapter five).

Of particular interest is the analysis of the glycosylation patterns of the GD3.5 antigen and WC1. As described in the results section, GD3.5 antigen can be distinguished from WC1 when comparing treatment of these molecules with O-sialoglycoprotease, PNGase F, and neuraminidase (Figure 6). Both molecules are sensitive to O-sialoglycoprotease, suggesting that these molecules possess O-linked carbohydrates with sialic acid residues which is characteristic of mucin-like molecules (33). Our study represents the first demonstration that WC1 may represent a family of mucin-like molecules on $\gamma\delta$ T cells. This is important information, which may give clues to the potential function of both molecules. For example, it has been previously reported that a T-lymphocyte ligand and myeloid PSGL-1, which mediate adhesion to P-selectin, possess O-linked carbohydrates that are sensitive to O-sialoglycoprotease treatment, which eliminates binding to P-selectin (34,35). We have previously shown that $\gamma\delta$ T cells bind P-selectin via an unknown receptor that is sensitive to O-sialoglycoprotease (36). Additionally, we found that O-sialoglycoprotease treatment of $\gamma\delta$ T cells inhibits their binding to another selectin (L-selectin) which is important in regulating leukocyte/leukocyte as well as leukocyte/endothelial cell interactions (36). Collectively, our data as well as the data of others have shown that mucins are important in a variety of aspects related to the trafficking of lymphocytes within the animal. Other mucins, such as CD45, are involved in cell functions likely separate from lymphocyte trafficking. Therefore, our demonstration of the sensitivity of WC1 and the GD3.5 antigen to O-sialoglycoprotease provides important information for future functional analyses of both molecules.

Earlier reports showed that treatment of neutrophils with low-dose chymotrypsin

leads to loss of L-selectin, inhibits neutrophil binding to high endothelial venules, and reduces the capacity of the cells to home to sights of inflammation (32). We have shown that GD3.5 antigen is very sensitive to low-dose chymotrypsin, exhibiting sensitivity greater than even L-selectin. Interestingly, P-selectin ligands also exhibit exquisite sensitivity to proteases (37-39). Based on our chymotrypsin and O-sialoglycoprotease results, we have pursued preliminary functional analyses of the GD3.5 antigen in the context of selectin binding. We have found that the low-dose chymotrypsin treatment that reduces GD3.5 antigen expression abrogates binding of $\gamma\delta$ T cells to activated endothelial cells and platelets (see chapter three). In addition, the same concentration of chymotrypsin abrogates binding of human P-selectin chimera (40) to bovine $\gamma\delta$ T cells by FACS analysis (data not shown). Thus, it is possible that the GD3.5 antigen represents a P-selectin ligand on $\gamma\delta$ T cells. If GD3.5 antigen does represent a P-selectin ligand, then it is somewhat unique from PSGL-1 since it does not demonstrate a shift of 110kD under reducing conditions like the myeloid molecule (41,42).

Even though WC1 was identified approximately 10 years ago, a specific function for the molecule has not been conclusively defined. Some reports have suggested that it may also be involved in the trafficking of $\gamma\delta$ T cells (4,23,26,28). Cloning of cDNAs encoding the various WC1 species has not cleared up the issue of function. Here we show that WC1 is quite sensitive to O-sialoglycoprotease treatment. Using the same line of reasoning as used for GD3.5 antigen, we support the hypothesis that WC1 is involved in trafficking, but that the molecular interaction will be distinct from GD3.5 antigen and its potential receptor. This latter conclusion is based on the clear molecular differences in the 2 molecules and that WC1 is not affected by low-dose chymotrypsin treatment. It is possible that WC1 could bind other selectins, such as E-selectin, which we have previously shown is bound by $\gamma\delta$ T cells via a low-dose chymotrypsin-resistant surface antigen on the lymphocyte (29), or it could mediate binding to other lectin-like

molecules.

In summary, GD3.5 antigen is clearly distinct from IL-A29-reactive WC1 as described using the various techniques presented above, thus, revealing a second lineage-specific $\gamma\delta$ T cell marker. Interestingly, GD3.5 and WC1 are sensitive to O-sialoglycoprotease treatment suggesting that these molecules possess sialomucin-like characteristics similar to other selectin ligands. In Chapter 3, I will present data that will address the regulation and potential function of GD3.5Ag.

References

1. Tsuji, M., P. Mombaerts, L. LeFrancois, R. S. Nussenzweig, F. Zavala, and S. Tonegawa. 1994. $\gamma\delta$ T cells contribute to immunity against the liver stages of malaria in $\alpha\beta$ T-cell-deficient mice. *Proc. Natl. Acad. Sci.* 91:345.
2. Muller, D., P. Pakpreo, J. Filla, K. Pederson, F. Cigel, and V. Malkovska. 1995. Increased gamma-delta T-lymphocyte response to *Mycobacterium bovis* BCG in major histocompatibility complex class I-deficient mice. *Infect. Immun.* 63:2361.
3. Bukowski, J. F., C. T. Morita, and M. B. Brenner. 1994. Recognition and destruction of virus-infected cells by human $\gamma\delta$ CTL. *J. Immunol.* 153:5133.
4. Mackay, C. R., M.-F. Beya, and P. Matzinger. 1989. $\gamma\delta$ T cells express a unique surface molecule appearing late during thymic development. *Eur. J. Immunol.* 19:1477.
5. Bonneville, M., C. A. Janeway Jr., K. Ito, W. Haser, I. Ishida, N. Nakanishi, and S. Tonegawa. 1988. Intestinal intraepithelial lymphocytes are a distinct set of $\gamma\delta$ T cells. *Nature* 336:479.
6. Clevers, H., N. D. MacHugh, A. Bensaid, S. Dunlap, C. L. Baldwin, A. Kaushal, K. Iams, C. J. Howard, and W. I. Morrison. 1990. Identification of a bovine surface antigen uniquely expressed on CD4⁻CD8⁻ T cell receptor $\gamma\delta^{+}$ T lymphocytes. *Eur. J. Immunol.* 20:809.
7. Rivas, A., J. Koide, M. L. Cleary, and E. G. Engleman. 1989. Evidence for involvement of the $\gamma\delta$ T cell antigen receptor in cytotoxicity mediated by human alloantigen-specific T cell clones. *J. Immunol.* 142:1840.
8. Matis, L. A., A. M. Fry, R. Q. Cron, M. M. Cotterman, R. F. Dick, and J. A. Bluestone. 1989. Structure and specificity of a class II MHC alloreactive $\gamma\delta$ T cell receptor heterodimer. *Science* 245:746.
9. Ciccone, E., O. Viale, C. Bottino, D. Pende, N. Migone, G. Casorati, G. Tambussi, A. Moretta, and L. Moretta. 1988. Antigen recognition by human T cell receptor g-positive lymphocytes: Specific lysis of allogeneic cells after activation in mixed lymphocyte culture. *J. Exp. Med.* 167:1517.
10. Weintraub, B. C., M. R. Jackson, and S. M. Hedrick. 1994. $\gamma\delta$ T cells can recognize nonclassical MHC in the absence of conventional antigenic peptides. *J. Immunol.* 153:3051.
11. Bukowski, J. F., C. T. Morita, Y. Tanaka, B. R. Bloom, M. B. Brenner, and H. Band. 1995. Vg2Vd2 TCR-Dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. *J. Immunol.* 154:998.
12. Pfeffer, K., B. Schoel, H. Gulle, S. H. E. Kaufmann, and H. Wagner. 1990. Primary responses of human T cells to mycobacteria: a frequent set of $\gamma\delta$ T cells are stimulated by protease-resistant ligands. *Eur. J. Immunol.* 20:1175.

13. Pfeffer, K., B. Schoel, N. Plesnila, G. B. Lipford, S. Kromer, K. Deusch, and H. Wagner. 1992. A lectin-binding, protease-resistant mycobacterial ligand specifically activates Vg9⁺ human $\gamma\delta$ T cells. *J. Immunol.* 148:575.
14. O'Brien, R. L., M. P. Happ, A. Dallas, E. Palmer, R. Kubo, and W. K. Born. 1989. Stimulation of a major subset of lymphocytes expressing T cell receptor $\gamma\delta$ by an antigen derived from *Mycobacterium tuberculosis*. *Cell* 57:667.
15. Haregewoin, A., G. Soman, R. C. Hom, and R. W. Finberg. 1989. Human $\gamma\delta^+$ T cells respond to mycobacterial heat-shock protein. *Nature.* 340:309.
16. Kaur, I., S. D. Voss, R. S. Gupta, K. Schell, P. Fisch, and P. M. Sondel. 1993. Human peripheral $\gamma\delta$ T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells. *J. Immunol.* 150:2046.
17. Schild, H., N. Mavaddat, C. Litzenberger, E. W. Ehrich, M. M. Davis, J. A. Bluestone, L. Matis, R. K. Draper, and Y. Chien. 1994. The nature of major histocompatibility complex recognition by $\gamma\delta$ T cells. *Cell* 76:29.
18. Mackay, C. R., J. F. Maddox, and M. R. Brandon. 1986. Three distinct subpopulations of sheep T lymphocytes. *Eur. J. Immunol.* 16:19.
19. Davis, W. C., S. Marusic, H. A. Lewin, G. A. Splitter, L. E. Perryman, T. C. McGuire, and J. R. Gorham. 1987. The development and analysis of species specific and cross reactive monoclonal antibodies to leukocyte differentiation antigens and antigens of the major histocompatibility complex for use in the study of the immune system in cattle and other species. *Vet. Immunol. Immunopathol.* 15:337.
20. Howard, C. J., P. Sopp, K. R. Parsons, and J. Finch. 1989. *In vivo* depletion of BoT4 (CD4) and non-T4/T8 lymphocyte subsets in cattle with monoclonal antibodies. *Eur. J. Immunol.* 19:757.
21. Morrison, W. I., N. D. MacHugh, A. Bensaid, B. M. Goddeeris, A. J. Teale, and D. J. McKeever. 1988. A monoclonal antibody which reacts specifically with a population of bovine lymphocytes lacking B cell and T cell markers. In *Histophysiology of the Immune System*, S. Fossum, and B. Rolstad, eds., Plenum Press, New York, NY, p. 591.
22. Morrison, W. I., and W. C. Davis. 1991. Differentiation antigens expressed predominantly on CD4⁻ CD8⁻ T lymphocytes (WC1,WC2). *Vet. Immunol. Immunopathol.* 27:71.
23. Wijngaard, P. L. J., M. J. Metzelaar, N. D. MacHugh, W. I. Morrison, and H. C. Clevers. 1992. Molecular characterization of the WC1 antigen expressed specifically on bovine CD4⁻CD8⁻ $\gamma\delta$ T lymphocytes. *J. Immunol.* 149:3273.
24. MacHugh, N. D., P. L. J. Wijngaard, H. C. Clevers, and W. C. Davis. 1993. Clustering of monoclonal antibodies recognizing different members of the WC1 gene family. *Vet Immunol. Immunopathol.* 39:155.

25. Crocker, G., P. Sopp, K. Parsons, W. C. Davis, and C. J. Howard. 1993. Analysis of the $\gamma\delta$ T cell restricted antigen WC1. *Vet. Immunol. Immunopathol.* 39:137.
26. Wijngaard, P. L. J., N. D. MacHugh, M. J. Metzelaar, S. Romberg, A. Bensaid, L. Pepin, W. C. Davis, and H. C. Clevers. 1994. Members of the novel WC1 gene family are differentially expressed on subsets of bovine CD4⁺CD8⁻ $\gamma\delta$ T lymphocytes. *J. Immunol.* 152:3476.
27. Mackay, C. R., and W. R. Hein. 1989. A large proportion of bovine T cells express the $\gamma\delta$ T cell receptor and show a distinct tissue distribution and surface phenotype. *Int. Immunol.* 1:540.
28. Hein, W. R., and C. R. Mackay. 1991. Prominence of $\gamma\delta$ T cells in the ruminant immune system. *Immunol. Today* 12:30.
29. Walcheck, B., G. Watts, and M. A. Jutila. 1993. Bovine $\gamma\delta$ T cells bind E-selectin via a novel glycoprotein receptor: First characterization of a lymphocyte/E-selectin interaction in an animal model. *J. Exp. Med.* 178:853.
30. Samelson, L. E. 1991. Iodination of soluble and membrane-bound proteins. In *Current Protocols in Immunology*, Vol. 1. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. National Institutes of Health, Wiley Interscience, p. 8.11.1.
31. Jutila, M. A., G. Watts, B. Walcheck, and G. S. Kansas. 1992. Characterization of a functionally important and evolutionarily well-conserved epitope mapped to the short consensus repeats of E-selectin and L-selectin. *J. Exp Med.* 175:1565.
32. Jutila, M. A., T. K. Kishimoto, and M. Finken. 1991. Low-dose chymotrypsin treatment inhibits neutrophil migration into sites of inflammation *in vivo*: Effects on Mac-1 and MEL-14 adhesion protein expression and function. *Cell. Immunol.* 132:201.
33. Abdullah, K. M., E. A. Udoh, P. E. Shewen, and A. Mellors. 1992. A neutral glycoprotease of *Pasteurella haemolytica* A1 specifically cleaves O-sialoglycoproteins. *Infect. Immun.* 60:56.
34. Alon, R., H. Rossiter, X. Wang, T. A. Springer, and T. S. Kupper. 1994. Distinct cell surface ligands mediate T lymphocyte attachment and rolling on P and E selectin under physiological flow. *J. Cell Biol.* 127:1485.
35. Steininger, C. N., C. A. Eddy, R. M. Leimgruber, A. Mellors, and J. K. Welply. 1992. The glycoprotease of *Pasteurella haemolytica* A1 eliminates binding of myeloid cells to P-selectin but not to E-selectin. *Biochem. Biophys. Res. Comm.* 188:760.
36. Jutila, M. A., and S. Kurk. 1996. Analysis of bovine $\gamma\delta$ T cell interactions with E-, P-, and L-selectin: Characterization of lymphocyte on lymphocyte rolling and the effects of O-glycoprotease. *J. Immunol.* 156:289.

37. Moore, K. L., A. Varki, and R. P. McEver. 1991. GMP-140 binds to a glycoprotein receptor on human neutrophils: Evidence for a lectin-like interaction. *J. Cell Biol.* 112:491.
38. Zannettino, A. C. W., M. C. Berndt, C. Butcher, E. C. Butcher, M. A. Vadas, and P. J. Simmons. 1995. Primitive human hematopoietic progenitors adhere to P-selectin (CD62P). *Blood* 85:3466.
39. Vachino, G., X.-J. Chang, G. M. Veldman, R. Kumar, D. Sako, L. A. Fouser, M. C. Berndt, and D. A. Cumming. 1995. P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells. *J. Biol. Chem.* 270:21966.
40. Jutila, M. A., R. F. Bargatze, S. Kurk, R. A. Warnock, N. Ehsani, S. R. Watson, and B. Walcheck. 1994. Cell surface P- and E-selectin support shear-dependent rolling of bovine $\gamma\delta$ T cells. *J. Immunol.* 153:3917.
41. Moore, K. L., N. L. Stults, S. Diaz, D. F. Smith, R. D. Cummings, A. Varki, and R. P. McEver. 1992. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. *J. Cell Biol.* 118:445.
42. Sako, D., X.-J. Chang, K. M. Barone, G. Vachino, H. M. White, G. Shaw, G. M. Veldman, K. M. Bean, T. J. Ahern, B. Furie, D. A. Cumming, and G. R. Larsen. 1993. Expression cloning of a functional glycoprotein ligand for P-selectin. *Cell* 75:1179.

CHAPTER 3

REGULATION AND FUNCTIONAL CHARACTERIZATION OF A NOVEL $\gamma\delta$ T CELL-SPECIFIC SURFACE ANTIGEN (GD3.5)

Introduction

A specific function of $\gamma\delta$ T cells has continued to elude researchers for over a decade now. Understanding the tissue distribution of $\gamma\delta$ T cells may lend some clues to their function. In ruminants, $\gamma\delta$ T cells comprise 60-80% of the peripheral blood lymphocyte (PBL) population (1,2), and they do not appreciably accumulate in the organized lymphoid tissues, such as the lymph node (1,3-5). However, studies have demonstrated considerable homing of bovine $\gamma\delta$ T cells into epithelial tissues (1,5,6). In addition, many reports have demonstrated homing of $\gamma\delta$ T cells into nonlymphatic tissues in the mouse. In these reports, $\gamma\delta$ T cells have been found in association with mucosal epithelia of the gut, tongue, and vaginal areas, as well as the skin (7-10). Interestingly, tissue localization seems to correlate with TCR gene usage in some cases (9-12). For example, skin $\gamma\delta$ T cells appear to present limited $\gamma\delta$ TCR V γ and V δ genes almost to the point where the population is oligoclonal or even monoclonal (9,12). Therefore, localization may either be linked to or correlate with TCR gene usage (9,12). Since TCR gene usage seems to "direct" specific $\gamma\delta$ T cell subpopulations to various epithelial tissues where invading pathogens might first be encountered, it has been

hypothesized that $\gamma\delta$ T cells play a major role in "the first line of defense" against these pathogens.

It has been shown that $\gamma\delta$ T cells can respond and migrate into sites of inflammation (13-18). For example, $\gamma\delta$ T cells accumulate in the intestinal mucosa upon infection with *Cryptosporidium parvum* (13). Using function-blocking mAb to E-selectin, migration of $\gamma\delta$ T cells into sites of inflammation caused by PPD, TNF, LPS, and PHA can be inhibited indicating that selectins are involved in transmigration of $\gamma\delta$ T cells into sites of inflammation (14, M. A. Jutila, unpublished observations). Furthermore, in vitro studies have shown that rolling of $\gamma\delta$ T cells on activated endothelial cells and platelets can be blocked by anti-E- and P-selectin mAbs, indicating that initial adhesion of $\gamma\delta$ T cells in sites of inflammation can be mediated by selectins (19). Finally, it has been shown that $\gamma\delta$ T cells interact with chronically activated endothelium independent of E- or P-selectin, suggesting the use of alternative or novel cell adhesion pairs in chronic inflammation (20,21).

Previously, we biochemically defined a novel $\gamma\delta$ T cell lineage-specific cell-surface molecule termed GD3.5Ag (24). Here, we describe the regulation and potential function of this molecule as an adhesion protein. Stimulatory compounds and various enzymes have been used to study the biochemical and regulatory characteristics of cell-surface adhesion molecules. For example, a known leukocyte adhesion molecule, L-selectin, is downregulated upon treatment with phorbol esters (14). In addition, L-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) are sensitive to low-dose protease treatment (22,23). We showed that GD3.5Ag expression is downregulated upon mitogen activation and expression returns upon loss of stimulation. Also, a large population of $\gamma\delta$ T cells in the spleen express lower levels of GD3.5Ag and WC1 when compared to peripheral blood $\gamma\delta$ T cells. In addition, chymotrypsin treatment of $\gamma\delta$ T cells results in a dose-dependent loss of their ability to roll on 24hr activated endothelium. Lastly, pretreatment of

bovine $\gamma\delta$ T cells with anti-GD3.5Ag polyclonal serum inhibits accumulation of these cells on 24hr activated endothelium.

Materials and Methods

Lymphocyte purification, $\gamma\delta$ T cell isolation, and biotin labeling

Blood was obtained by jugular venipuncture from Holstein calves housed at the Montana State University Large Animal Facility. Lymphocytes were purified by Histopaque gradient centrifugation (Sigma Chemical Co., St. Louis, MO). Lymphocytes were resuspended in HBSS and platelets were removed by Percoll gradient centrifugation (Sigma Chemical Co., St. Louis, MO) with subsequent incubation of lymphocytes in T175 flasks for 30min at 37°C to allow monocytes to adhere and be removed from suspension. $\gamma\delta$ T cell lymphocytes were purified from whole lymphocytes by incubation for 30min at room temperature (RT) in T175 flasks coated with 7×10^6 adherent E-selectin L-cell transfectants. Remaining unbound cells were discarded and bound $\gamma\delta$ T cells lifted with 2mM EDTA (14). This purification protocol provided >90% pure $\gamma\delta$ T cells (14). In some experiments, $\gamma\delta$ T cells were then surface labeled with biotin. Briefly, 1×10^8 cells were washed 3 times with sterile PBS and resuspended in 1ml of NHS-LC-Biotin/PBS (550ug/ml Pierce, Rockford, IL). After a 30min incubation at RT, cells were washed 3 times with PBS and lysed for 30min on ice with NP-40 lysis buffer (2% NP-40, 100mM NaCl, 1mM MgCl₂, 1mM CaCl₂, 5mM NaN₃, 10mM Hepes, and protease inhibitors: pepstatin A, 1,10-phenanthroline, phenylmethylsulfonyl fluoride, benzamidine, antipain, leupeptin, and chymostatin (Sigma Chemical Co., St. Louis, MO). Rabbit serum (5% v/v) was added to all lysates for 1hr at RT and then precleared with protein G beads (Boehringer Mannheim Biochemicals, Indianapolis, IN) overnight at 4°C with constant rotation.

Beads were subsequently removed and lysates were either used immediately or frozen at -80°C.

mAbs, polyclonal antibodies, and FACS analysis

Monoclonal antibodies included IL-A29 (anti-WC1), GD3.5, and GD3.8. GD3.5 is a non-TCR, lineage-specific, $\gamma\delta$ T cell antibody that recognizes a 220-240kD glycoprotein on the cell surface (24). GD3.8 is against the $\gamma\delta$ TCR and is a pan- $\gamma\delta$ T cell marker (Wilson, E., et al., manuscript in preparation). Both antibodies were generated, as described previously (24,25). The GD3.5 antigen was purified by affinity column chromatography. Briefly, GD3.5 mAb was conjugated to protein G beads per manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN). Bovine lymphocyte lysates were incubated with the column matrix, washed, and bound GD3.5Ag was eluted with 0.5M NaCl, 0.1M glycine, pH 2.5 elution buffer and immediately neutralized with 10% 1.5M pH 8.8 Tris buffer. Purified antigen was concentrated and anti-GD3.5 polyclonal antibody was generated in BALB/C mice. Briefly, mice were first injected i.p. with GD3.5Ag mixed with Gerbu Adjuvant (Biotech, Poway, CA). Two weeks later, the mice were injected a second time with purified GD3.5Ag alone and one week after the second injection, the mice were bled and their serum analyzed by flow cytometry. Single-color FACS was performed on ice as follows: cells were incubated with IL-A29, GD3.5 or GD3.8 for 30min, washed, incubated with appropriate PE- or FITC conjugated goat α -mouse secondary antibody (Jackson ImmunoResearch, West Grove, PA), washed again, and analyzed on a BD FACscan or FACScalibur (Becton Dickinson). Two-color FACS analysis was performed on ice as follows: cells were incubated with anti-GD3.5 polyclonal serum (1/100) for 30min, washed, and incubated with appropriate PE-conjugated goat α -mouse secondary Ab (Jackson ImmunoResearch). Cells were blocked for 10min with 10% mouse serum and

subsequently washed, followed by incubation with FITC-labeled GD3.8 mAb for 30min, washed again, and analyzed on a FACScan or FACScalibur (Becton Dickinson). Control cells were incubated with preimmune mouse serum for 30min and treated, as stated above.

Tissue distribution of bovine $\gamma\delta$ T cells

Tissues were obtained from control Holstein calves housed at the Montana State University Large Animal Facility. Prior to sacrifice, 15mls of peripheral blood were obtained, as described above. Immediately postmortem, a portion of spleen, thymus, mesenteric lymph node (MesLN), prescapular lymph node (PreLN), and flanking lymph node (FlaLN) were removed and placed in cold HBSS. Tissues were cut into small pieces after removal of excess connective tissues. Several pieces were placed into tissue grinders and single cell suspensions were made by gently moving the plunger up and down inside the glass cylinder. Cells were passed through Nitex filters to remove large particulates, resulting in single cell suspensions, which were used in single-color FACS analyses, as described above.

Immunoprecipitation/Crossprecipitation

Crossprecipitation experiments were performed as follows. Separate biotinylated lysates were precleared of Workshop Cluster 1 (WC1) or GD3.5 antigen by incubation with 20ug of either IL-A29 or GD3.5 mAb for 1hr at room temperature and then immunoprecipitated with protein G beads at 4°C overnight. After bead removal, WC1 and GD3.5 antigen cleared lysates were incubated a second time with 15ug of IL-A29 or GD3.5 mAb, respectively, and immunoprecipitated a second time, as described above. Three subsequent clearing steps with protein G beads were performed on the lysates to ensure removal of all Ab/Ag complexes. Anti-GD3.5 polyclonal serum was used to

immunoprecipitate lysates cleared of either GD3.5 antigen or WC1. Polyclonal Ab/Ag complexes were precipitated with protein G beads, as described above. The beads were washed 3 times with wash buffer (0.1% NP-40, 100mM NaCl, 1mM CaCl_2 , 1mM MgCl_2 , 5mM sodium azide, and 10mM Hepes), mixed with nonreducing loading buffer and loaded onto 8% SDS-polyacrylamide gels (24). Gels were electrophoresed and transferred to PVDF membranes (Bio-Rad, Hercules, CA). After transfer, membranes were washed briefly with 1x TBST (10mM Tris pH 8.0, 150mM NaCl, and 0.05% Tween 20) and then blocked with 7% BSA/TBST for 2hrs at RT. Membranes were then washed with several changes of 1x TBST for 1.75hrs. Streptavidin horseradish peroxidase conjugate (Amersham Life Science, Buckinghamshire, England) was diluted 1/5000 in sterile PBS and incubated with the membrane for 40min and then washed for 1.75hrs with several changes of 1x TBST. ECL detection reagents were used according to manufacturer's recommendations (Amersham Life Science, Buckinghamshire, England) and incubated with the membranes for 1 min. Membranes were then covered with cellophane, exposed to X-OMAT film for 1-10 minutes, and the film was developed (Kodak, Rochester, New York).

Mitogen stimulation of total lymphocyte populations

Bovine lymphocytes were prepared by Histopaque (Sigma Chemical Co., St. Louis, MO) separation and incubation on plastic, as described earlier. Cells (3×10^7) were incubated in 15mls 10% cRPMI in T75 flasks at 37°C. Cells were either sham-treated (control) or treated with 2ug/ml Concanavalin A (ConA) or 2ug/ml Phytohemagglutinin (PHA) (Sigma Chemical Co.). Cells were removed at 0, 24, 48, 72, and 144hr time points, and single-color FACS analysis was performed, as described earlier.

In vitro low-shear adhesion assay

Bovine umbilical vein endothelial cells (BUVECs) and human umbilical vein endothelial cells (HUVECs) were plated in 8-well Lab-Tek slides (Nunc Inc., Napperville, IL) and allowed to adhere overnight. Subconfluent BUVEC monolayers or HUVEC monolayers were then activated with 500U/ml TNF or 10ng/ml IL-1B, respectively, for four hours at 37°C. Purified bovine lymphocytes (1×10^6) were either untreated or pretreated with GD3.5 mAb supernatant fluid for 30min at room temperature. Treated or untreated lymphocytes were added to each well and allowed to adhere for 30min with gentle shaking. After incubation, the slides were gently washed in PBS and the cells were fixed in glutaraldehyde/HBSS. The number of lymphocytes bound/BUVEC or HUVEC were counted in three separate fields/well.

In vitro capillary tube shear-dependent rolling assay

The shear-dependent assay has been described previously (19,26-28). Briefly, BUVECs, HUVECs, or E-selectin L-cell transfectants were grown to confluency on the inside surface of 1.4-mm (i.d.) capillary tubes (Drummond Scientific, Broomall, PA). BUVECs were treated with bovine IFN- γ for 20hrs with subsequent incubation using bovine TNF- α for 4hrs. In addition, BUVECs were sometimes activated with 100ng/ml LPS for 24hrs (Sigma Chemical Co., St. Louis, MO). HUVECs were treated with either 10ng/ml rhIL-1 β or 100ng/ml LPS for 24hrs. Platelets were adhered to the glass capillary tubes as follows: Capillary tubes were pretreated with Cel-Tak (Collaborative Biomedical Products) for 30min at 37°C to facilitate platelet binding to the inside surface of the tube. Purified human platelets (1.5×10^9 /ml) were activated with 1U/ml bovine thrombin, injected into the capillary tube, and allowed to adhere for 10min.

The capillary tubes were integrated into the closed recirculating loop system as described previously (19,26-28). Purified bovine lymphocytes or $\gamma\delta$ T cells were rolled on endothelial cells or platelets at 2-3 dynes/cm² as predicted by the Hagen-Poiseuille equation. Video microscopy was used to record endothelial cell/lymphocyte or platelet/lymphocyte interactions allowing individual frame analysis every 60 seconds using macro-driven National Institutes of Health Image software and a Macintosh 660 AV computer.

Various antibodies and anti-GD3.5 polyclonal sera were tested to determine their effect on cell/cell interactions. Purified $\gamma\delta$ T cells were pretreated with anti-GD3.5 polyclonal antibody for 1hr at room temperature and infused into the loop assay system. Monoclonal and polyclonal antibody effects were analyzed, as describe above, to determine the effects on existing as well as new cell/cell interactions.

Results

Distribution of $\gamma\delta$ T cells in organized lymphatic tissue

FACs analysis was performed on single cell suspensions from lymphoid tissues and peripheral blood to determine $\gamma\delta$ T cell distribution and expression of WC1 and GD3.5Ag (Figure 8). As expected, $\gamma\delta$ T cells represented a large percentage (46 +/- 7.1) of the total peripheral blood lymphocyte population. GD3.5 and IL-A29 mAbs stained approximately 95% and 60% of the total $\gamma\delta$ T cell population, respectively, as reported earlier (24). $\gamma\delta$ T cells represented approximately 10% of the total lymphocyte population in peripheral and mesenteric lymph nodes. In contrast, spleen lymphocyte populations were comprised of approximately 55% $\gamma\delta$ T cells. Expression of GD3.5Ag and WC1 was markedly reduced on the splenic $\gamma\delta$ T cells when compared to peripheral

blood; GD3.5 and WC1 mAbs stained 40% and 27% of the splenic $\gamma\delta$ T cell population, respectively. Finally, approximately 10% of the lymphocytes in the thymus were $\gamma\delta$ T cells and approximately 20% of these cells expressed GD3.5Ag and WC1.




Figure 8. $\gamma\delta$ T cells found in organized lymphatic tissues express varying levels of GD3.5Ag. Blood, thymus, spleen, and lymph nodes were obtained from bovine calves and single cell suspensions analyzed for WC1, GD3.5Ag, and $\gamma\delta$ TCR expression by flow cytometry, as described in Materials and Methods. Solid bars, hatched bars, and crosshatched bars represent percent of lymphocytes expressing WC1, GD3.5, or TCR, respectively in the indicated tissue. Percentages are an average of four or five experiments $\pm$ SEM.

Mitogen stimulation of bovine lymphocyte populations

Since GD3.5Ag and WC1 were downregulated in the spleen, we tried to reproduce this change in vitro. Specifically, we wanted to determine if overt signalling events, initiated by phorbol esters, mitogens, or calcium ionophores, would affect expression of these antigens in vitro. In addition, we wanted to know if these surface expressed molecules were regulated similarly to adhesion molecules, such as L-selectin, when

treated with these compounds. When lymphocytes were activated with mitogens, they increase in size forming blasts, which could be seen when analyzing their distinctive forward light-scatter profiles. Of interest, by 144hrs of incubation with mitogens, the lymphocytes diminished in size, indicating that the stimulus had subsided (data not shown). In Figure 9a, activation of bovine lymphocytes with ConA resulted in a continual increase in the percentage of the $\gamma\delta$ T cell subset from 0-144hrs. GD3.5Ag expression dropped dramatically at 48hrs and was lowest at 72hrs. In contrast, WC1 did not exhibit a precipitous drop in expression, as seen with GD3.5Ag. Of interest, the ConA-treated cells began to return to a resting state by 144hrs, which resulted in a recovery of GD3.5Ag expression. Figure 9b shows that treatment of bovine lymphocytes with PHA resulted in the downregulation of both GD3.5Ag and WC1. Interestingly, WC1 was downregulated more rapidly (48hrs) than GD3.5Ag (72hrs), further distinguishing these antigens. As with ConA, the percentage of the $\gamma\delta$ T cell subset increased from 0-144hrs of culture. Expression of WC1 and GD3.5Ag recovered at different rates when the stimulus subsided. Specifically, WC1 expression recovered more rapidly than GD3.5Ag expression. Treatment of lymphocytes with ionomycin, PMA or a combination of ionomycin and PMA did not result in any detectable changes in GD3.5Ag or WC1 expression.

Effect of GD3.5 mAb on established lymphocyte rolling or tight adhesion to 4hr activated endothelium

Since GD3.5Ag possesses biochemical and regulatory characteristics that are consistent with other known adhesion molecules, we focused our functional analyses on cell adhesion. First, we tested the ability of GD3.5 mAb to block lymphocyte adhesion to activated endothelial cells in a low-shear stress assay. Rolling and tight adhesion are indistinguishable in these assays. Thus, blocking could occur during initial adhesive




Figure 9. Mitogen stimulation differentially downregulates cell surface expression of GD3.5Ag and WC1. Purified bovine lymphocytes were activated with (a) 2ug/ml ConA or (b) 2ug/ml PHA. Cells were analyzed by flow cytometry for WC1, GD3.5Ag, and TCR expression at 0, 24, 48, 72, and 144hrs. Figure 9 is representative of at least three separate experiments.

events or tight adhesion. BUVECs and HUVECs were adhered to slides and activated for 4hrs, as described in Materials and Methods. Bovine lymphocytes were purified and either untreated or pretreated for 30min with GD3.5 mAb supernatant fluid. As shown in Figure 10a and 10b, GD3.5 mAb did not block adhesion to BUVECs or HUVECs.

In the past, we have used activated platelets and E-selectin-expressing mouse L-cell transfectants to study E- and P-selectin interactions (28). Here, we decided to test whether GD3.5 mAb would specifically block bovine lymphocyte interactions with E- or P-selectin. For P-selectin assays, platelets were activated for 10min and adhered to the inside surface of glass capillary tubes and integrated into the loop assay system. For E-selectin assays, E-selectin transfectants were adhered to the inside surface of glass capillary tubes and integrated into the loop assay system. After allowing the bovine lymphocytes to establish an interaction with either E- or P-selectin, 100ug/ml of control and GD3.5 mAbs were sequentially injected. As seen in Figure 11a and b, injection of control and GD3.5 mAb did not inhibit lymphocyte interactions with P- or E-selectin.

Effect of pretreating bovine lymphocytes with GD3.5 mAb on their interaction with 24hr activated endothelium

Since GD3.5 mAb did not inhibit lymphocyte adhesion to 4hr activated endothelium or to E- or P-selectin, we decided to pursue alternative adhesion assays. Lymphocytes have been shown to adhere to 24hr activated endothelium independent of E- and P-selectin (20,21). Therefore, we allowed bovine lymphocytes to interact with 24hr activated BUVECs (as described in Materials and Methods), and then sequentially injected 100ug/ml of control and GD3.5 mAbs to determine their affect on lymphocyte/endothelial cell interactions. As seen in Figure 12, injection of control or GD3.5 mAb did not inhibit lymphocyte/endothelial interactions.




Figure 10. GD3.5 mAb does not block lymphocyte adhesion to 4hr activated BUVECs or HUVECs. a) Lymphocytes were untreated or pretreated with GD3.5 mAb supernatant fluid and allowed to adhere to 4hr activated BUVECs. b) Lymphocytes were untreated or pretreated with GD3.5 mAb supernatant fluid and allowed to adhere to 4hr activated HUVECs. The number of adherent cells/BUVEC or HUVEC were counted in three separate microscopic fields/well and the average was recorded.




Figure 11. GD3.5 mAb does not block lymphocyte binding to E- or P-selectin. a) Bovine lymphocytes were allowed to interact with activated platelets and then control and GD3.5 mAbs were injected to determine their effect on lymphocyte/P-selectin interactions. b) Bovine lymphocytes were allowed to interact with E-selectin mouse L-cell transfectants and then control and GD3.5 mAbs were injected to determine their effect on lymphocyte/E-selectin interactions. The time of antibody injection is indicated by the arrows.




Figure 12. Injection of GD3.5 mAb does not block lymphocyte binding to 24hr activated endothelium. Bovine lymphocytes were allowed to interact with activated BUVECs and then control and GD3.5 mAbs were injected to determine their effect on lymphocyte/endothelial cell interactions. The time of antibody injection is indicated by the arrows.

Next, we determined if pretreatment of the lymphocytes with antibody would affect their ability to interact with 24hr activated endothelium. Bovine lymphocytes were pretreated with either 150ug/ml of GD3.8 or GD3.5 mAbs and integrated into the loop assay, as described above. As seen in Figure 13, lymphocyte treatment with GD3.5 mAb inhibited lymphocyte interactions with 24hr activated endothelium when compared to the GD3.8-treated controls. Thus, GD3.5 antibody appeared to inhibit $\gamma\delta$ T cell/endothelial cell interactions. Of interest, in some experiments, untreated cells were not significantly different than GD3.5 mAb-treated cells.




Figure 13. Pretreatment of lymphocytes with GD3.5 mAb blocks lymphocyte interactions with 24hr activated endothelium. Lymphocytes were pretreated with 150ug/ml of either GD3.8 or GD3.5 mAb and then infused into the in vitro shear-dependent assay to assess lymphocyte interactions with 24hr activated BUVEC monolayers. Data were analyzed, as described above, and recorded as the number of cells/frame at one minute intervals. Cells treated with GD3.8 or GD3.5 mAb are as marked.

Chymotrypsin-treated bovine lymphocyte interactions in adhesion assays

Previously, we reported that treatment of bovine $\gamma\delta$ T cells with increasing concentrations of α -chymotrypsin resulted in a concomitant loss of GD3.5Ag on the cell surface (24). Therefore, we tested whether chymotrypsin-treated bovine lymphocytes would interact in any of our adhesion assays. Since protease treatment results in the loss of GD3.5 expression on the cell surface, we surmised that if GD3.5Ag represented an E- or P-selectin ligand, then loss of expression would inhibit lymphocyte rolling on E- or P-selectin. For E-selectin assays, E-selectin transfectants were grown on the inside

surface of glass capillary tubes and integrated into the loop assay. For P-selectin assays, platelets were activated for 10min and adhered to the inside surface of glass capillary tubes and integrated into the loop assay system. Bovine lymphocytes were treated with 1U/ml α -chymotrypsin or sham treated for 1hr at 37°C, resuspended in DMEM/20mM Hepes and infused into the assay; cell/cell interactions were assessed, as described above. As shown in Figure 14a, chymotrypsin-treated lymphocytes rolled as well or better on E-selectin, suggesting that lymphocyte/E-selectin interactions were not dependent upon chymotrypsin-sensitive molecules, such as GD3.5Ag. In addition, we have previously shown in the low-shear assay that chymotrypsin treatment of bovine lymphocytes does not block binding of cells to E-selectin transfectants (14). In Figure 14b, we show that lymphocyte rolling on P-selectin was inhibited by chymotrypsin treatment when compared to control. Bovine lymphocyte E- and P-selectin ligands are further characterized in Chapter 4.

Next, we wanted to determine if chymotrypsin removal of GD3.5Ag from the cell surface would affect lymphocyte rolling on 24hr activated endothelium. Cells (1×10^7) were resuspended in HBSS with Ca^{2+} and Mg^{2+} and 0, 62.5, 125, or 250 mU α -chymotrypsin/ml and incubated for 1hr at 37°C. After completion of incubation, cells were washed and resuspended in DMEM/20mM Hepes for use in the rolling assays. In addition, treated and control cells were analyzed by single-color, indirect FACS analysis for GD3.5 antigen expression. FACS analysis of the chymotrypsin-treated cells demonstrated that, in fact, GD3.5Ag expression decreased with increasing concentrations of α -chymotrypsin (Figure 15a, see also Figure 7). Figure 15b shows a representative experiment demonstrating rolling of chymotrypsin-treated $\gamma\delta$ T cells on 24hr activated BUVECs. As $\gamma\delta$ T cells were treated with increasing concentrations of chymotrypsin (0-250mU/ml), they exhibited a stepwise loss in ability to interact with the activated




Figure 14. Loss of GD3.5Ag expression inhibits lymphocyte rolling on P-selectin, but not E-selectin. Chymotrypsin-treated or mock-treated bovine lymphocytes were allowed to adhere to E-selectin transfectants (a) or activated platelets (b) in the shear-dependent adhesion assay. The number of cells interacting with E- or P-selectin was assessed, as described in Materials and Methods. Control and treated are as marked.

endothelium, which correlated well with loss of expression on the cell surface. Importantly, bovine lymphocyte rolling on 24hr activated HUVEC monolayers revealed similar results (data not shown).

Characterization of polyclonal antibodies against GD3.5Ag

To further investigate GD3.5 function, we raised polyclonal sera against purified GD3.5Ag (see Materials and Methods). Mice were injected two separate times with purified GD3.5Ag and then bled for screening of antibody titers against bovine $\gamma\delta$ T cells. To test serum titers, mouse serum was serially diluted (1/10, 1/100, and 1/1000) and tested by FACS analysis. Dilution of the mouse serum (1/100) resulted in intense staining of bovine $\gamma\delta$ T cells (Figure 16). Clearly, purification of GD3.5Ag and injection into the mice, as described in the Materials and Methods, resulted in polyclonal antibodies that specifically stained bovine $\gamma\delta$ T cells, indicating that our antigen purification procedure worked well. Also, the polyclonal serum, which contains antibodies against multiple GD3.5 epitopes, specifically stained $\gamma\delta$ T cells, further supporting the idea that GD3.5Ag is a lineage-specific $\gamma\delta$ T cell marker.




Figure 15. $\gamma\delta$ T cell rolling on 24hr activated endothelium is inhibited by low-dose chymotrypsin treatment of the rolling cells. 15a) Purified $\gamma\delta$ T cells were treated with 0-250 mU α -chymotrypsin/ 1×10^7 cells for 1hr at 37°C and analyzed by FACS for GD3.5 antigen expression. 15b) Cells were then resuspended in media and infused into the loop assay system, as described in Materials and Methods. Figure 15 is representative of at least three separate experiments.




Figure 16. Anti-GD3.5 polyclonal sera stains bovine $\gamma\delta$ T cells. Polyclonal antibody was raised against GD3.5Ag, as described in Materials and Methods. Two color FACS analysis illustrating polyclonal staining vs pan- $\gamma\delta$ T cell antibody (GD3.8). Figure 16 is representative of at least three assays.

Next, we wanted to see if GD3.5 polyclonal antibodies specifically immunoprecipitated GD3.5Ag. Biotin-labeled $\gamma\delta$ T cell lysates were immunoprecipitated with GD3.5 polyclonal serum, control serum, and GD3.5 mAb (Figure 17, lanes 1,2, and 3, respectively). As expected, the polyclonal serum immunoprecipitated a 230kD band which was precleared by GD3.5 mAb (data not shown and see Chapter 5). Therefore, the polyclonal antibodies recognized GD3.5 antigen.




Figure 17. Anti-GD3.5 polyclonal sera immunoprecipitates GD3.5Ag. Biotinylated bovine $\gamma\delta$ T cell lysates were immunoprecipitated with anti-GD3.5 polyclonal antibody (lane 1), control serum (lane 2), or GD3.5 mAb (lane 3), as described in Materials and Methods. Figure 17 is representative of two experiments.

Since GD3.5 mAb appeared to inhibit lymphocyte accumulation on 24hr activated BUVECs, we wanted to determine if the polyclonal serum could block $\gamma\delta$ T cell interactions under the same conditions. Purified $\gamma\delta$ T cells were treated for 1hr at room

temperature with immune serum (1/100 dilution) or preimmune serum (1/100 dilution). Cells were then suspended in DMEM/20mM Hepes and infused into the loop assay system, as described in Materials and Methods. As seen in Figure 18, pretreatment of the cells with GD3.5 polyclonal serum resulted in the partial blocking of $\gamma\delta$ T cell accumulation on 24hr activated BUVECs. Thus, GD3.5Ag may be involved in adhesion of $\gamma\delta$ T cells to chronically activated endothelium.




Figure 18. Anti-GD3.5 polyclonal sera specifically inhibits accumulation of bovine $\gamma\delta$ T cells on 24hr activated endothelial cells. Purified bovine $\gamma\delta$ T cells were pretreated with control or anti-GD3.5 polyclonal antibody and infused into the in vitro shear-dependent adhesion assay, as described in Materials and Methods. Figure 18 is representative of at least three separate experiments using polyclonal antibodies from two different mice.

Discussion

The identification and characterization of $\gamma\delta$ T cell-specific surface molecules will be useful in understanding the biology and function of this cell type. In this report, we have characterized the regulation and potential function of a novel $\gamma\delta$ T cell-specific marker (GD3.5 antigen).

Bovine $\gamma\delta$ T cells are a unique subset of lymphocytes that are associated with epithelial tissues (1,5). $\gamma\delta$ T cells do not appreciably accumulate in the organized lymphoid tissues, such as the lymph node (1,4,5); however, several reports have demonstrated that larger populations of $\gamma\delta$ T cells are found in the spleens of ruminants when compared to lymph nodes (2,3). We confirmed that in fact $\gamma\delta$ T cells do not appreciably accumulate in the lymph nodes. The few $\gamma\delta$ T cells which are found in the lymph nodes possibly enter the node through the afferent lymph from the surrounding tissue on their way back to the blood (5). In addition, we showed that large populations of $\gamma\delta$ T cells are found in the spleen. Interestingly, the number of $\gamma\delta$ T cells in the spleen compared to the blood is not significantly different; however, the expression of GD3.5Ag and WC1 is significantly lower in the spleen population than in the blood. Perhaps the spleen population represents cells that were partially activated, or older, dying cells.

It has been shown that adhesion molecules are shed upon activation with artificial and natural compounds. For example, L-selectin is downregulated on murine T cells upon treatment with ConA and L-selectin expression returns when mitogen stimulation is removed (29). Thus, we wanted to determine if GD3.5Ag expression could be downregulated in vitro by treatment with various artificial activating compounds. We showed that $\gamma\delta$ T cells downregulate GD3.5Ag when treated with both ConA and PHA. In

addition, PHA downregulates WC1 expression. Incidentally, others have reported that higher concentrations of ConA result in the downregulation of WC1 (30), indicating that 2uM ConA treatment is suboptimal for WC1 downregulation under these conditions. Interestingly, after four days of culture, the lymphocytes begin to return to a resting state which coincides with a return of both GD3.5Ag and WC1 expression by the sixth day. These results indicate that GD3.5 and WC1 expression correlate with the mitogen activation profile. Since GD3.5Ag and WC1 demonstrate similar regulation upon mitogen activation when compared to L-selectin, we initially hypothesized that these molecules may represent adhesion ligands on $\gamma\delta$ T cells. Therefore, we tested whether or not GD3.5 mAb would block bovine lymphocyte adhesion in our panel of functional assays.

Initially, we tested whether GD3.5 mAb would block adhesion of lymphocytes to 4hr activated BUVECs and HUVECs. Leukocyte adhesion and transmigration through endothelial layers involves a multistep process requiring many adhesion molecules. Using the low-shear assay, initial and tight adhesion events can occur. Therefore, if GD3.5 mAb blocked binding of lymphocytes in this assay, it could be due to blocking initial or tight adhesion events; however, GD3.5 mAb does not have any effect in these assays.

In an attempt to look more closely at binding to E- or P-selectin, we used our in vitro shear-dependent assay to address whether or not GD3.5 mAb specifically inhibits binding to E- or P-selectin. As shown above, lymphocytes were allowed to adhere to E- or P-selectin and then control and GD3.5 mAb were injected (100ug/ml) to determine if it would block adhesion to these selectins. As shown above, GD3.5 mAb does not inhibit lymphocyte rolling on E- or P-selectin.

Since GD3.5 mAb did not block adhesion to E- or P-selectin or inhibit tight adhesion to 4hr activated endothelium, we decided to study its effect in other adhesion assays.

Recent reports have indicated that lymphocytes roll on 24hr activated endothelium independent of E- and P-selectin (20). More recently, we determined that $\gamma\delta$ T cells interact with chronically activated endothelium in an E- and P-selectin-independent manner (21). Thus, we tested whether GD3.5 mAb injected into the shear-dependent adhesion assay would inhibit bovine lymphocyte interactions with 24hr activated endothelium. GD3.5 mAb, when compared to control, does not inhibit established lymphocyte interactions with the 24hr activated endothelium. In contrast, when bovine lymphocytes are pretreated with GD3.5 mAb vs. another $\gamma\delta$ T cell-specific antibody (GD3.8), only GD3.5 has an inhibitory effect on lymphocyte interactions with 24hr activated endothelium. However, since considerable variability was seen in these assays, we pursued other approaches to further address this issue (see below).

Earlier reports showed that treatment of neutrophils with low-dose chymotrypsin leads to loss of L-selectin, inhibits neutrophil binding to high endothelial venules, and reduces the capacity of the cells to home to sites of inflammation (22). We have previously shown that GD3.5 antigen is very sensitive to low-dose chymotrypsin, exhibiting sensitivity greater than even L-selectin (24). Based on this information, we tested whether chymotrypsin-treated cells would interact with E- and/or P-selectin. We showed that $\gamma\delta$ T cell rolling on E-selectin is unaffected by low-dose chymotrypsin treatment. Thus, consistent with our previous report (14), we showed that $\gamma\delta$ T cell E-selectin ligands are resistant to low-dose chymotrypsin treatment.

Several investigators have described a glycoprotein ligand for P-selectin on neutrophils and lymphocytes (31,32). This ligand, termed P-selectin glycoprotein ligand-1 (PSGL-1), is sensitive to protease treatment (31,32). Since GD3.5Ag is sensitive to chymotrypsin treatment, we proposed that perhaps this antigen was a P-selectin ligand. In fact, chymotrypsin-treated lymphocytes do not roll efficiently on P-selectin, suggesting that perhaps GD3.5Ag is the ligand. However, further investigation

into this possibility suggests that GD3.5Ag is not a P-selectin ligand (see Chapter 4).

Next, we tested whether chymotrypsin-treated $\gamma\delta$ T cells would interact with 24hr activated endothelium. In fact, rolling of chymotrypsin-treated $\gamma\delta$ T cells on 24hr activated endothelium is inhibited in a dose-dependent manner, which correlates well with the loss of GD3.5Ag expression as measured by FACS analysis. Therefore, we proposed that perhaps GD3.5Ag was mediating the adhesion of $\gamma\delta$ T cells to the 24hr activated endothelium; although, it is possible that other adhesion ligands could share similar chymotrypsin sensitivity.

Since pretreatment of lymphocytes with GD3.5 mAb appeared to partially, though variably, inhibit their interactions with 24hr activated endothelium, and the loss of GD3.5Ag expression correlated with the loss in ability to roll on 24hr activated endothelium, we generated polyclonal anti-serum against GD3.5Ag to further study this interaction. Anti-GD3.5 polyclonal antibody stains only bovine $\gamma\delta$ T cells indicating that this molecule is a lineage-specific $\gamma\delta$ T cell-surface antigen. Due to the specific staining of $\gamma\delta$ T cells by the anti-GD3.5 polyclonal antibodies, we decided to determine if it would block lymphocyte adhesion to 24hr activated endothelium. Three mice exhibited GD3.5Ag serum titers, two of which provided serum that partially blocked $\gamma\delta$ T cell interactions with 24hr activated endothelium. Importantly, the polyclonal antibody inhibits bovine lymphocyte interactions with 24hr activated endothelium similarly to GD3.5 mAb.

We have recently identified an adhesion molecule expressed on 24hr activated endothelium (21). In these experiments, we discovered that platelets secrete a soluble form of the antigen that specifically binds $\gamma\delta$ T cells. Preliminary results indicate that polyclonal serum does not block this interaction (data not shown). Recent results in our lab indicate that bovine umbilical vein endothelial cells express E-selectin, and since GD3.5Ag does not appear to be an E-selectin ligand, it is possible that it binds a different

ligand on the endothelial cell surface. Possibly, GD3.5 mediates binding to the endothelium independent of E-selectin, but shares an overlapping function with E-selectin similar to the apparent overlapping functions of E- and P-selectin.

Another possibility regarding function could involve downstream adhesion events. Leukocyte adhesion and transmigration through endothelial layers requires a multistep process including rolling, tight adhesion and transmigration. It is possible that GD3.5Ag is involved in these types of adhesion events; however, preliminary results suggest that GD3.5 polyclonal antibodies do not inhibit tight adhesion or transmigration (data not shown).

Finally, it is possible that engagement of GD3.5Ag with antibody doesn't directly block lymphocyte/endothelial interactions but may provide a signal that alters the expression of the directly involved lymphocyte adhesion ligand. In fact, some adhesion molecules are expressed in a less active form until the cell is activated. For example, P-selectin glycoprotein ligand-1 (PSGL-1), which binds to P-selectin, is expressed in a less functional form on lymphocytes. However, once the lymphocyte is activated, a more functional form is expressed (32). Perhaps pretreatment of the lymphocytes with GD3.5 antibodies inhibits the expression of higher avidity adhesion ligands, such as PSGL-1. If GD3.5 is a signalling molecule then we could begin to explore the involvement of various signalling pathways. For instance, the inhibitory effects of GD3.5 mAb treatment may be overcome by treating cells with activating compounds, such as phorbol esters and calcium ionophores. In addition, cell signalling inhibitors, such as kinase inhibitors, could be used to determine if the engagement of GD3.5 requires a signal to elicit the inhibitory effect.

In summary, GD3.5Ag expression is downregulated *in vivo* and this can be mimicked *in vitro*. In addition, chymotrypsin removal of GD3.5Ag from the cell surface correlates well with the loss in ability of $\gamma\delta$ T cells to roll on 24hr activated

endothelium. Finally, pretreatment of bovine $\gamma\delta$ T cells with monoclonal antibodies or polyclonal antibodies against GD3.5Ag inhibits their accumulation on 24hr activated endothelium.

References

1. Hein, W. R., and C. R. Mackay. 1991. Prominence of $\gamma\delta$ T cells in the ruminant immune system. *Immunol. Today* 12:30.
2. Wyatt, C. R., C. Madruga, C. Cluff, S. Parish, M. J. Hamilton, W. Goff, and W. C. Davis. 1994. Differential distribution of $\gamma\delta$ T-cell receptor lymphocyte subpopulations in blood and spleen of young and adult cattle. *Vet Immunol. Immunopath.* 40:187.
3. Mackay, C. R., J. F. Maddox, and M. R. Brandon. 1986. Three distinct subpopulations of sheep T lymphocytes. *Eur. J. Immunol.* 16:19.
4. Clevers, H., N. D. MacHugh, A. Bensaid, S. Dunlap, C. L. Baldwin, A. Kaushal, K. Iams, C. J. Howard and W. I. Morrison. 1990. Identification of a bovine surface antigen uniquely expressed on CD4/CD8-negative, T cell receptor $\gamma\delta$ + T lymphocytes. *Eur. J. Immunol.* 20:809.
5. Mackay, C. R., and W. R. Hein. 1989. A large proportion of bovine T cells express the $\gamma\delta$ T cell receptor and show a distinct tissue distribution and surface phenotype. *Int. Immunol.* 1:540.
6. Mackay, C. R., and W. R. Hein. 1990. Analysis of $\gamma\delta$ T cells in ruminants reveals further heterogeneity in $\gamma\delta$ T-cell features and function among species. *Research Immunol.* 141:611.
7. Davis, W. C., S. Marusic, H. A. Lewin, G. A. Splitter, L. E. Perryman, T. C. McGuire, and J. R. Gorham. 1987. The development and analysis of species specific and cross reactive monoclonal antibodies to leukocyte differentiation antigens and antigens of the major histocompatibility complex for use in the study of the immune system in cattle and other species. *Vet. Immunol. Immunopathol.* 15:337.
8. Howard, C. J., P. Sopp, K. R. Parsons, and J. Finch. 1989. *In vivo* depletion of BoT4 (CD4) and non-T4/T8 lymphocyte subsets in cattle with monoclonal antibodies. *Eur. J. Immunol.* 19:757.
9. Itohara, S., A. G. Farr, J. J. Lafaille, M. Bonneville, Y. Takagake, W. Haas, and S. Tonegawa. 1990. Homing of a $\gamma\delta$ thymocyte subset with homogenous T-cell receptors to mucosal epithelia. *Nature* 343:754.
10. Nandi, D., and J. P. Allison. 1991. Phenotypic analysis and $\gamma\delta$ -T cell receptor repertoire of murine T cells associated with the vaginal epithelium. *J. Immunol.* 147:1773.
11. Bukowski, J. F., C. T. Morita, Y. Tanaka, B. R. Bloom, M. B. Brenner, and H. Band. 1995. V γ 2V δ 2 TCR-Dependent recognition of non-peptide antigens and daudi cells analyzed by TCR gene transfer. *J. Immunol.* 154:998.
12. Kronenberg, M., 1994. Antigens recognized by $\gamma\delta$ T cells. *Curr Opin Immunol.* 6:64.

13. Abrahamsen, M. S., C. A. Lancto, B. Walcheck, W. Layton, and M. A. Jutila. 1997. Localization of α/β and γ/δ T lymphocytes in *Cryptosporidium parvum*-infected tissues in naive and immune calves. *Infect Immun.* 65:2428.
14. Walcheck, B., G. Watts, and M. A. Jutila. 1993. Bovine γ/δ T cells bind E-selectin via a novel glycoprotein receptor: First characterization of a lymphocyte/E-selectin interaction in an animal model. *J. Exp. Med.* 178:853.
15. Doherty, M. L., H. F. Bassett, P. J. Quinn, W. C. Davis, A. P. Kelly, and M. L. Monaghan. 1996. A sequential study of the bovine tuberculin reaction. *Immunol.* 87:9.
16. Woolley, S. T., A. Whyte, S. T. Licence, D. O. Haskard, F. B. P. Wooding, and R. M. Binns. 1995. Differences in E-selectin expression and leucocyte infiltration induced by inflammatory agents in a novel subcutaneous sponge matrix model. *Immunol.* 84:55.
17. Whyte, A., D. O. Haskard, and R. M. Binns. 1994. Infiltrating γ/δ T-cells and selectin endothelial ligands in the cutaneous phytohaemagglutinin-induced inflammatory reaction. *Vet. Immunol. Immunopath.* 41:31.
18. Binns, R. M., A. Whyte, S. T. Licence, A. A. Harrison, Y. T. M. Tsang, D. O. Haskard, and M. K. Robinson. 1996. The role of E-selectin in lymphocyte and polymorphonuclear cell recruitment into cutaneous delayed hypersensitivity reactions in sensitized pigs. *J. Immunol.* 157:4094.
19. Jutila, M. A., R. F. Bargatze, S. Kurk, R. A. Warnock, N. Ehsani, S. R. Watson, and B. Walcheck. 1994. Cell surface P- and E-selectin support shear-dependent rolling of bovine γ/δ T cells. *J. Immunol.* 153:3917.
20. Jones, D. A., L. V. McIntire, C. W. Smith, and L. J. Picker. 1994. A two-step adhesion cascade for T cell/endothelial cell interactions under flow conditions. *J. Clin. Invest.* 94:2443.
21. Jutila, M. A., E. Wilson, and S. Kurk. 1997. Characterization of an adhesion molecule that mediates leukocyte rolling on 24-hr cytokine or LPS-activated endothelial cells under flow conditions. Submitted to The Journal of Experimental Medicine.
22. Jutila, M. A., T. K. Kishimoto, and M. Finken. 1991. Low-dose chymotrypsin treatment inhibits neutrophil migration into sites of inflammation *in vivo*: Effects on Mac-1 and MEL-14 adhesion protein expression and function. *Cell. Immunol.* 132:201.
23. Moore, K. L., A. Varki, and R. P. McEver. 1991. GMP-140 binds to a glycoprotein receptor on human neutrophils: evidence for a lectin-like interaction. *J. Cell Biol.* 112:491.
24. Jones, W. M., B. Walcheck, and M. A. Jutila. 1996. Generation of a new γ/δ T cell-specific monoclonal antibody (GD3.5): biochemical comparisons of GD3.5 antigen with the previously described workshop cluster 1 (WC1) family. *J. Immunol.* 156:3772.

25. Jutila, M. A., G. Watts, B. Walcheck, and G. S. Kansas. 1992. Characterization of a functionally important and evolutionarily well-conserved epitope mapped to the short consensus repeats of E-selectin and L-selectin. *J. Exp Med.* 175:1565.
26. Bargatze, R. F., S. Kurk, G. Watts, T. K. Kishimoto, C. A. Speer, and M. A. Jutila. 1994. In vivo and in vitro functional examination of a conserved epitope of L- and E-selectin crucial for leukocyte-endothelial cell interactions. *J. Immunol.* 152:5814.
27. Bargatze, R. F., S. Kurk, E. C. Butcher, and M. A. Jutila. 1994. Neutrophils roll on adherent neutrophils bound to cytokine-induced endothelial cells via L-selectin on the rolling cells. *J. Exp. Med.* 180:1785.
28. Jutila, M. A., and S. Kurk. 1996. Analysis of bovine $\gamma\delta$ T cell interactions with E-, P-, and L-selectin: characterization of lymphocyte on lymphocyte rolling and the effects of O-glycoprotease. *J. Immunol.* 156:289.
29. Jung, T. M., W. M. Gallatin, I. L. Weissman, and M. O. Dailey. 1988. Down-regulation of homing receptors after T cell activation. *J. Immunol.* 141:4110.
30. Lund, B. T., C. W. Evans, W. C. Davis, I. McConnell, and R. Bujdoso. 1993. Expression of T19 (WC1) molecules by ovine lymphocytes. *Vet. Immunol. Immunopath.* 39:145.
31. Moore, K. L., A. Varki, and R. P. McEver. 1991. GMP-140 binds to a glycoprotein receptor on human neutrophils: Evidence for a lectin-like interaction. *J. Cell Biol.* 112:491.
32. Vachino, G., X.-J. Chang, G. M. Veldman, R. Kumar, D. Sako, L. A. Fouser, M. C. Berndt, and D. A. Cumming. 1995. P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells. *J. Biol. Chem.* 270:21966.

CHAPTER 4

COMPARISON OF E-SELECTIN BINDING GLYCOPROTEIN LIGANDS ON HUMAN LYMPHOCYTES, NEUTROPHILS, AND BOVINE $\gamma\delta$ T CELLS: IDENTIFICATION OF NOVEL E-SELECTIN LIGANDS ON HUMAN LYMPHOCYTES AND BOVINE $\gamma\delta$ T CELLS

Introduction

Many of the initial adhesion events between leukocytes and endothelial cells require a unique group of molecules called selectins (1-4). To date, three proteins have been identified and classified as selectins. These include E-selectin, P-selectin, and L-selectin (CD62E, CD62P, and CD62L, respectively). The selectins are defined by an NH₂-terminal, Ca²⁺-dependent, C-type lectin domain, an EGF (epidermal growth factor-like) region, several short consensus repeat (SCR) units depending upon the selectin, and a transmembrane region with a cytoplasmic tail (1,2,5). E-selectin is expressed on endothelial cells while P-selectin is expressed on endothelium and platelets. L-selectin is expressed on leukocytes and is characterized by a different molecular mass depending upon the expressing cell type. The two vascular selectins, E- and P-selectin, support interactions of myeloid cells and unique subsets of T cells, including memory cells and $\gamma\delta$ T cells (6-11). Because of their critical role in the initial leukocyte tethering to endothelium, many investigators have devoted a great deal of time to defining the ligands for each selectin on various target cells.

All three selectins bind to both sialyl Lewis a (SLe^a) and sialyl Lewis x (SLe^x)

tetrasaccharide structures, which are expressed by many different cell types (12-18). Specific high molecular mass glycoproteins present these carbohydrates in appropriate fashion to support cell/cell adhesion (17,19). In the context of the vascular selectins, E- and P-selectin, high molecular mass ligands on neutrophils have been well defined (20-28). For example, P-selectin glycoprotein ligand-1 (PSGL-1) on neutrophils serves as a ligand for P-selectin (20,21), and, perhaps, E-selectin as well (22-26). E-selectin ligand-1 (ESL-1) is another neutrophil glycoprotein that has been shown to bind E-selectin (27,28). Finally, some studies have shown that human neutrophil L-selectin is decorated by SLe^x and supports E-selectin binding (29-32).

In contrast to neutrophils, far less is known about the glycoprotein ligands for the vascular selectins expressed by lymphocytes. An appropriate post-translationally modified form of PSGL-1 is likely to be the lymphocyte ligand for P-selectin (8,33); however, the lymphocyte ligands for E-selectin are unknown. Lymphocyte PSGL-1 does not appear to interact appreciably with E-selectin (6,34,35), as has been shown with neutrophil PSGL-1 (22-26). Indeed, O-sialoglycoprotease treatment of lymphocytes, which hydrolyzes PSGL-1, blocks their binding to P-selectin, but not E-selectin (6,34,35). Interestingly, the mAb HECA-452 recognizes the E-selectin binding human lymphocytes, but HECA-452 staining does not correlate with the P-selectin binding subset, further distinguishing the two (34,36,37). The HECA-452 epitope is a carbohydrate structure called cutaneous lymphocyte-associated antigen (CLA) that decorates many different cell surface ligands (9) and directly interacts with E-selectin (36,37). Which of the different CLA glycoproteins serve as the predominant E-selectin-binding molecule is unknown at this time.

Recently, we showed that virtually all bovine $\gamma\delta$ T cells in newborn animals have the capacity to bind E-selectin (11). In contrast, $\alpha\beta$ T cells acquire this binding

capacity only after conversion to a memory phenotype (9,10,37). We isolated a 250kD E-selectin binding molecule from $\gamma\delta$ T cells using an affinity isolation procedure (11) that involved using purified, recombinant E-selectin immobilized on Sepharose beads by a nonblocking anti-E-selectin mAb. Until now, we were unable to fully confirm the 250kD molecule as the first defined lymphocyte E-selectin ligand.

A powerful tool to study selectin ligands are selectin/immunoglobulin chimeras that in effect can be used as an antibody. These constructs are comprised of the adhesion binding portion of the selectins (lectin domain, and sometimes EGF and SCR domains) attached to the constant domain of Ig. We have had success in the past using a P-selectin/Ig chimera to study $\gamma\delta$ T cells (7). In this report, we describe new studies using an E-selectin/immunoglobulin chimera containing a lectin domain from porcine E-selectin, which apparently has a much higher affinity for E-selectin ligand (38). The E-selectin chimera was used to analyze $\gamma\delta$ T cell ligands for E-selectin and to compare and contrast these ligands with those expressed by human neutrophils and lymphocytes.

Materials and Methods

Human and bovine leukocyte purification and biotin labeling

Bovine blood was obtained, and $\gamma\delta$ T cells were purified as described previously (39). Briefly, lymphocytes were purified from Holstein calf blood by Histopaque (Sigma Chemical Co., St. Louis, MO) separation and then incubated in T175 flasks to allow monocyte removal. $\gamma\delta$ T cells were purified from whole lymphocyte preparations by incubation in T175 flasks coated with 7×10^6 adherent E-selectin cDNA L-cell transfectants. Unbound cells were discarded and bound $\gamma\delta$ T cells removed by treatment with 2mM EDTA/PBS providing >90% pure $\gamma\delta$ T cells (11). Human lymphocytes were

prepared by Histopaque separation with subsequent incubation in T175 flasks to remove monocytes, resulting in >95% pure lymphocyte populations by scatter profile analysis. Human neutrophils were purified by 1% dextran separation for 1hr at 4°C, and then the top layer was removed and neutrophils were pelleted by Histopaque separation. $\gamma\delta$ T cells, human neutrophils, and human lymphocytes were separately biotinylated as described below. 1×10^8 cells were washed 3 times with sterile PBS and resuspended in 1ml of NHS-LC-Biotin/PBS (550ug/ml Pierce, Rockford, IL). After 30min incubation at room temperature (RT), cells were washed 3 times with PBS and lysed for 30min on ice with Nonidet P-40 (NP-40 lysis buffer) (39). 5% rabbit serum was added to lysates for 1hr at RT and then precleared with protein G beads (Boehringer Mannheim Biochemicals, Indianapolis, IN) overnight at 4°C with constant rotation. Beads were subsequently removed and lysates were either used immediately or frozen at -80°C.

mAbs. E- and P-selectin chimeras. and FACS analysis

Monoclonal antibodies used included IL-A29 (anti-WC1), DREG-56 (anti-L-selectin), HECA-452 (anti-CLA), YT11.1 (anti-pig E-selectin) (40,41), anti-ESL-1 polyclonal antibody (42), and two in-house bovine $\gamma\delta$ T cell-specific mAbs GD3.5 and GD3.8 (pan $\gamma\delta$ TCR) (39, Wilson, E., and M. A. Jutila, manuscript in preparation). Human E- and P-selectin chimeras were kindly provided by S. Watson. Pig E-selectin chimera (P11.4) was kindly provided by M. Robinson. Pig chimera was used to immunoprecipitate relevant selectin ligands on human neutrophils, lymphocytes, and bovine $\gamma\delta$ T cells.

<u>Antibody/Chimera</u>	<u>Antigen/Specificity</u>	<u>Species</u>
IL-A29	WC1	Cattle
GD3.5	GD3.5Ag	Cattle
GD3.8	TCR	Cattle
DREG-56	L-selectin	Cattle/Human
HECA-452	CLA	Human
ESL-1 polyclonal	ESL-1	Mouse/Human/Cattle
YT11.1	anti-E-selectin chimera	Pig
P11.4 (E-selectin chimera)	E-selectin ligands	Human/Cattle

Table 1. List of reagents used for E-selectin ligand analysis. The antibody and chimera reagents used in these studies are listed above describing antigen specificity in the indicated species.

FACS analysis was performed on ice as follows: cells were incubated with pig E-selectin chimera supernatant for 30min (4°C). Staining of human lymphocytes with P11.4 required incubation for 90min at RT. Cells were washed and incubated with PE-conjugated α -human secondary antibody (Jackson ImmunoResearch, West Grove, PA) for 30min, washed again, and analyzed. In blocking experiments, pig E-selectin chimera was incubated with excess blocking antibody (YT11.1) for 30min and then added to cells. Two-color analysis was performed using PE-conjugated secondary antibody followed by a 10min block with 10% mouse serum and subsequent 30min incubation with FITC-conjugated second stage antibody. Staining of bovine lymphocytes with GD3.8 and anti-ESL-1 antibodies was performed by incubation with GD3.8 mAb and anti-mouse PE-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA) and blocked as described above. Cells were then stained with anti-ESL-1 polyclonal antibody, washed, and incubated with FITC-conjugated anti-rabbit secondary antibody (Jackson ImmunoResearch). HECA-452 positive human lymphocytes were gated for analysis to reduce background resulting from B-cells stained with anti-human PE-conjugated secondary antibody. Irrelevant rabbit polyclonal anti-serum

was used as a negative control to ensure specificity of ESL-1 FACS analyses. All analyses were performed using a FACScan flow cytometer (Becton Dickinson).

Western Blot

Purified $\gamma\delta$ T cell lysates were run under nonreducing conditions through a SDS-8% polyacrylamide gel and then transferred to PVDF membrane overnight (Bio Rad, Hercules, CA). After transfer, the membrane was blocked for 30 minutes with 50% calf serum, 5% goat serum, in HBSS containing Ca^{2+} and Mg^{2+} at 4°C. The membrane was then placed in a miniblotted apparatus and selected lanes were incubated with E-selectin chimera (P11.4) at 4°C for 1 hour. Chimera was gently removed by hand and washed by aspiration with blocking buffer. The lanes were filled with clean blocking buffer and incubated for 5-10 minutes at room temperature. After aspiration of blocking buffer, anti-human alkaline phosphatase second stage (Jackson ImmunoResearch Laboratory) was diluted 1:100 in the blocking buffer and added to appropriate lanes for 15 minutes at 4°C and then incubated for 15 minutes at room temperature. Second stage antibody was aspirated off and lanes were gently aspirated up and down by hand using blocking buffer. A second wash with blocking buffer was performed followed by two additional washes with Hepes buffered (10 mM) HBSS containing Ca^{2+} and Mg^{2+} . Membranes were removed from the miniblotted and gently rinsed with PBS before developing to desired intensity using nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (Sigma Chemical Co., St. Louis, MO) in AP buffer (100mM Tris, pH 9.5, 100mM NaCl, and 5mM MgCl_2).

Immunoprecipitation/Crossprecipitation

Precleared biotin-labeled lysates were incubated with 10-20ug GD3.5, IL-A29, DREG-56, control, or E-selectin chimera for 1hr at RT. Ab/Ag or chimera/ligand

complexes were precipitated with protein G beads at 4°C overnight under constant rotation. The beads were washed 3 times with wash buffer (0.1% NP-40, 100mM NaCl, 1mM CaCl₂, 1mM MgCl₂, 5mM sodium azide, and 10mM Hepes) and mixed with nonreducing loading buffer and loaded onto 8% SDS-polyacrylamide gels (39). Gels were electrophoresed and transferred to PVDF membranes (Bio-Rad, Hercules, CA). After transfer, membranes were washed briefly with 1x TBST and then blocked with 7% BSA/TBST for 2hrs at RT. Membranes were then washed with several changes of 1x TBST for 1.75hrs. Streptavidin horseradish peroxidase conjugate (Amersham Life Science, Buckinghamshire, England) was diluted 1/5000 in sterile PBS, incubated with the membrane for 40min, and then washed for 1.75hrs with several changes of 1x TBST. ECL detection reagents were used according to manufacturer's recommendations (Amersham Life Science, Buckinghamshire, England) and incubated with the membranes for 1 min. Membranes were then covered with cellophane, exposed to X-OMAT film for 1-10 minutes, and the film was developed (Kodak, Rochester, New York). YT11.1 mAb was used to block E-selectin chimera by first incubating mAb with chimera for 15min at RT, then adding it to the appropriate lysate.

Crossprecipitation experiments were performed as follows. Separate biotinylated lysates were cleared of Workshop Cluster 1 (WC1) or GD3.5 antigen by incubation with 20ug of either IL-A29 or GD3.5 mAbs, respectively, and immunoprecipitated with protein G beads, as described above. After bead removal, WC1 and GD3.5 antigen cleared lysates were incubated a second time with 15ug of IL-A29 or GD3.5 mAbs, respectively, and immunoprecipitated. Three subsequent clearing steps with protein G beads were performed on the lysates to ensure removal of all Ab/Ag complexes. E-selectin chimera or P-selectin chimera was used to immunoprecipitate lysates cleared of either GD3.5 antigen or WC1. Chimera/ligand complexes were precipitated with protein G beads and mixed with standard 2x nonreducing loading buffer, boiled for two

minutes, and loaded onto 8% SDS-polyacrylamide gels. Gels were electrophoresed, transferred, and developed, as described above.

Crossprecipitation of human neutrophil lysates was performed as follows: Separate biotinylated lysates were cleared with 20ug control or DREG-56 mAb (anti-L-selectin) and immunoprecipitated with protein G beads, as described above. After bead removal, lysates were cleared a second time with 15ug of control or DREG-56 mAb, respectively, and immunoprecipitated a second time. Three subsequent clearing steps with protein G beads were performed on the lysates to ensure removal of all Ab/Ag complexes. E-selectin chimera was used to immunoprecipitate lysates cleared with either control or DREG-56 mAb. Chimera/ligand complexes were precipitated with protein G beads and mixed with standard 2x nonreducing loading buffer, boiled for two minutes, and loaded onto 8% SDS-polyacrylamide gels. Gels were electrophoresed, transferred, and developed, as described above. Developed gels were scanned into Adobe Photoshop using a Hewlett Packard ScanJet 4c and images were imported into Microsoft PowerPoint and printed on high grade laser copier paper.

Results

Flow cytometric analysis of bovine leukocytes

First, we determined if the pig E-selectin chimera could be used in flow cytometric analysis to confirm our earlier results that $\gamma\delta$ T cells in newborn animals have the capacity to bind E-selectin. Figure 19a shows a two-color analysis comparing P11.4 staining versus staining with a bovine pan- $\gamma\delta$ T cell mAb. Virtually all of the lymphocytes that were stained by P11.4 were $\gamma\delta$ T cells and most of the $\gamma\delta$ T cells were stained by the chimera. Figure 19b demonstrates a histogram overlay showing control, P11.4, and P11.4 plus E-selectin blocking YT11.1 mAb staining profiles.

Preincubation of the chimera with anti-E-selectin mAb YT11.1 completely blocked binding of the chimera, indicating that binding of P11.4 to bovine lymphocytes was specific. These results are exactly the same as those described previously using cell/cell binding assays, and they confirm the specificity of the P11.4 chimera (7, 11).

Western Blot and immunoprecipitation of bovine E-selectin ligands

Due to the intense staining of bovine $\gamma\delta$ T cells with P11.4 by flow cytometry, we evaluated whether the chimera could be used to probe E-selectin ligands expressed by $\gamma\delta$ T cells. In our first experiment, we tested whether P11.4 reacted with affinity-purified 250kD ligand isolated, as described in our earlier study (11). Affinity-purified 250kD ligand was dotted onto PVDF membrane and then probed with P11.4. P11.4 reacted intensely with the 250kD fraction (data not shown). To determine if other $\gamma\delta$ T cell antigens react with P11.4, total $\gamma\delta$ T cell lysate was probed with P11.4. In Figure 20, lanes 2 and 4, we show that P11.4 reacted with a 250kD species as well as three other molecules at 180kD, 200kD, and 300kD. These results confirm that the 250kD ligand described in our earlier report does indeed bind E-selectin; however, E-selectin also appears to have the potential to interact with three additional molecules.

Our next series of analyses was intended to determine if any of the ligands detected by the Western blot procedure are expressed on the cell surface. Cell surface antigens on $\gamma\delta$ T cells were labeled with biotin, detergent extracts made, immunoprecipitation procedures performed, and the immunoprecipitated fractions run on an 8% PAGE gel. The gel was transferred to PVDF membrane and biotin-labeled proteins were detected by streptavidin horseradish peroxidase conjugate, as described in Materials and Methods. In Figure 21, lane 1, two distinct bovine $\gamma\delta$ T cell E-selectin ligands of 180-200kD and 250kD were precipitated by this procedure (indicated by arrows). The




Figure 19. Bovine $\gamma\delta$ T cells are specifically stained by E-selectin chimera. 19a) Two-color analysis of bovine lymphocytes stained with P11.4 and GD3.8 (pan $\gamma\delta$ T cell marker). 19b) Single-color histogram overlay illustrating second-stage control (hashed line), cells stained with P11.4 (solid line), and cells stained with P11.4 that was incubated with function-blocking mAb YT11.1 (dotted line), as described in Materials and Methods. Figure 19 is representative of at least three separate experiments.




Figure 20. $\gamma\delta$ T cell lysates contain four E-selectin-reactive molecules by Western Blot. Lanes 1 and 3 are negative controls (media alone), while lanes 2 and 4 represent duplicate lanes probed with P11.4. Arrows indicate E-selectin chimera-reactive bands. Western blots were analyzed, as described in Materials and Methods. Molecular standards are as marked. Figure 20 is representative of at least three separate experiments.

interaction of P11.4 with these two ligands was inhibited by preincubation of the chimera with the YT11.1 E-selectin blocking mAb (Figure 21, lane 2), once again illustrating specificity of the interaction. Although the 250kD ligand is completely blocked, a small percentage of the 180-200kD molecule is not blocked indicating the blockage was incomplete or a second 200kD nonspecific contaminant exists. In addition,

pretreatment with EDTA blocked binding of P11.4 to these ligands indicating that the chimera/ligand interaction was divalent cation-dependent (data not shown). In some experiments, we immunoprecipitated a 300kD ligand, but it was not consistently detected (data not shown). Therefore, we have confirmed that one of the E-selectin ligands expressed by $\gamma\delta$ T cells is a 250kD molecule, as previously reported. In addition, P11.4 chimera immunoprecipitation provided evidence for additional ligands of 200kD and, inconsistently, 300kD.




Figure 21. Two distinct E-selectin ligands are immunoprecipitated from surface biotinylated $\gamma\delta$ T cell lysates using E-selectin chimera. $\gamma\delta$ T cell lysates were immunoprecipitated with E-selectin chimera (lane 1) or functionally blocked E-selectin chimera (YT11.1) (lane 2) and analyzed by SDS-PAGE, as described in Materials and Methods. Arrows indicate relevant E-selectin ligands on $\gamma\delta$ T cells. Molecular standards are indicated on the left. Figure 21 is representative of at least three separate experiments using blocking antibody YT11.1 or EDTA.

The above data suggest that GD3.5Ag (230kD) is electrophoretically distinct from the immunoprecipitated E-selectin ligands (200kD and 250kD). In addition, as shown in Chapter 3, GD3.5 mAb does not block lymphocyte adhesion to E- or P-selectin. However, it is possible that GD3.5 antibody is not a function blocker. Also, the chymotrypsin data in Chapter 3 showed that E-selectin ligands were chymotrypsin resistant and P-selectin ligands were chymotrypsin sensitive, characteristics of WC1 and GD3.5Ag, respectively. Therefore, we decided to use crossprecipitation experiments to determine if GD3.5Ag and WC1 represented E- or P-selectin ligands. Biotinylated $\gamma\delta$ T cell lysates were precleared of GD3.5Ag or WC1 and then crossprecipitated with E- or P-selectin chimera. In Figure 22a and 22b, lanes 1 and 2 show the first round of lysates cleared with 20ug of IL-A29 or GD3.5 mAbs, respectively. Lanes 3 and 4 show lysates cleared of all IL-A29/WC1 and GD3.5Ag/GD3.5Ab complexes, respectively. In Figure 22a, lanes 5 and 6, both the 180-200kD and 250kD E-selectin ligands were precipitated from WC1 and GD3.5Ag cleared lysates, respectively. In addition, P-selectin chimera precipitated ligands from WC1 and GD3.5Ag cleared lysates, respectively (Figure 22b, lanes 5 and 6). Importantly, crossprecipitated E- or P-selectin ligands were not diminished in the WC1 or GD3.5 cleared lysates, indicating that GD3.5Ag and WC1 do not represent E- or P-selectin ligands.

Flow cytometric analysis of human leukocytes

Next, we used P11.4 to examine E-selectin ligands on human neutrophils and lymphocytes. Importantly, previous reports indicate that P11.4 binds human HL-60 cells, suggesting that it reacts with human E-selectin ligands as well (38). To confirm the binding specificity of P11.4 on human leukocytes, we performed two-color FACS analyses on human neutrophils and lymphocytes. As shown in Figure 23a, all human neutrophils stained with P11.4 and HECA-452, and P11.4 staining was inhibited by





Figure 22. E- and P-selectin chimeras do not immunoprecipitate GD3.5Ag or WC1. Biotinylated bovine $\gamma\delta$ T cell lysates were cleared of WC1 or GD3.5Ag and crossprecipitated with E- or P-selectin chimera. a) lanes 1 and 2 represent the first preclearing step of WC1 and GD3.5Ag lysates. Lanes 3 and 4 show the complete removal of WC1/IL-A29 and GD3.5Ag/GD3.5 mAb complexes. Lanes 5 and 6 represent the crossprecipitation of WC1- and GD3.5Ag-cleared lysates crossprecipitated with E-selectin chimera. b) lanes 1 and 2 represent the first preclearing step of WC1 and GD3.5Ag lysates. Lanes 3 and 4 show the complete removal of WC1/IL-A29 and GD3.5Ag/GD3.5 mAb complexes. Lanes 5 and 6 represent the crossprecipitation of WC1- and GD3.5Ag-cleared lysates crossprecipitated with P-selectin chimera. Figure 22 is the result of two experiments.

blocking mAb YT11.1 (Figure 23b). Upon initial analysis of lymphocytes, we found that a subset of HECA-452^{high} lymphocytes consistently stained with P11.4. Figure 23c shows staining of gated HECA-452^{high} human lymphocytes with P11.4. In addition, P11.4 staining was blocked by YT11.1 mAb (Figure 23d). HECA-452^{low} lymphocytes displayed variable staining with P11.4 that was only partially blocked by YT11.1 mAb (data not shown). As stated above, HECA-452 staining correlates with E-selectin binding cell populations; however, the correlation is not necessarily absolute. In any case, P11.4 E-selectin chimera specifically stains both human neutrophils and a subset of lymphocytes.

Immunoprecipitation of human leukocyte E-selectin ligands

To identify potential human E-selectin binding ligands, we attempted to immunoprecipitate ligands from biotin-labeled detergent extracts of human neutrophil and lymphocyte membrane preparations. First, neutrophil lysates were precipitated under nonreducing conditions with the chimera which resulted in at least three specific high molecular mass glycoproteins of 80-90kD, 130kD, and 230kD, (Figure 24, lane 1 indicated by arrows) whose interaction with the chimera could be blocked by YT11.1 (Figure 24, lane 2) or EDTA (data not shown). Bands at 150kD and 60kD were only partially reduced in their intensity following the mAb block. The molecular mobility of




Figure 23. Human neutrophils and a subset of lymphocytes are specifically stained by E-selectin chimera. Neutrophil and lymphocyte populations were identified by their distinctive light-scatter profiles. 23a) Two-color analysis of human neutrophils shows the entire neutrophil population stained with P11.4 and HECA-452. 23b) Neutrophils stained with HECA-452 and P11.4, which was previously blocked with E-selectin blocking mAb YT11.1. 23c) Two-color analysis shows gated HECA-452^{high} lymphocytes stained with P11.4. 23d) HECA-452^{high} gated lymphocytes stained with P11.4 that was previously incubated with function-blocking mAb YT11.1. Cells in these experiments were incubated at RT for 90min with chimera (P11.4 or P11.4/YT11.1) and then stained, as described in Materials and Methods. Figure 23 is representative of at least three separate experiments.

the three neutrophil E-selectin ligands corresponded exactly with the previously defined ligands L-selectin (80-90kD) (29-32), ESL-1 (130kD) (27,28), and PSGL-1 (230kD) (22-26). Additional analyses of these neutrophil ligands are described below. Of note, the 230kD ligand is inconsistently precipitated, perhaps due to variable biotin labeling when using this technique.

As discussed in the introduction, few analyses have been done on human lymphocyte ligands for E-selectin. After verifying our approach with human neutrophils, we then examined the nature of the ligands expressed by lymphocytes. As shown in Figure 24, lane 3 (indicated by arrows), P11.4 immunoprecipitated glycoproteins of 120kD, ~220kD, and 260kD. Figure 24, lane 4 demonstrates that immunoprecipitation of all three bands was inhibited by YT11.1. A weak band at 65-70kD is also present in this experiment, but it was not consistently seen. Importantly, immunoprecipitation of the ~220kD and 260kD ligands from human lymphocytes was variable; however, the 120kD ligand was seen in all immunoprecipitations. The ~220kD and 260kD bands may be analogous to the bovine $\gamma\delta$ T cell ligands, whereas the 120kD ligand is unique to the human cells. The 260kD ligand was not consistently immunoprecipitated using the P11.4 chimera; however, the relevance of this ligand is supported by the immunoprecipitation of a 260kD ligand using a human E-selectin chimera (data not shown). The 120kD ligand was immunoprecipitated in at least eleven separate experiments and was the most consistently seen ligand, suggesting that it may be the most relevant of the three. Importantly, the 120kD band is not a result of contaminating monocytes in the lymphocyte lysate since immunoprecipitation of labeled monocyte lysates results in absolutely no band at 120kD (data not shown and see Materials and Methods). Of particular interest is that a band corresponding to the molecular mass of PSGL-1 under nonreducing conditions (230-240kD) was never isolated from lymphocytes. Therefore, in contrast to neutrophils, lymphocyte PSGL-1




Figure 24. Distinct E-selectin ligands are immunoprecipitated from biotinylated human neutrophil and human lymphocyte lysates using E-selectin chimera. Neutrophil and lymphocyte cell lysates were immunoprecipitated with E-selectin chimera (lanes 1 and 3, respectively) or functionally blocked E-selectin chimera (YT11.1) (lanes 2 and 4, respectively) and analyzed by SDS-PAGE, as described in Materials and Methods. Arrows indicate relevant E-selectin ligands on lymphocytes and neutrophils. Molecular standards are indicated on the left. Figure 24 is representative of at least three separate experiments using blocking antibody YT11.1 or EDTA.

may not interact with E-selectin, though it clearly can bind P-selectin (6,8,33-35). However, it is possible that lymphocyte PSGL-1, which has been shown to be smaller than neutrophil PSGL-1, may be contained in the smear at ~220kD (33).

Role of L-selectin and ESL-1 as neutrophil and lymphocyte ligands for E-selectin

As stated earlier, the three neutrophil E-selectin ligands likely correspond to L-selectin, ESL-1 and PSGL-1. ESL-1 and PSGL-1 are well accepted as ligands; however, L-selectin is controversial. Human neutrophil L-selectin can be affinity-isolated with an E-selectin-IgG chimera and reprecipitated with L-selectin mAb (44). Also, as stated earlier, several studies have shown that human neutrophil L-selectin is decorated by SLe^x and supports E-selectin binding (29-32). We show that the 80-90kD neutrophil E-selectin ligand was electrophoretically similar to DREG-56 immunoprecipitated neutrophil L-selectin (compare lanes 1 and 6, Figure 25). In addition, we attempted a simple preclearing experiment to determine if partial removal of neutrophil L-selectin would result in reduced crossprecipitation of the 80-90kD E-selectin ligand. In Figure 25, lanes 1 and 2 were precleared with DREG-56 mAb or control antibody. Lanes 3 and 4 show that all ag/ab complexes were removed. In lanes 5 and 6, chimera crossprecipitated the 80-90kD ligand; however, this band was greatly reduced in the L-selectin cleared lysate (lane 5). Thus, preclearing neutrophil lysates with anti-L-selectin mAb (DREG-56) resulted in a dramatic decrease in the crossprecipitation of the 80-90kD E-selectin ligand, suggesting that soluble L-selectin interacts with E-selectin. Therefore, these results support the hypothesis that neutrophil L-selectin can indeed interact with E-selectin as originally proposed (30,31) and recently confirmed (44).




Figure 25. Human neutrophil L-selectin binds to E-selectin. Biotinylated human neutrophil lysates were cleared with control or anti-L-selectin mAb and crossprecipitated with E-selectin chimera. Lanes 1 and 2 represent the first preclearing step of L-selectin and control lysates. Lanes 3 and 4 show the complete removal of Ag/Ab complexes. Lanes 5 and 6 represent the crossprecipitation of L-selectin and control cleared lysates with E-selectin chimera. Figure 25 is representative of two separate experiments.

To further study potential expression of ESL-1 on lymphocytes and distinguish the 130kD neutrophil E-selectin ligand from the 120kD lymphocyte E-selectin ligand, we stained both bovine and human lymphocytes with anti-ESL-1 polyclonal antibody. In Figure 26a, bovine cells were stained with anti- $\gamma\delta$ T cell (GD3.8) and anti-ESL-1 antibodies. Clearly, a population of lymphocytes stained with anti-ESL-1; however, it was not the major E-selectin binding $\gamma\delta$ T cell population (11). Figure 26b illustrates staining of human lymphocytes with anti-ESL-1 and the HECA-452 antibody. Interestingly, only 20-30% of the HECA-452 positive lymphocyte population stained with anti-ESL-1. A larger population of lymphocytes was positive for ESL-1 but negative for HECA-452. Therefore, we propose that ESL-1 may be expressed on specific human lymphocyte subsets, but it does not correlate with the expression of the HECA-452 epitope.




Figure 26. ESL-1 is not the major E-selectin-binding ligand on human and bovine lymphocytes. 26a) Two-color analysis of bovine lymphocytes stained with anti- $\gamma\delta$ T cell (PE) and anti-ESL-1 (FITC) antibodies. 26b) Human lymphocytes stained with anti-ESL-1 (PE) and HECA-452 (FITC). Irrelevant rabbit polyclonal anti-serum was used as a negative control to ensure specificity of anti-ESL-1 polyclonal antibody (data not shown). Figure 26 is representative of at least three separate experiments.

Discussion

Memory human T cells and bovine $\gamma\delta$ T cells represent unique subsets that traffic throughout the body via pathways unlike other lymphocytes. They tend to exclude secondary lymphoid organs and preferentially migrate through extralymphoid sites of inflammation. The trafficking behavior of these cells likely is critical to their function in response to infectious disease. In some instances, accumulation of these cell types in certain sites of inflammation may actually be detrimental, since they can contribute to autoimmune reactions (43). Therefore, an important goal is the molecular characterization of the molecules regulating the migration of these cells that could be targeted by new therapies that turn them on or off when it is beneficial to the host. One common feature of the T cells is their binding to the vascular selectin, E-selectin. Description of selectin ligands may provide important information regarding the specific recruitment of these cells into sites of inflammation.

In this report, we describe the differences and similarities of bovine and human leukocyte E-selectin ligands using an E-selectin/Ig chimera P11.4. In our bovine model, we show by two-color FACS analysis that only $\gamma\delta$ TCR-positive lymphocytes are bound by P11.4. In addition, this binding was specifically blocked by E-selectin blocking mAb (YT11.1). These results complement our earlier studies showing that $\gamma\delta$ T cells in newborn calves have the capacity to bind E-selectin (11). Due to the intense staining of bovine $\gamma\delta$ T cells with P11.4, we used several techniques to study the relevant E-selectin ligands expressed by bovine $\gamma\delta$ T cells. When $\gamma\delta$ T cells were lysed and used for Western blotting, four distinct bands were detected by probing with P11.4. Consistent with our earlier reports, a 250kD band was identified (11) as well as three additional bands of 180kD, 200kD, and 300kD. Biotinylating cell surface molecules before cell lysis resulted in consistent immunoprecipitation of the 180-200kD and

250kD ligands. Interestingly, the 300kD band was inconsistently immunoprecipitated, possibly due to low level expression on the cell surface. It is also possible that poor labeling or variability in the immunoprecipitation procedure reduced efficiency of precipitating the 300kD ligand. To our knowledge this is the first report describing bovine E-selectin ligands other than our previously published 250kD molecule (11).

In Chapter 3, we showed that GD3.5 mAb did not block bovine lymphocyte adhesion to E- or P-selectin. However, chymotrypsin treatment of the lymphocytes inhibits their rolling on P-selectin, but not E-selectin. Therefore, E-selectin ligands are chymotrypsin resistant while P-selectin ligands are sensitive to chymotrypsin treatment, a characteristic of WC1 and GD3.5Ag, respectively. Additionally, we showed that $\gamma\delta$ T cells bind to E-selectin via large molecular mass glycoproteins (11). Thus, we decided to perform crossprecipitation experiments to determine if WC1 or GD3.5Ag represented E- or P-selectin ligands. Crossimmunoprecipitation analyses of GD3.5Ag and WC1 revealed that neither one of these lineage-specific cell surface antigens represented E- or P-selectin ligands. Lysates cleared of WC1 or GD3.5Ag did not diminish precipitation of E- or P-selectin ligands. Also, the E-selectin and P-selectin ligands are electrophoretically distinct from GD3.5Ag and WC1. Of note, P-selectin chimera precipitated a single ligand of ~220kD that was reduced upon treatment with β -mercaptoethanol (data not shown). Since PSGL-1, a known leukocyte ligand for P-selectin (20,33), possesses similar electrophoretic characteristics and sensitivity to reduction when compared to the bovine $\gamma\delta$ T cell ligand, we propose that the major P-selectin ligand on bovine $\gamma\delta$ T cells is a PSGL-1-like molecule. Importantly, neither WC1 or GD3.5Ag electrophoretic mobilities are significantly altered when treated with reducing agents, further distinguishing them from the P-selectin ligand.

Many reports have shown that various cell types in several species can bind selectins. We chose to study the human system in comparison to the bovine system

because of the lack of specific biochemical information of the surface molecules on human lymphocytes that form adhesive/tethering interactions with the selectins. Previously, the P11.4 chimera has been demonstrated to bind both human and pig leukocytes, and, in fact, this chimera stains human leukocytes with greater intensity than some human E-selectin lectin and EGF domain chimeras (38). In addition, anti-human E-selectin mAbs specifically bind pig E-selectin, suggesting that pig and human E-selectin share crossreactive epitopes (38). In our study, FACS analysis indicated that human neutrophils and lymphocytes are specifically bound by the E-selectin chimera, supporting the previously published report (38). Previous results have shown that only a fraction of the total lymphocyte population is stained by HECA-452, and this population interacts with E-selectin (9,37). Consistent with these results, only a fraction of lymphocytes were stained with chimera while virtually all neutrophils were stained.

Interestingly, previous reports have shown that a larger subset of human $\gamma\delta$ T cells are HECA-452 positive when compared to $\alpha\beta$ T cell subsets (9). In addition, it has been reported that human $\gamma\delta$ T cells bind P-selectin with greater ability than $\alpha\beta$ T cells (6). Although the circulating pool of $\gamma\delta$ T cells in adult humans is far less than $\alpha\beta$ T cells, it is tempting to propose that perhaps human $\gamma\delta$ T cells possess a greater initial capacity to bind activated endothelium via E- and P-selectin interactions similar to bovine $\gamma\delta$ T cells, indicating that these cells may share similar immunological roles involving initial host responses in cattle and human systems. It should be noted that some reports indicate that human $\gamma\delta$ and $\alpha\beta$ T cells bind E-selectin with similar ability (6).

We were particularly interested in determining if our immunoprecipitation approach could isolate previously described human neutrophil ligands and whether human lymphocyte molecules analogous to the bovine ligands could be identified as well.

Three different E-selectin ligands have been defined on neutrophils: L-selectin (29-32), ESL-1 (27,28), and PSGL-1 (22-26). A model has been proposed in which common E- and P-selectin receptors initiate neutrophil E-selectin interactions, while ESL-1 represents an E-selectin-specific binding molecule (27). L-selectin, as an E-selectin ligand, is more controversial, but a number of studies support a role for it as well. For example, anti-L-selectin mAb blocks neutrophil rolling on recombinant E-selectin (30). We found that immunoprecipitation of biotinylated neutrophil membrane preparations with P11.4 resulted in the isolation of three major species with molecular mobilities corresponding exactly with the three ligands discussed above. The most controversial of these ligands, L-selectin, was confirmed through our preclearing experiments. In addition, crossprecipitation experiments using HECA-452 indicated that neutrophil L-selectin was decorated with CLA (data not shown), which has been described previously (31). Almost identical results have been obtained using human neutrophils and an affinity column approach. Specifically, human neutrophil L-selectin could be reprecipitated from affinity-purified E-selectin ligand eluates (44). Thus, soluble neutrophil L-selectin can interact with E-selectin, which supports the original hypothesis that neutrophil L-selectin interacts with E-selectin (30,31). Importantly, these results are consistent with many reports in the literature on neutrophil ligands for E-selectin and serve to validate our assay system. Whether other neutrophil ligands exist is unknown, since ligands that do not label well by our biotin procedure would be missed.

After verifying the effectiveness of our immunoprecipitation approach for the analysis of human neutrophil E-selectin ligands, similar procedures were performed with human lymphocytes. We showed that three distinct ligands of 120kD, ~220kD, and 260kD were specifically immunoprecipitated by the E-selectin chimera. In separate analyses, we found that the three ligands likely express CLA, since they were partially

precleared from lysates with the HECA-452 mAb (data not shown). Of interest, the ~220kD ligand is consistent with previous reports describing a 200kD CLA molecule (9). In addition, although not emphasized in this report, Picker et al. (9) reported a lymphocyte CLA antigen of approximately 125kD which is also consistent with our results describing a 120kD E-selectin ligand.

We hypothesize that the ~220kD and 260kD ligands are analogous to the ligands defined on bovine $\gamma\delta$ T cells and their inconsistent isolation from human cells suggests that their molecular characterization will be better done in the bovine model. Of specific interest and relevance to human lymphocytes was our finding of a ligand unique to only those cells. In every lymphocyte lysate examined to date, the P11.4 chimera immunoprecipitated a ligand of approximately 120kD under nonreducing conditions. A band of similar molecular mass has never been isolated from bovine $\gamma\delta$ T cells. The 120kD lymphocyte ligand is similar to the ESL-1 ligand on neutrophils (130kD nonreducing, 150kD reducing) (28). It is possible that this molecule represents a lymphocyte form of ESL-1 that lacks certain post-translational modification, affecting molecular mobility, or it represents a completely distinct molecule. We have shown, using a polyclonal anti-ESL-1 antibody, that a subset of bovine lymphocytes expresses ESL-1 epitopes. Interestingly, $\gamma\delta$ T cells were not stained by anti-ESL-1, suggesting that the E-selectin binding population of bovine lymphocytes do not express ESL-1 epitopes. Furthermore, we demonstrated that only 20-30% of the E-selectin-binding lymphocyte population, as defined by HECA-452, expressed ESL-1 epitopes, indicating that the 120kD human lymphocyte E-selectin ligand is likely a unique molecule and not a modified form of ESL-1. Another possibility is that the polyclonal serum may not be monospecific for ESL-1 epitopes when analyzing lymphocyte populations. If this is the case, ESL-1 staining of lymphocytes would not necessarily represent expression of ESL-1 epitopes. Regardless, the major populations of bovine and human E-selectin

binding lymphocytes are not stained by anti-ESL-1 polyclonal antibody suggesting that lymphocytes use surface molecules other than ESL-1 to bind E-selectin.

In summary, we confirm that a major E-selectin ligand on $\gamma\delta$ T cells is the 250kD glycoprotein described in our earlier report (11). Furthermore, we provide evidence for at least one more cell-surface ligand on these cells. In similar studies with human leukocytes we show that our isolation procedure leads to the precipitation of the known major E-selectin ligands previously described for neutrophils: L-selectin, ESL-1, and PSGL-1. Our analyses of human lymphocytes are the first for this cell type and we provide evidence for ligands expressed by human lymphocytes which are analogous to those expressed by bovine $\gamma\delta$ T cells as well as a ligand that is unique to the human cells. It is possible that lymphocyte-specific E-selectin ligands could serve as new molecules to base inhibitory strategies that selectively block the migration of memory cells into tissues versus the migration of other cells, such as neutrophils.

References

1. Bevilacqua, M. P. 1993. Endothelial-leukocyte adhesion molecules. *Annu. Rev. Immunol.* 11:767.
2. Carlos, T. M., and J. M. Harlan. 1994. Leukocyte-endothelial adhesion molecules. *Blood* 84:2068.
3. D'Amico, U., and F. Malavasi. 1995. Lymphocyte adhesion to endothelium. *Critical Rev. Immunol.* 15:167.
4. Tedder, T. F., D. A. Steeber, A. Chen, and P. Engel. 1995. The selectins: vascular adhesion molecules. *FASEB J.* 9:866.
5. Bevilacqua, M. P., and R. M. Nelson. 1993. Selectins. *J. Clin. Invest.* 91:379.
6. DiCicco, T. G., S. J. Roth, C. T. Morita, J.-P. Rosat, M. B. Brenner, and T. A. Springer. 1996. Interactions of human α/β and γ/δ T lymphocyte subsets in shear flow with E-selectin and P-selectin. *J. Exp. Med.* 183:1193.
7. Jutila, M. A., R. F. Bargatze, S. Kurk, R. A. Warnock, N. Ehsani, S. R. Watson, and B. Walcheck. 1994. Cell surface P- and E-selectin support shear-dependent rolling of bovine γ/δ T cells. *J. Immunol.* 153:3917.
8. Moore, K. L., and L. F. Thompson. 1992. P-selectin (CD62) binds to subpopulations of human memory T lymphocytes and natural killer cells. *Biochem. Biophys. Res. Commun.* 186:173.
9. Picker, L. J., S. A. Michie, L. S. Rott, and E. C. Butcher. 1990. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. *Am. J. Pathol.* 136:1053.
10. Shimizu, Y., S. Shaw, N. Graber, T. V. Gopal, K. J. Horgan, G. A. Van Seventer, and W. Newman. 1991. Activation-independent binding of human memory T cells to adhesion molecule ELAM-1. *Nature* 349:799.
11. Walcheck, B., G. Watts, and M. A. Jutila. 1993. Bovine γ/δ T cells bind E-selectin via a novel glycoprotein receptor: First characterization of a lymphocyte/E-selectin interaction in an animal model. *J. Exp. Med.* 178:853.
12. Berg, E. L., M. K. Robinson, O. Mansson, E. C. Butcher, and J. L. Magnani. 1991. A carbohydrate domain common to both sialyl Le^a and sialyl Le^x is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. *J. Biol. Chem.* 266:14869.
13. Berg, E. L., J. Magnani, R. A. Warnock, M. K. Robinson, and E. C. Butcher. 1992. Comparison of L-selectin and E-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Le^x and sialyl Le^a. *Biochem. Biophys. Res. Commun.* 184:1048.

14. Foxall, C., S. R. Watson, D. Dowbenko, C. Fennie, L. A. Lasky, M. Kiso, A. Hasegawa, D. Asa, and B. K. Brandley. 1992. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis^x oligosaccharide. *J. Cell Biol.* 117:895.
15. Handa, K., E. D. Nudelman, M. R. Stroud, T. Shiozawa, and S.-I. Hakomori. 1991. Selectin GMP-140 (CD62; PADGEM) binds to sialosyl-Le^a and sialosyl-Le^x, and sulfated glycans modulate this binding. *Biochem. Biophys. Res. Commun.* 181:1223.
16. Phillips, M. L., E. Nudelman, F. C. A. Gaeta, M. Perez, A. K. Singhal, S.-I. Hakomori, and J. C. Paulson. 1990. ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Le^x. *Science* 250:1130.
17. Polley, M. J., M. L. Phillips, E. Wayner, E. Nudelman, A. K. Singhal, S.-I. Hakomori, and J. C. Paulson. 1991. CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-lewis x. *Proc. Natl. Acad. Sci. USA.* 88:6224.
18. Tyrrell, D., P. James, N. Rao, C. Foxall, S. Abbas, F. Dasgupta, M. Nashed, A. Hasegawa, M. Kiso, D. Asa, J. Kidd, and B. K. Brandley. 1991. Structural requirements for the carbohydrate ligand of E-selectin. *Proc. Natl. Acad. Sci. USA.* 88:10372.
19. Larsen, G. R., D. Sako, T. J. Ahern, M. Shaffer, J. Erban, S. A. Sajer, R. M. Gibson, D. D. Wagner, B. C. Furie, and B. Furie. 1992. P-selectin and E-selectin: Distinct but overlapping leukocyte ligand specificities. *J. Biol. Chem.* 267:11104.
20. Moore, K. L., A. Varki, and R. P. McEver. 1991. GMP-140 binds to a glycoprotein receptor on human neutrophils: evidence for a lectin-like interaction. *J. Cell Biol.* 112:491.
21. Moore, K. L., N. L. Stults, S. Diaz, D. F. Smith, R. D. Cummings, A. Varki, and R. P. McEver. 1992. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. *J. Cell Biol.* 118:445.
22. Asa, D., L. Raycroft, L. Ma, P. A. Aeed, P. S. Kaytes, A. P. Elhammer, and J.-G. Geng. 1995. The P-selectin glycoprotein ligand functions as a common human leukocyte ligand for P- and E-selectins. *J. Biol. Chem.* 270:11662.
23. Li, F., P. P. Wilkins, S. Crawley, J. Weinstein, R. D. Cummings, and R. P. McEver. 1996. Post-translational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin. *J. Biol. Chem.* 271:3255.
24. Patel, K. D., K. L. Moore, M. U. Nollert, and R. P. McEver. 1995. Neutrophils use both shared and distinct mechanisms to adhere to selectins under static and flow conditions. *J. Clin. Invest.* 96:1887.

25. Sako, D., X-J. Chang, K. M. Barone, G. Vachino, H. M. White, G. Shaw, G. M. Veldman, K. M. Bean, T. J. Ahern, B. Furie, D. A. Cumming, and G. R. Larsen. 1993. Expression cloning of a functional glycoprotein ligand for P-selectin. *Cell* 75:1179.
26. Sako, D., K. M. Comess, K. M. Barone, R. T. Camphausen, D. A. Cumming, and G. D. Shaw. 1995. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. *Cell* 83:323.
27. Lenter, M., A. Levinovitz, S. Isenmann, and D. Vestweber. 1994. Monospecific and common glycoprotein ligands for E- and P-selectin on myeloid cells. *J. Cell Biol.* 125:471.
28. Levinovitz, A., J. Mühlhoff, S. Isenmann, and D. Vestweber. 1993. Identification of a glycoprotein ligand for E-selectin on mouse myeloid cells. *J. Cell Biol.* 121:449.
29. Hallmann, R., M. A. Jutila, C. W. Smith, D. C. Anderson, T. K. Kishimoto, and E. C. Butcher. 1991. The peripheral lymph node homing receptor, LECAM-1, is involved in CD18-independent adhesion of human neutrophils to endothelium. *Biochem. Biophys. Res. Comm.* 174:236.
30. Kishimoto, T. K., R. A. Warnock, M. A. Jutila, E. C. Butcher, C. Lane, D. C. Anderson, and C. W. Smith. 1991. Antibodies against human neutrophil LECAM-1 (LAM-1/Leu-8/DREG-56 antigen) and endothelial cell ELAM-1 inhibit a common CD18-independent adhesion pathway in vitro. *Blood* 78:805.
31. Picker, L. J., R. A. Warnock, A. R. Burns, C. M. Doerschuk, E. L. Berg, and E. C. Butcher. 1991. The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. *Cell* 66:921.
32. Smith, C. W., T. K. Kishimoto, O. Abbass, B. Hughes, R. Rothlein, L. V. McIntire, E. Butcher, and D. C. Anderson. 1991. Chemotactic factors regulate lectin adhesion molecule 1 (LECAM-1)-dependent neutrophil adhesion to cytokine-stimulated endothelial cells in vitro. *J. Clin. Invest.* 87:609.
33. Vachino, G., X-J. Chang, G. M. Veldman, R. Kumar, D. Sako, L. A. Fouser, M. C. Berndt, and D. A. Cumming. 1995. P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells. *J. Biol. Chem.* 270:21966.
34. Alon, R., H. Rossiter, X. Wang, T. A. Springer, and T. S. Kupper. 1994. Distinct cell surface ligands mediate T lymphocyte attachment and rolling on P and E selectin under physiological flow. *J. Cell Biol.* 127:1485.
35. Jutila, M. A., and S. Kurk. 1996. Analysis of bovine $\gamma\delta$ T cell interactions with E-, P-, and L-selectin: characterization of lymphocyte on lymphocyte rolling and the effects of O-glycoprotease. *J. Immunol.* 156:289.

36. Berg, E. L., T. Yoshino, L. S. Rott, M. K. Robinson, R. A. Warnock, T. K. Kishimoto, L. J. Picker, and E. C. Butcher. 1991. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. *J. Exp. Med.* 174:1461.
37. Picker, L. J., T. K. Kishimoto, C. W. Smith, R. A. Warnock, and E. C. Butcher. 1991. ELAM-1 is an adhesion molecule for skin-homing T cells. *Nature* 349:796.
38. Tsang, Y. T. M., P. E. Stephens, S. T. Licence, D. O. Haskard, R. M. Binns, and M. K. Robinson. 1995. Porcine E-selectin: cloning and functional characterization. *Immunol.* 85:140.
39. Jones, W. M., B. Walcheck, and M. A. Jutila. 1996. Generation of a new $\gamma\delta$ T cell-specific monoclonal antibody (GD3.5): biochemical comparisons of GD3.5 antigen with the previously described workshop cluster 1 (WC1) family. *J. Immunol.* 156:3772.
40. Allen, M. H., M. K. Robinson, P. E. Stephens, D. M. MacDonald, and J. N. W. N. Barker. 1996. E-selectin binds to squamous cell carcinoma and keratinocyte cell lines. *J. Invest. Dermatol.* 106:611.
41. Binns, R. M., A. Whyte, S. T. Licence, A. A. Harrison, Y. T. M. Tsang, D. O. Haskard, and M. K. Robinson. 1996. The role of E-selectin in lymphocyte and polymorphonuclear cell recruitment into cutaneous delayed hypersensitivity reactions in sensitized pigs. *J. Immunol.* 157:4094.
42. Steegmaier, M., A. Levinovitz, S. Isenmann, E. Borges, M. Lenter, H. P. Kocher, B. Kleuser, and D. Vestweber. 1995. The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor. *Nature* 373:615.
43. Catálfamo, M., C. Roura-Mir, M. Sospedra, P. Aparicio, S. Costagliola, M. Ludgate, R. Pujol-Borrell, and D. Jaraquemada. 1996. Self-reactive cytotoxic $\gamma\delta$ T lymphocytes in Graves' disease specifically recognize thyroid epithelial cells. *J. Immunol.* 156:804.
44. Zöllner, O., M. C. Lenter, J. E. Blanks, E. Borges, M. Steegmaier, H-G. Zerwes, and D. Vestweber. 1997. L-selectin from human, but not from mouse neutrophils binds directly to E-selectin. *J. Cell Biol.* 136:707.

CHAPTER 5

CONCLUSIONS AND RECENT RESULTS

Introduction

In pursuit of a greater understanding of T cell biology, especially $\gamma\delta$ T cell biology, I have endeavored to explore cell-surface antigens expressed by this lymphocyte subset. In our laboratory, we have generated many monoclonal antibodies against several $\gamma\delta$ T cell surface antigens. Specifically, multiple monoclonal antibodies have been raised against both the $\gamma\delta$ TCR and a known antigen called WC1. In the process of generating these antibodies, one particular mAb, called GD3.5, was of great interest to me. Initial investigation indicated that GD3.5Ag was different than both TCR and WC1. Thus, it was the intent of my thesis proposal to further characterize this antigen via biochemical, regulatory, and functional analyses and in that process I learned more about additional cell surface antigens including, WC1 and potential E-selectin ligands expressed by bovine and human lymphocytes.

Description of GD3.5Ag by biochemical, regulatory, and functional analyses

In this thesis, I describe GD3.5Ag, a new lineage-specific $\gamma\delta$ T cell marker that is distinct from TCR, and known WC1 isotypes. GD3.5Ag is expressed on approximately 90% of the peripheral blood $\gamma\delta$ T cell population and GD3.5Ag is characterized by a ~230kD molecule under reducing and nonreducing conditions and is electrophoretically distinct from IL-A29-reactive WC1. Additionally, GD3.5 antigen and WC1 possess

disparate sensitivity to glycosidases and proteases. Both GD3.5 antigen and WC1 are sialomucin-like molecules that share similar O-sialoglycoprotein endopeptidase sensitivity with other cell surface molecules such as PSGL-1. Therefore, my data in Chapter 2 suggest that GD3.5 antigen is a previously uncharacterized, lineage-specific, $\gamma\delta$ T cell antigen.

In Chapter 3, I follow with characterization of GD3.5Ag by regulatory and functional analyses while further distinguishing GD3.5Ag from WC1. Bovine tissue distribution studies reveal an unusually high number of $\gamma\delta$ T cells in the spleen that express lower levels of GD3.5 and WC1 when compared to PBL cell populations. The in vivo downregulation in the spleen is mimicked in vitro by activation of mixed lymphocyte populations with PHA or ConA, which downregulated WC1 and GD3.5Ag.

Treatment of $\gamma\delta$ T cells with increasing concentrations of chymotrypsin resulted in a dose-dependent loss of GD3.5Ag expression on the cell surface. The loss of GD3.5Ag cell-surface expression correlates with a stepwise loss in ability of these cells to roll on 24hr activated endothelium, suggesting that GD3.5Ag is involved in this process. Polyclonal antibodies from several mice immunized with GD3.5Ag partially inhibit $\gamma\delta$ T cell accumulation on 24hr activated endothelium. However, further analysis will be necessary to determine how much and to what extent GD3.5Ag contributes to this interaction. Finally, GD3.5 polyclonal antibodies immunoprecipitate GD3.5 antigen and specifically stain bovine $\gamma\delta$ T cells, further supporting the hypothesis that it represents a lineage-specific $\gamma\delta$ T cell-surface marker.

GD3.5Ag as a unique WC1 isotype?

In the process of generating mAbs against $\gamma\delta$ T cell-specific antigens, our lab has generated other mAbs against WC1 isotypes. These antibodies include GD6-22a and BW-71. As stated above, IL-A29 recognizes the known WC1 isotypes; however, it stains

only 70% of the total $\gamma\delta$ T cell population. When cells are stained with a combination of IL-A29, GD6-22a, and BW-71, the entire $\gamma\delta$ T cell population is stained indicating that all three antibodies may serve, in concert, as a pan-marker for WC1 isotypes. In addition, all three antibodies recognize overlapping and distinct WC1 isotypes. Recently, I performed a crossprecipitation experiment where a single biotinylated lysate was precleared of IL-A29, BW-71, and GD6-22a WC1 antigens and then crossprecipitated with GD3.5mAb. In Figure 27, lanes 1-4 represent biotinylated lysates cleared with IL-A29/BW-71/GD6-22a, GD3.8 (anti-TCR), GD3.5, and IL-A29, respectively. Lanes 5-8 show that all Ag/Ab complexes were removed. Lanes 9-12 show the crossprecipitation experiment. Lysates cleared of IL-A29/BW-71/GD6-22a, GD3.8 (anti-TCR), and IL-A29 (lanes 9,10, and 12, respectively) possessed GD3.5Ag. In addition, the intensity of the crossprecipitated GD3.5Ag was equivalent in the GD3.8 cleared lysate (lane 10) when compared to the WC1 cleared lysates (lanes 9 and 12). Therefore, GD3.5Ag does not represent one of the known WC1 isotypes as defined by our mAbs against WC1.

The GD3.5 polyclonal antibody predominantly recognizes GD3.5Ag; however, a band at 300kD was also precipitated (Figure 17, lane 1, and Figure 28, lane 6). Therefore, I performed crossprecipitation experiments to determine if lysates precleared of IL-A29-reactive WC1 would diminish crossprecipitation of GD3.5 polyclonal antigen. In Figure 28, I show lymphocyte lysates precleared with IL-A29 and GD3.5 mAbs (lanes 1 and 2) and then crossprecipitated with anti-GD3.5 polyclonal sera. GD3.5 mAb-cleared lysates (lane 2) do not contain GD3.5Ag (lane 6) while WC1-cleared lysates (lane 1) contain GD3.5Ag (lane 5). Interestingly, preclearing lysates of IL-A29-reactive WC1 resulted in the loss of a weak 210-220kD smear and the 300kD band, but not GD3.5Ag (lane 5). In contrast, lysates cleared of GD3.5Ag resulted in the loss of the upper 230kD band, but not the smear at 210-220kD and 300kD band. These results show that




Figure 27. Multiple monoclonal antibodies against WC1 do not immunoprecipitate GD3.5Ag. Biotinylated bovine lymphocyte lysates were precleared of WC1, GD3.5Ag and TCR and crossprecipitated with GD3.5 mAb. Lanes 1-4 represent biotinylated lysates cleared with IL-A29/BW-71/GD6-22a, GD3.8 (anti-TCR), GD3.5, and IL-A29, respectively. Lanes 5-8 show that all Ag/Ab complexes were removed. Lanes 9-12 show the lysates cleared with IL-A29/BW-71/GD6-22a, GD3.8 (anti-TCR), GD3.5, and IL-A29, respectively, and crossprecipitated with GD3.5 mAb. Molecular standards are as marked. Figure 27 is representative of one experiment.

the polyclonal antibodies recognize GD3.5 antigen; however, they also recognize crossreactive epitopes expressed on IL-A29-reactive WC1. Thus, it is possible that GD3.5Ag is related to WC1, or the antigen preparation used to generate GD3.5 polyclonal serum may have been contaminated with WC1. I propose that if GD3.5Ag is related to WC1, then it is a previously uncharacterized member since considerable evidence illustrates that GD3.5Ag is distinct from known WC1 isotypes (see Chapters 2 and 3).




Figure 28. GD3.5 polyclonal antibody crossprecipitation of IL-A29 and GD3.5 cleared biotinylated lysates. Biotinylated bovine lymphocyte lysates were precleared of WC1 and GD3.5Ag and crossprecipitated with anti-GD3.5 polyclonal antibody. Lanes 1 and 2 show immunoprecipitation of WC1 and GD3.5Ag, respectively. Lanes 3 and 4 show that IL-A29Ab/WC1 and GD3.5Ab/GD3.5Ag complexes have been completely cleared from their respective lysates. Lanes 5 and 6 represent the crossprecipitation experiment using anti-GD3.5Ag polyclonal antibody. Molecular standards are as marked. Figure 28 is representative of one experiment.

Biochemically, the known WC1 isotypes are characterized by 180kD, 205-215kD, and 300kD Mr species (see Figure 27, lane 1). As shown above, the GD3.5 polyclonal antibody recognizes WC1 epitopes, suggesting that GD3.5 could be another member of the WC1 family. Thus, I have accomplished another objective by potentially identifying GD3.5Ag which can be confirmed by peptide sequence analysis and/or cloning. The known WC1 isotypes share 90% identity at the nucleic acid level except in the N-terminal portion of the molecule. Therefore, if GD3.5Ag is related to WC1, then it may be possible to screen cDNA libraries and clone the GD3.5Ag cDNA using probes based upon the 90% identical regions of the known WC1 isotypes.

E-selectin ligands expressed on bovine and human leukocytes

To test my hypothesis that GD3.5Ag or WC1 may be E-selectin ligands, I found that preclearing lysates of GD3.5Ag or WC1 did not abrogate E- or P-selectin chimera precipitation of their respective ligands. In addition, using functional assays directed at studying specific E- and P-selectin interactions, GD3.5Ag did not appear to be involved in adhesion to either of these selectins. Importantly, bovine $\gamma\delta$ T cells likely express a P-selectin ligand that is similar to PSGL-1. Therefore, I tested my hypothesis that these molecules may represent E-selectin ligands and found that neither of these molecules interact with E-selectin.

Although, as described above, GD3.5Ag and WC1 do not represent E-selectin ligands, I found that $\gamma\delta$ T cells possess several potential E-selectin ligands. Therefore, using an E-selectin/immunoglobulin chimeric molecule I studied E-selectin ligand expression on bovine $\gamma\delta$ T cells and human leukocytes. The chimera specifically stains bovine $\gamma\delta$ T cells and immunoprecipitates at least two E-selectin ligands, 180-200kD and 250kD, from lysates of cell-surface biotinylated $\gamma\delta$ T cells. Thus, I confirmed our earlier reports describing a 250kD ligand as well as another potential ligand of 200kD.

Using these same techniques, I found that human neutrophils possess at least three E-selectin-binding ligands of approximately 80-90kD, 130kD, and 230kD, consistent with previously published neutrophil ligands. Additionally, crossprecipitation experiments confirm the results of others that neutrophil L-selectin serves as the 80-90kD E-selectin ligand. Importantly, human lymphocytes possess three ligands of 120kD, ~220kD, and 260kD. I hypothesize that the human lymphocyte ~220kD and 260kD ligands may be analogous to the bovine $\gamma\delta$ T cell molecules. Critically, the 120kD ligand is unique to the human lymphocytes and this is the first report describing potential human lymphocyte ligands. Lastly, ESL-1, a neutrophil E-selectin ligand sharing similar electrophoretic migratory patterns, apparently has a minimal role, if any, in lymphocyte/E-selectin interactions, since a polyclonal anti-ESL-1 sera stains a minimal number of CLA-positive human lymphocytes and bovine $\gamma\delta$ T cells.

Summary

In performing these studies, I describe several cell-surface antigens, some of which are involved in important mechanisms of cell recruitment into sites of inflammation. Therefore, it is my hope that these discoveries will assist in the pursuit of treatments for inflammatory diseases.

CHAPTER 6

FUTURE AND COLLABORATIVE STUDIES

We have described data related to the characterization of bovine and human cell-surface antigens. Currently, we are pursuing further analysis of GD3.5Ag and bovine and human lymphocyte E-selectin ligands.

Affinity column chromatography is being used to purify sufficient amounts of GD3.5 antigen for peptide sequencing. Once done, the sequence will be compared with others from protein data banks in hopes that it may reveal GD3.5Ag relationships with other known proteins. Peptide sequencing may reveal whether or not GD3.5Ag is related to WC1, thereby helping to explore function. Further generation of anti-GD3.5 polyclonal serum is underway to assist in additional functional assays; mice that exhibit blocking antibody titers will be used to generate potential mAbs that block GD3.5Ag function.

In the future, the GD3.5Ag peptide sequence information will be used to derive nucleic acid probes to search bovine cDNA libraries, leading to sequencing of the gene encoding GD3.5Ag. Once again, if peptide analyses reveal that GD3.5Ag is related to WC1, then polymerase chain reaction (PCR) primers based upon the 90% identical regions of the known WC1 isotypes would allow the unique regions of GD3.5Ag to be amplified and sequenced by 5' rapid amplification of cDNA ends (5' RACE). In addition, we may be able to screen bovine expression libraries with GD3.5 polyclonal antibodies to elucidate the genetic sequence encoding GD3.5Ag.

Finally, the information gained here will likely be used to pursue the

characterization of human lymphocyte E-selectin ligands. We have presented data describing E-selectin ligands on bovine and human lymphocytes, and would like to test the sensitivity of these ligands to various deglycosidase enzymes and provide more insight into their biochemical characteristics. The E-selectin chimera will also be used for affinity column purification of ligands for the purpose of generating polyclonal and monoclonal antibodies that block ligand function.

While developing the experimental techniques used in our studies, we were able to perfect the biotin/streptavidin HRP detection system. The development of this expertise has led to a collaborative study with Dr. Paul Kubes involving detection of E-selectin expression on activated cat endothelium. Specifically, using anti-E-selectin mAb, we immunoprecipitated E-selectin from activated cat endothelial cell lysates, as documented in a recent publication (Hickey, et al. see below).

Hickey, M. J., P. H. Reinhardt, L. Ostrovsky, **W. M. Jones**, M. A. Jutila, D. Payne, J. Elliott, and P. Kubes. 1997. Tumor necrosis factor- α induces leukocyte recruitment by different mechanisms in vivo and in vitro. *J. Immunol.* 158:3391.

In the analysis of the GD3.5Ag provided herein, this molecule is described as a lineage-specific $\gamma\delta$ T cell antigen. To support this statement, a collaborative study with Dr. William Davis has been initiated to further differentiate this antigen. Dr. Davis has an extensive battery of anti-TCR and anti-WC1 mAbs. Using flow cytometry, we compared GD3.5Ag expression with several of the anti-TCR and anti-WC1 mAbs. These results indicate that GD3.5Ag expression is unique and further supports our statement that this antigen is a unique lineage-specific $\gamma\delta$ T cell-surface antigen.

MONTANA STATE UNIVERSITY LIBRARIES



3 1762 10293213 2